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IAbstract
Natural as well as unnatural 1-methyl-2-quinolones (MeQones) are heterocyclic
compounds with a wide range of pharmacologically important activities. In addition, they also
serve as important building blocks and intermediates in organic synthesis. Therefore, a
number of methods have been studied in great detail for the preparation of MeQones.
However, among these methods, only a few methods for direct functionalization of the
MeQone framework are currently available because of the inertness caused by the aromaticity.
Accordingly, development of a facile method for direct modification of the MeQone
framework is one of the highly demanded projects.
A nitro group is one of the most important functional groups in organic syntheses because
of its strongly electron-withdrawing ability to activate the scaffold, facilitating the reaction
with nucleophilic reagents. Moreover, a nitro group serves not only as a precursor of versatile
functionalities but also as a good leaving group. Inspired by these properties of the nitro group,
I successfully achieved the direct 4-alkoxylation and 3-halogenation of the MeQone
framework by a sequential treatment of 3-nitrated MeQones with sodium alkoxides and
N-halosuccinimide under mild conditions (Scheme 1, a). In addition, direct
amino-halogenation and aziridination of the MeQone framework was also developed by
replacing sodium alkoxides with amines as nucleophiles (Scheme 1, b).
Scheme 1. Direct functionalization of theMeQone framework
II
C-Nitroaziridines serve as useful building blocks in organic synthesis because of the high
reactivity caused by strongly electron-withdrawing nitro group and ring strain. Although
direct aziridination of nitroalkenes is the most efficient approach to C-nitroaziridines, there is
no report with regard to preparing N-alkyl derivatives.
I demonstrate here an efficient and highly diastereoselective one-pot synthesis of
trans-N-alkyl-C-nitroaziridines upon treatment of nitroalkenes with aliphatic amines and
N-chlorosuccinimide. The resultant aziridines are found to isomerize into
(Z)-β-aryl-β-nitroenamines with high diastereoselectivity through Lewis acid-mediated ring
opening and rearrangement of the aryl group (Scheme 2).
Scheme 2. Direct aziridination of nitroalkenes and the subsequent isomerization
Overall, several facile and efficients methods for direct functionalization of the MeQone
framework and nitroalkenes were successfully developed. The tolerance of a wide range of
functional groups and operational simplicity are the notable advantages of these protocol. The
resultant products can be easily transformed into other useful building blocks. Therefore,
these methods will be surely useful as powerful tools for preparation of novel compounds
with structural diversity and complexity. The results of these investigations are disclosed in
this thesis.
III
Table of contents
Abstract...................................................................................................................................... I
Chapter 1. General Introduction.............................................................................................1
Part I...........................................................................................................................................1
1. Significance of 1-methyl-2-quinolones (MeQones).......................................................1
2. Synthesis of functionalizedMeQones............................................................................3
3. Chemsitry of nitroquinolones..........................................................................................5
3.1 Preparation ofMeQone from quinoline............................................................... 5
3.2 Nitration of theMeQone framework....................................................................6
3.3 Nitro-induced direct functionalization of theMeQone framework....................10
3.4 High reactivity of 1-methyl-3,6,8-trinitro-2-quinolone...................................... 15
4. Research purpose.......................................................................................................... 25
References.........................................................................................................................26
Part II....................................................................................................................................... 30
1. Property of aziridines.................................................................................................... 30
2. Synthesis of C-nitroaziridines.......................................................................................34
2.1 Synthesis of N-Imido-C-nitroaziridines.............................................................. 34
2.2 Synthesis of N-alkoxycarbonyl-C-nitroaziridines...............................................35
2.3 Synthesis of N-aryl-C-nitroaziridines................................................................. 35
3. Research purpose.......................................................................................................... 36
References.........................................................................................................................37
Chapter 2. Direct 4-Alkoxylation and 3-Halogenation of the 1-Methyl-2-quinolone
Framework.............................................................................................................................. 40
1. Introduction...................................................................................................................40
2. Results and Discussion..................................................................................................41
2.1 Micheal addition of TNQ with sodium alkoxide................................................41
2.2 Optimization of the chlorination conditions....................................................... 42
2.3 Study on alkoxide scope..................................................................................... 43
2.4 Scanning of halogenating agents.........................................................................44
2.5 Scanning of 3-nitratedMeQones........................................................................45
2.6 cine-Substitution of 1,8-dimethyl-3,5-dinitro-2-quinolone 12........................... 46
2.7 Control experiments............................................................................................46
IV
2.8 A plausible mechanism for the formation ofMeO-Cl-DNQ and 2................... 47
2.9 Transformations ofMeO-Cl-DNQ and 2...........................................................48
3. Conclusion.................................................................................................................... 49
4. Experimental section.....................................................................................................49
4.1 General information............................................................................................ 49
4.2 General procedure for the preparation of 3-nitrated quinolones.........................50
4.3 General procedure for synthesis of 1a and 1b.................................................... 50
4.4 General procedure for synthesis ofMeO-Cl-DNQ and EtO-Cl-DNQ..............50
4.5 General procedure for one-pot method of synthesis of RO-Cl-DNQ................ 51
4.6 Synthesis of 4-methoxy-1,8-dimethyl-5-nitroquinolin-2(1H)-one ................... 54
4.7 Synthesis of 2,5-dioxopyrrolidino substitutedMeQone 2..................................55
4.8 Hydrazinolysis of 2............................................................................................. 55
4.9 Suzuki-Miyaura coupling reaction ofMeO-Cl-DNQ........................................ 55
Chapter 3. Direct Amino-halogenation and Aziridination of the 1-Methyl-2-quinolone
Framework.............................................................................................................................. 59
1. Introduction...................................................................................................................59
2. Results and Discussion..................................................................................................61
2.1 Amino-halogenation and aziridination of theMeQone Framework.................. 61
2.2 Control reaction involving radical scavenger..................................................... 62
2.3 A plausible mechanism for the formation of 3Aa and 4Aa................................62
2.4 Conditions screening for one-pot amino-chlorination........................................ 64
2.5 Study on amine scope......................................................................................... 65
2.6 Scanning of halogenating agents.........................................................................66
2.7 Scanning of 3-nitratedMeQones........................................................................67
2.8 Selectivity in amino-chlorination and aziridination............................................69
2.9 cine-Substitution of 1,8-dimethyl-3,5-dinitro-2-quinolone 12........................... 70
2.10 Conversion of the obtained products 6Af, 5A and 4Fa.................................... 70
3. Conclusion.................................................................................................................... 71
4. Experimental section.....................................................................................................72
4.1 General information............................................................................................ 72
4.2 General procedure for the preparation of 3-nitrated quinolones.........................72
4.3 Reaction of trinitroquinolone 1A with propylamine 2a......................................72
4.4 General procedure for amino-halogenation and aziridination of the 2-quinolone
framework................................................................................................................. 73
V4.5 cine-Substitution of 1,8-dimethyl-3,5-dinitro-2-quinolone (1I)......................... 79
4.6 Suzuki-Miyaura coupling reaction of benzylamino-brominated 6Af................. 80
4.7 Hydrazinolysis of 5A.......................................................................................... 80
4.8 Acid-catalyzed ring opening of aziridine ring.................................................... 80
References.........................................................................................................................81
Chapter 4. Direct Aziridination of Nitroalkenes Affording N-Alkyl-C-nitroaziridines
and the Subsequent Lewis Acid Mediated Isomerization to β-Nitroenamines................. 84
1. Introduction...................................................................................................................84
2. Results and Discussion..................................................................................................86
2.1 Optimization of reaction conditions for aziridination.........................................86
2.2 A plausible mechanism for aziridination............................................................ 88
2.3 Instability of N-alkyl-C-nitroaziridine 3a........................................................... 88
2.4 Lewis acid mediated ring opening and rearrangement of aziridine.................... 89
2.5 A plausible mechanism for isomerization of 3a into 8a..................................... 92
2.6 Study on nitroalkene scope................................................................................. 92
2.7 Scanning of amines............................................................................................. 95
3. Conclusion.................................................................................................................... 96
4. Experimental section.....................................................................................................96
4.1 General information............................................................................................ 96
4.2 General procedure for the preparation of nitroalkenes....................................... 97
4.3 General procedure for one-pot synthesis of trans-N-alkyl-C-nitroaziridine 3....97
4.4 Isomerization of trans-N-alkyl-C-nitroaziridine 3a to β-nitroenamine 8a....... 101
References.......................................................................................................................105
1Chapter 1. General Introduction
Part I
1. Significance of 1-methyl-2-quinolones (MeQones)
The 1-methyl-2-quinolone (MeQone) framework can be found in more than 300 quinoline
alkaloids exhibiting a wide range of biological activities such as melanogenesis inhibitory
activity,1 nicotinic agonistic activity,2 SRS-A antagonistic activity,3 cytotoxic activity,4 and
antitumor activity (Figure 1).5 Due to the important role of these alkaloids in medicinal
chemistry, numerous efforts have been dedicated to the the isolation, structural determination,
total synthesis and structral modification of quinoline alkaloids containing the MeQone
skeleton.
Figure 1. Biological activities of naturally occurringMeQone derivatives
Besides naturally occurring MeQones, a large number of unnatural MeQone derivatives
with structural diversity and complexity have also been synthesized with the aim of finding
more useful biological compounds. Indeed, various medicinal properties of MeQone
derivatives have been disclosed, such as antitumor activity,6 antianemia activity,7
antimicrobial activity,8 anti-HIV activity,9 and so on (Figure 2).10
2Figure 2. Biological activities of unnatural MeQone derivatives
Except for the widespread use in medicinal field, the functionalized MeQones also serve as
an important building block in functional materials such as photosensitizers11 and cyanine
dyes (Figure 3).12
Figure 3. MeQone framework in functional materials
3Due to these significant applications, highly efficient methods for synthesis and
functionalization of the MeQones are highly demanded over the past decades. In particular, it
is very important to find a useful scaffold leading to various kinds of MeQones, which
enables the construction of a new compound libraries for biological evaluation.
2. Synthesis of functionalized MeQones
Conventional strategies for the synthesis of functionalized MeQones involve (1)
construction of MeQone frameworks from pre-functionalized starting materials, (2) ring
transformation leading to MeQone frameworks, and (3) direct functionalization of the
MeQone framework, which are supplementary to each other (Figure 4).13
Figure 4. Strategies for synthesizingMeQones
Among these three protocols, direct functionalization of the MeQone framework for
preparing newly and diversely functionalized MeQones is the most efficient approach from a
practical viewpoint, as it requires only simple experimental manipulations. However, only a
few methods for direct functionalization of the MeQone framework are currently available
because of the inertness caused by the aromaticity from the betaine resonance structure
(Figure 5).13
Figure 5. Resonance structure ofMeQone
To the best of our knowledge, the current methods for direct functionalization of the
MeQone framework are mainly limited to the C-C or C-N bond formation through
4transition-metal-catalyzed cross-coupling reaction or C-H activation (Scheme 1 and 2).14-19
However, most of these methods suffer from some limitations such as the use of potentially
poisonous and expensive noble metal together with harsh reaction conditions.
Scheme 1. Transition-metal-catalyzed C-C bond formation
Scheme 2. Transition-metal-catalyzed C-N bond formation
5As an alternative, the electrophilic nitration has been proved as a highly efficient manner
for directly introducing nitro groups into theMeQone framework (Scheme 3).13
Scheme 3. Electrophilic nitration of theMeQone framework
It is well known that a nitro group is one of the most important functional groups in organic
synthesis because of its strongly electron-withdrawing ability to activate the scaffold,
facilitating the reaction with nucleophilic reagents.20 Moreover, a nitro group serves not only
as a precursor of versatile functionalities but also as a good leaving group (Scheme 4).21
Scheme 4. Properties of a nitro group
Inspired by these significant properties of the nitro group, the synthetic utility of nitrated
MeQones in preparation of unnatural MeQone derivatives have been widely investigated.
Indeed, the introduction of the nitro groups has been proved to facilitate the straightforward
introduction of other functional groups to afford diversely functionalizedMeQones.
3. Chemsitry of nitroquinolones
3.1 Preparation of MeQone from quinoline
The most facile and efficient method for the preparation of MeQone is methylation of
6quinoline, followed by oxidation. As indicated, a N-methylquinolinum salt is prepared by
methylation of quinoline with dimethyl sulfate, and then is oxidized by potassium
ferricyanide under alkaline conditions to form theMeQone framework (Scheme 5).22
Scheme 5. Preparation ofMeQone from quinoline
3.2 Nitration of the MeQone framework
3.2.1 Nitration of unsubstituted MeQone
The electrophilic nitration using fuming HNO3 or a combination of HNO3 and H2SO4 as
nitrating agent is the most common and straightforward way to introduce a nitro group into
the scaffold.23
Treatment of MeQone with 15 M nitric acid in sulfuric acid at 50 ℃ for 5 h exclusively
introduces the nitro group at the 6-position, affording 6-NQ in 72% yield (Table 1, entry 1).24
After increasing the reaction temperature to 70 ℃ and 80 ℃, di-nitrated MeQones, 3,6-DNQ
and 6,8-DNQ, are main products (entries 2–3). On the other hand, when MeQone is nitrated
with 15 M nitric acid under higher temperature, 1-methyl-3,6,8-trinitro-2-quinolone
(abbreviated as TNQ) is the only product (entry 4). The yield of TNQ is further increased by
replacing 15 M nitric acid with fuming nitric acid (entry 5). On the basis of these results, the
nitro group is introduced following the order of 6- > 3- ≈ 8-positions, in which nitration at the
3-position is somewhat easier than at the 8-position.
7Table 1. Nitration ofMeQone
Entry
Nitrating
Reagent
Temp./°C Time/h
Yield/%
TNQ 3,6-DNQ 6,8-DNQ 6-NQ
1 HNO3/H2SO4 50 5 0 0 0 72
2 HNO3/H2SO4 70 5 4 26 10 19
3 HNO3/H2SO4 80 5 8 41 29 18
4 HNO3/H2SO4 120 7 63 0 0 0
5 fuming HNO3 120 7 90 0 0 0
3.2.2 Nitration of substituted MeQones
In addition to the unsubstituted MeQone, the nitration of other MeQones with diffrent
substitutents on the benzene ring was also investigated by organic chemists.
3.2.2.1 Nitration of 1,6-dimethyl-2-quinolone
1,6-Dimethyl-2-quinolone (abbreviated as MeQone-Me6) is easily prepared from
commercially available 6-methylquinoline through methylation with dimethyl sulfate and
oxidation with potassium ferricyanide under alkaline conditions.25
In the nitration of MeQone-Me6, the nitro groups are mainly introduced at the 5- and the
7-positions as well as at the 3-position, in which the electron-donating 6-methyl group serves
as an ortho-directing group (Table 2).25 Moreover, the steric hindrance of 1-methyl group
prevented the nitration at the 8-position.
When the nitration of MeQone-Me6 is conducted at 50 ℃, dinitroquinolones B and C are
obtained as main products (Table 2, entry 1). The reaction at higher temperature and for
longer time leads to the formation of products A and B (entries 2 and 3). On the other hand,
harsh reaction conditions using fuming HNO3 at 120 ℃ induce the decomposition of substrate
and product, leading to nitrated quinolones with low yields (entry 4). On the basis of these
experimental results, the nitro groups are found to be introduced in the order of 5- > 3- ≈
87-positions.
Table 2. Nitration ofMeQone-Me6
Entry
Nitrating
Reagent
Temp./°C Time/h
Yield/%
A B C
1 HNO3/H2SO4 50 24 16 21 45
2 HNO3/H2SO4 80 5 11 11 5
3 HNO3/H2SO4 80 24 33 49 0
4 fuming HNO3 120 7 10 0 0
3.2.2.2 Nitration of 1,8-dimethyl-2-quinolone
1,8-Dimethyl-2-quinolone (abbreviated as MeQone-Me8) is prepared from commercially
available 8-methylquinoline through methylation with dimethyl sulfate and oxidation with
potassium ferricyanide under alkaline conditions.25
Due to the stronger ortho, para-direction ability of the methyl group than the acylamino
group (the ring nitrogen), the nitro groups are mainly introduced at the 5- and 7-positions
when MeQone-Me8 is subjected to the nitration conditions (Table 3).25 Therefore,
1,8-dimethyl-3,5,7-trinitro-2-quinolone D and 1,8-dimethyl-3,5-dinitro-2-quinolone E are
formed as the products (entry 1). 1,8-Dimethyl-3,6-dinitro-2-quinolone F is also formed
owing to the para-directing ability of the acylamino group (entry 1).
While relatively mild conditions afford the 3,5-dinitrated quinolone as the major product,
harsh reaction conditions with higher temperature and longer time lead to the formation of
3,5,7-trinitrated quinolone D (entries 2–5). On the basis of these experimental results, the nitro
groups are found to be introduced in the order of 5- ≈ 3- > 7- > 6-positions.
9Table 3. Nitration ofMeQone-Me8
Entry
Nitrating
Reagent
Temp./°C Time/h
Yield/%
D E F
1 HNO3/H2SO4 50 12 12 47 28
2 HNO3/H2SO4 50 24 27 40 28
3 HNO3/H2SO4 80 5 trace 39 0
4 HNO3/H2SO4 80 24 45 17 0
5 fuming HNO3 120 24 31 0 0
3.2.2.3 Nitration of other substituted MeQones
When 5-fluoro or 6-fluoro-1-methyl-2-quinolone is used as the substrate, nitration takes
place at the vicinal position of the fluoro group predominately (Scheme 6).26-27
Scheme 6. Nitration ofMeQone-F5 or 6
On the other hand, an electron-donating hydroxy group at the 4-position activates the
pyridone moiety, facilitating the nitration at the 3-position (Scheme 7). The resultant vicinal
functionalities are useful for the successive construction of a new condensed ring on the
pyridone ring, leading to polycyclic compounds.28-29
10
Scheme 7. Nitration ofMeQone-OH4
However, the replacement of a hydroxy group at the 4-position with a methyl group leads
to the nitration at the 6-position rather than 3-position.30 This might be caused by the steric
hindrance of the methyl group, preventing the nitration at the adjacent position and facilitating
the nitration at the para-direction of the electron-donating acylamino group (Scheme 8).
Scheme 8. Nitration ofMeQone-Me4
3.3 Nitro-induced direct functionalization of the MeQone framework
Nitro compounds play an important role in organic synthesis because the facile
transformation of the nitro group into other functionalities. Additionally, the strong
electron-withdrawing ability of the nitro group can efficiently activate the scaffold,
facilitating the reaction with nucleophiles. Furthermore, the nitro group having a good leaving
ability can be easily eliminated after nucleophilic additions. According to these properties of
nitro group, direct functionalization of the MeQone framework using nitroquinolones as
useful precursors have been developed.
3.3.1 Chemical transformation of a nitro Group
Nitro compounds are versatile precursors for diverse functionalities.31 Their conversion into
carbonyl compounds by the Nef reaction, conversion into amines by reduction, and
conversion into nitrile oxides by dehydration are the most widely used processes in organic
synthesis. Nitro compounds are also good precursors for various nitrogen derivatives such as
nitriles, oximes, hydroxylamines, and imines. Moreover, nitroarenes can replace haloarenes to
undergo the transition-metal-catalyzed cross-coupling reactions to construct C-C and C-N
bonds.32,33 Furthermore, SNAr fluorination of nitroarenes proceeds to afford fluoroarenes
which appear in a variety of pharmaceuticals and agrochemicals.34 All of these
11
transformations of nitro compounds are well established and are used routinely in organic
synthesis.
1,3-Dimethyl-6-nitro-2-quinolone is reduced by palladium-catalyzed hydrogenation
followed by sulfoamidation with benzenesulfonyl chloride to prepare functionalized
aminoquinolones as anticancer agents (Scheme 9).35
Scheme 9. Transformation of a nitro group
The vicinal functions of 4-hydroxy-3-nitro-2-quinolone are used for construction of a fused
ring on the [c]-face. The reduction of the nitro group with zinc in acetic acid followed by
acylation with acetic anhydride, and the succeeding cyclization successfully affords an
isoxazoloquinoline (Scheme 10).36
Scheme 10. Construction of the [c]-fused isoxazole ring
An efficient method for preparing diarylamines is developed by treating nitroarenes with
aryl Grignard reagents (Scheme 11).13
Scheme 11. Reaction of nitroarene and aryl Grignard reagent
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5,8-Dimethoxy-6-nitroquinolone reacts with aryl Grignard reagents to furnish 6-arylamino
derivatives (Scheme 12). The subsequent palladium-catalyzed successive oxidative coupling
and demethylation yield pyrido[3,2-b]carbazolequinones with potential anti-tumor activity.37
Scheme 12. Arylamination of nitroquinolone followed by cyclization
3.3.2 Activation of the vicinal position by a nitro group
The vicinal position of the nitro group is especially electron-deficient because of its both
electron-withdrawing inductive and resonance effects. The nitro group at the 3-position of
MeQone markedly activates a chloro group at the 4-position, promoting the nucleophilic
substitution of the chloro group to give 4-functionalized 3-nitroquinolones (Table 4). By this
method, functional groups such as fluoro, alkoxy, amino, azide, alkylthio groups, and
malonates are introduced at the 4-position.38-40
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Table 4. Nucleophilic substitution of 4-chloro-3-nitroquinolone.
Nucleophile Nu Yield/% Nucleophile Nu Yield/%
KF / 18-Crown-6 F 95 PhNH2 PhNH 98
MeONa MeO 85 PhCH2NH2 PhCH2NH 94
PhOH / K2CO3 PhO 93 piperidine piperidino 96
EtSH / NEt3 EtS 95
CH2(COOMe)2/
K2CO3
CH(COOMe)2 95
PhSH + pyridine PhS 96
CH2(COOEt)2 /
K2CO3
CH(COOEt)2 94
NaN3 N3 95
AcCH2COOEt /
K2CO3
AcCHCOOEt 90
NH3 NH2 91
NCCH2COOEt/
K2CO3
NCCHCOOEt 95
On the other hand, when 1,2-ethanedithiol is used as the nucleophile in this transformation,
substitution followed by intramolecular conjugate addition proceeds to afford spiro thioacetal
(Scheme 13).41
Scheme 13. Tandem addition of ethanedithiol leading to a spiro compound
The malonate moieties at the 4-position of on the MeQone ring are activated by the
adjacent nitro group, and then an unsymmetrical amide ester is readily formed in the presence
of morpholine (Scheme 14).39 Interestingly, the reactivity of quinolylmalonate varies with the
alkoxy group of the ester function. While dealkoxycarbonylation proceeds in the case of
diethyl ester, an isoxazole ring is constructed on the [c]-face in the case of the dimethyl
ester.40
14
Scheme 14. Chemical transformation of malonylquinolones
Furthermore, when 5,8-dimethoxy-6-nitroquinolone is subjected to reaction with vinyl/aryl
Grignard reagents, the substitution of the methoxy group with vinyl or aryl group at the
5-position is also facilitated by the vicinal nitro group (Scheme 15).37,42
Scheme 15. Substitution with Grignard reagents
15
3.3.3 Cycloaddition of nitroalkene moiety
Diels-Alder reactions at the nitroalkene moiety of 3-nitrated MeQones with electron-rich
dienes lead to benzoquinoline derivatives, which undergo aromatization accompanied by
elimination of a nitrous acid (Scheme 16). Although this method enables simultaneous C-C
bond formation at the 3- and 4-positions of the MeQone framework, severe reaction
conditions must be employed.43,44 To the contrary, trinitroquinolone (TNQ) quite easily
undergoes cycloaddition under mild conditions as detailed in the next section.
Scheme 16. Diels-Alder reactions of 3-nitroquinolones
3.4 High reactivity of 1-methyl-3,6,8-trinitro-2-quinolone
Interested in the abovementioned results and with the aim of achieving versatile
functionalization of the MeQone framework, our group have always been focusing on the
chemistry of nitrated MeQones, especially highly electron-deficient
1-methyl-3,6,8-trinitro-2-quinolone (abbreviated as TNQ). TNQ exhibits significantly high
reactivity, and is used as a key precursor for versatile functionalizedMeQone derivatives.13
Indeed, TNQ reacts with versatile nucleophiles to undergo cine-substitution to prepare
4-functionalized 6,8-dinitro-1-methyl-2-quinolones (4FDNQ). Initially, the nucleophilic
substitution proceeds at the 4-position of TNQ to form adduct intermediate, then the proton is
transferred from basic group to the 3-position of adduct intermediate affording
3,4-dihydroquinolone. As a result of elimination of the vicinal nitro group, 4FDNQ is formed
16
(Scheme 17). This reaction enables the functionalization at the 4-position of TNQ with
forming a C-C or a C-N bond regioselectively.
Scheme 17. cine-substitution of TNQ
3.4.1 cine-Substitution of TNQ with carbon nucleophiles
Direct C-C bond formation at the 4-position of the MeQone framework is achieved upon
treatment of TNQ with carbon nucleophiles, including 1,3-dicarbonyl compounds,
nitroalkanes, aldehydes/ketones, enamines and phenoxides, leading to versatile skeletons.
When 1,3-dicarbonyl compounds such as β-diketones, β-keto esters and β-diesters easily
react with TNQ in the presence of triethylamine at room temperature, dicarbonyl methyl
groups are smoothly introduced at the 4-position (Table 5).22
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Table 5. Reactions of TNQ with 1,3-dicarbonyl compounds
R1 R2 Yield/%
CH2COOEt OEt 26
-(CH2)3- 60
Me Me 88
Me OEt 93
OEt OEt 93
Nitroalkylation of TNQ with a nitroalkane as a C-H acid proceeds in the presence of
triethylamine. While primary nitroalkanes undergo the cine-substitution efficiently, secondary
nitroalkanes with steric hindrance are less reactive, requiring longer reaction time (Table 6).45
Table 6. Reactions of TNQ with nitroalkanes
R1 R2 Yield/%
Me H 80
Et H 98
Me Me 77
Functionalized ketones such as aliphatic, alicyclic, aromatic, and heteroaromatic ketones
also work well as carbon nucleophiles in the cine-substitution of TNQ, giving acylmethylated
product (Table 7).46 Since the acylmethyl group is expected to serve as a scaffold for further
chemical transformations, this method would be useful for construction of a new libraries of
18
compounds having aMeQone framework.
Table 7. Reactions of TNQ with aldehydes/ketones
R1 R2 R3 Yield/%
H Me Me 41
2-furyl H H 45
2-pyridyl H H 74
Me H H 83
Ph H H 83
Et Me H 18
Ph Ph H 69
Ph Me H 77
-(CH2)4- H 82
Treatment of TNQ with enamines lead to the formation of morpholinium salts, in which
intermediate iminium ions are hydrolyzed and deprotonation at the 3-position by the liberated
morpholine (Table 8).46
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Table 8. Reactions of TNQ with enamines
R1 R2 R3 Yield/%
-(CH2)3- H 40
Ph Me H 43
Ph Ph H 98
H Me H 98
A combination of electrophilic TNQ and nucleophilic phenoxide ions results in the direct
arylation of the MeQone framework (Table 9).47 While phenol, 2-methylphenol, and
4-methoxyphenol undergo double substitution to afford bis(quinolyl)phenols, bulky or
electron-poor phenoxides give monoquinolylphenols as a sole product. As it is quite difficult
to straightforwardly introduce an aryl group into the MeQone framework, this method is
surely regarded as one of the more useful modifications.
20
Table 9. Reactions of TNQ with phenoxides
R Product Yield/%
H a 51
2-Me a 91
4-MeO b 67
3-Me c 35
4-Me c 82
4-NO2 c 36
O-Phenylene d 75
Nitriles represent an important structural motif in medicinal chemistry due to their versatile
biological activities.48 Besides, nitriles have also been recognized as extremely useful
intermediates for the preparation of other useful building blocks.49 Therefore, numerous
efforts have been dedicated to the development of methods for introducing cyano groups into
organic molecules.50 Inspired by the above methods for direct C-C bond formation on the
MeQone framework, potassium cyanide was used as a carbon nucleophile to react with TNQ
to prepare 4-cyano-2-quinolone derivative together with a dimeric product (Scheme 17).25
Scheme 17. Reaction of TNQ with KCN
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When trimethylsilyl cyanide/cesium fluoride was employed to replace potassium cyanide,
cyanoquinolone was formed as the sole product without any detectable dimer (Scheme 18).25
While conventional strategies for cyanation of the MeQone framework often involve
multi-step reactions or severe conditions, the present method enables the cyanation through
facile schemes.51 Thus, this protocol will be used as a powerful tool for constructing a library
of versatile MeQone derivatives by the further chemical conversion of the cyano and nitro
functionalities.31,49
Scheme 18. Reaction of TNQ with Me3SiCN
3.4.2 cine-Substitution of TNQ with amines
When amines as the nucleophiles are reacted with TNQ, a C-N bond is formed at the
4-position (Table 10).52 Initially, a Meisenheimer complex is formed by the conjugate
addition of primary amines at the 4-position of TNQ and the subsequent deprotonation of
another molecule of amine. When Meisenheimer complex is heated, a small amount of
cine-substituted product is formed, together with recovery of a large amount of TNQ. In this
reaction, 3,4-dihydroquinolone is formed under equilibrium at reflux temperature, from which
the former product is afforded by deprotonation at the 4-position via route a, and the latter
product is a result of deprotonation at the 3-position via route b.
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Table 10. Reactions of TNQ with primary amines
R
Yield/%
ammonium cine-substituted product
Pr 71 36
i-Bu 74 29
s-Bu 56 0
t-Bu 74 0
On the other hand, when TNQ is treated with less nucleophilic tertiary amines,
dimerization proceeds to afford a dimer connected between the 3- and the 4’-positions (Table
12).53 The length and the number of alkyl chains of the amine have a significant impact on the
reaction rate. While tributylamine causes the reaction faster than tripropylamine and
triethylamine, no reaction proceeds in the cases of trimethylamine and tribenzylamine.
Therefore, more than two long alkyl chains are necessary for the reaction to occur efficiently.
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Table 12. Reactions of TNQ with tertiary amines
R1 R2 R3 Yield/%
Me Me Bu 18
Et Et Et 34
Pr Pr Pr 76
Bu Bu Me 79
Bu Bu Bu 93
3.4.3 Cycloaddition of TNQ
Nitro compounds have been converted into various cyclic compounds via cycloaddition
reactions. In particular, nitroalkenes have proved to be useful in Diels-Alder reactions. Under
thermal conditions, they behave as electron-deficient dienophiles and react with dienes to
afford 3-nitrocyclohexenes (Scheme 19, a).54 Nitroalkenes can also act as heterodienes and
react with olefins in the presence of Lewis acid to yield alkyl nitronates, which undergo the
[3+2] cycloaddition (Scheme 19, b).55 Thus, nitro compounds play important roles in the
chemistry of cycloaddition reactions.
Scheme 19. Dual reactivity of nitroalkene in the cycloaddition
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The pyridone moiety of TNQ exhibits nitroalkene property rather than aromaticity, which
means that the C3-C4moiety could undergo cycloaddition with electron-rich dienes under mild
conditions, compared with Diels-Alder reactions of 3-nitroquinlone and 3,6-dinitroquinolone
with electron-rich dienes require quite severe conditions.43,44 Indeed, cycloaddition of TNQ
with cyclopentadiene proceeds to furnish tetracyclic compounds (Scheme 20).56 The
cycloadduct aromatizes with elimination of nitrous acid in the presence triethylamine.
Scheme 20. Diels-Alder reaction of TNQ with cyclopentadiene
On the other hand, the nitroalkene moiety of TNQ also serves as a heterodiene in the
reaction with ethoxyethene to construct a fused oxazine ring. The subsequent treatment of the
cycloadduct with alcohol under heating conditions yields an acetal through a ring opening
reaction (Scheme 21).57
Scheme 21. Cycloaddition of TNQ with ethoxyethene in the absence of Et3N
Interestingly, a quinolino[3,4-b][1,9]diazaphenanthrene derivative is formed when the same
substrates are treated in the presence of triethylamine (Scheme 22).57
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Scheme 22. Cycloaddition of TNQ with ethoxyethene in the presence of Et3N
In the present process, the former intermediate oxime behaves as an electron-rich
heterodiene and the latter TNQ behaves as an electron-poor dienophile. This mechanism is
supported by the experimental fact that polycyclic diazaphenanthrene is isolated in a moderate
yield as a result of cycloaddition of TNQ with α,β-unsaturated oxime as the electron-rich
heterodiene (Scheme 23).57
Scheme 23. Cycloaddition of TNQ with ethoxyethene in the presence of Et3N
4. Research purpose
Although MeQone derivatives play an important role in both medicinal chemistry and
organic synthesis, only few methods for direct functionalization of the MeQone framework
are currently available because of the inertness caused by the aromaticity. Accordingly,
development of a facile method for directly modifying the MeQone framework is one of the
highly demanded projects.
On the other hand, a variety of unnatural MeQone derivatives are easily prepared from
nitroquinolones. Especially, TNQ is highly reactive in direct C-C or C-N bond formation at
the 4- and 3-positions through cine-substitution or cycloaddition. However, in these protocols,
the substrate is only restricted to the highly electron-deficient quinolone TNQ. In order to
improve the synthetic utility of this method for directly modifying the MeQone framework,
novel functionalization protocols using diversely functionalized nitroquinolones are necessary
to be explored.
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In this thesis, direct 4-alkoxylation and 3-halogenation of the MeQone framework is
achieved by a sequential treatment of 3-nitrated MeQone with sodium alkoxide and
N-halosuccinimide (Scheme 24, a). Moreover, direct amino-halogenation and aziridination of
the MeQone framework was also achieved by replacing sodium alkoxides with amines as
nucleophiles (Scheme 24, b). In these two methods, based on the employment of alkoxide
anions or amines as nucleophiles, the scope of nitroquinolones has been successfully
expanded to 3-nitrated MeQones with different substituents on the benzene ring. Therefore,
these protocols will be surely useful as powerful tools for constructing a compound library of
MeQones with the purpose of finding bioactive compounds.
Scheme 24. Direct and vicinal functionalization of 3-nitratedMeQones
References
1. Akihisa, T.; Yokokawa, S.; Ogihara, E.; Matsumoto, M.; Zhang, J.; Kikuchi, T.; Koike, K.;
Abe, M. Chem. Biodiversity., 2017, 14, e1700105.
2. Seya, K.; Miki, I.; Murata, K.; Junke, H.; Motomura, S.; Araki, T.; Itoyama, Y.; Oshima, Y.
J. Pharm. Pharmacol., 1998, 507, 803.
3. Kamikawa, T.; Hanaoka, Y.; Fujie, S.; Saito, K.; Yamagiwa, Y.; Fukuhara, K.; Kubo, I.
Bioorg. Med. Chem., 1996, 4, 1317.
4. Chen, I. S.; Wu, S. J.; Tsai, I. L.; Wu, T. S.; Pezzuto, J. M.; Lu, M. C.; Chai, H.; Suh, N.;
Teng, C. M. J. Nat. Prod., 1994, 57, 1206.
5. Ito, C.; Itoigawa, M.; Furukawa, A.; Hirano, T.; Murata, T.; Kaneda, N.; Hisada, Y.; Okuda,
K.; Furukawa, H. J. Nat. Prod., 2004, 67, 1800.
27
6. Joseph, B.; Darro, F.; Béhard, A.; Lesur, B.; Collignon, F.; Decaestecker, C.; Frydman, A.;
Guillaumet, G.; Kiss, R. J. Med. Chem., 2002, 45, 2543.
7. Murray, J. K.; Balan, C.; Allgeier, A. M.; Kasparian, A.; Viswanadhan, V.; Wilde, C.;
Allen, J. R.; Yoder, S. C.; Biddlecome, G.; Hungate, R. W.; Miranda, L. P. J. Comb. Chem.,
2010, 12, 676.
8. Hassan, M. M.; Farouk, O. J. Heterocycl. Chem., 2017, 54, 3133.
9. Patel, P. K.; Patel, R. V.; Mahajan, D. H.; Parikh, P. A.; Mehta, G. N.; Pannecouque, C.;
Clercq, E. D.; Chikhalia, K. H. J. Heterocycl. Chem., 2014, 51, 1641.
10. (a) Hassan, M. M.; Abdel-Kariem, S, M.; Ali, T. E. Phosphorus Sulfur and Silicon and the
Related Elements 2017, 192, 866; (b) Asghari, S.; Ramezani, S.; Mohseni, M. Chin. Chem.
Lett., 2014, 25, 431; (c) Audisio, D.; Messaoudi, S.; Cojean, S.; Peyrat, J. F.; Brion, J. D.;
Bories, C.; Huteau, F.; Loiseau, P. M.; Alami, M. Eur. J. Med. Chem., 2012, 52, 44; (d)
Tani, M.; Gyobu, Y.; Sasaki, T.; Takenouchi, O.; Kawamura, T.; Kamimura, T.; Harada, T.
J. Antibiot., 2004, 57, 83.
11. Menezes, J. C.; Faustino, M. A.; Oliveira, K. T.; Uliana, M. P.; Ferreira, V. F.; Hackbarth,
S.; Roder, B.; Teixeira, T. T.; Furuyama, T.; Kobayashi, N.; Silva, A. M.; Neves, M. G.;
Cavaleiro, J. A. Chem. Eur. J., 2014, 20, 13644.
12. Yelenich, O. V.; Lytvyn, R. Z.; Skrypska, O. V.; Pitkovych, K. Y.; Kachkovskii, A. D.;
Obushak, M. D.; Yagodinets, P. I. Russ. J. Gen. Chem., 2016, 86, 1838.
13. Nishiwaki, N. Molecules 2010, 15, 5159.
14. Chen, Y.; Wang, F.; Jia, A.; Li, X. Chem. Sci., 2012, 3, 3231.
15. Nakatani, A.; Hirano, K.; Satoh, T.; Miura, M. Chem. Eur. J., 2013, 19, 7691.
16. Feng, Z.; Min, Q.; Zhao, H.; Gu, J.; Zhang, X. Angew. Chem. Int. Ed., 2014, 53, 1.
17. Nakatani, A.; Hirano, K.; Satoh, T.; Miura, M. J. Org. Chem., 2014, 79, 1377.
18. Elenicha, O. V.; Lytvyn, R. Z.; Skripskaya, O. V.; Lyavinets, O. S.; Pitkovych, K. E.;
Yagodinets, P. I.; Obushak, M. D. Russ. J. Org. Chem., 2016, 52, 373.
19. Li, J.; Hu, D.; Liang, X.; Wang, Y.; Wang, H.; Pan, Y. J. Org. Chem., 2017, 82, 9006.
20. (a) Le, S. T.; Asahara, H.; Nishiwaki, N. J. Org. Chem., 2015, 80, 8856; (b) Halimehjani,
A. Z.; Namboothiri, I. N. N.; Hooshmand, S. E. RSC Adv., 2014, 4, 48022; (c)
Halimehjani, A. Z.; Namboothiri, I. N. N.; Hooshmand, S. E. RSC Adv., 2014, 4, 51794.
21. (a) Asahara, N.; Nishiwaki, N. Oleoscience 2015, 15, 165; (b) Asahara, M.; Ohtsutsumi,
M.; Tamura, M.; Nishiwaki, N.; Ariga, M. Bull. Chem. Soc. Jpn., 2005, 78, 2235.
22. Nishiwaki, N.; Tanaka, A.; Uchida, M.; Tohda, Y.; Ariga M. Bull. Chem. Soc. Jpn., 1996,
69, 1337.
28
23. Olah, G. A.; Malhotra, R.; Narang, S. C. Nitration; VCH: New York, 1990.
24. Nishiwaki, N.; Sakashita, M.; Azuma, M.; Tanaka, C.; Tamura, M.; Asaka, N.; Hori, K.;
Tohda, Y.; Ariga, M. Tetrahedron 2002, 58, 473.
25. Chen, X.; Kobiro, K.; Asahara, H.; Kakiuchi, K.; Sugimoto, R.; Saigo, K.; Nishiwaki, N.
Tetrahedron 2013, 69, 4624.
26. Igoe, N.; Bayle, E. D.; Tallant, C.; Fedorov, O.; Meier, J. C.; Savitsky, P.; Rogers, C.;
Morias, Y.; Scholze, S.; Boyd, H.; Cunoosamy, D.; Andrews, D. M.; Cheasty, A.;
Brennan, P. E.; Müller, S.; Knapp, S.; Fish, P. V. J. Med. Chem., 2017, 60, 6998.
27. Haga, T.; Nagano, H.; Morita, K.; Sato, M. Jpn. Kokai Tokkyo Koho 1986, JP
61194072A.
28. Roschger, P.; Flala, W.; Stadlbauer, W. J. Heterocycl. Chem., 1992, 29, 225.
29. Buckle, D. R.; Cantello, B. C. C.; Smith, H.; Spicer, B. A. J. Med. Chem., 1975, 18, 726.
30. Nabih, I.; Nasr, M. J. Pharm. Sci., 1966, 55, 736.
31. Ono, N. The Nitro Group in Organic Synthesis; Wiley-VCH: New York, 2001.
32. Yadav, M. R.; Nagaoka, M.; Kashihara, M.; Zhong, R.; Miyazaki, T.; Sakaki, S.; Nakao,
Y. J. Am. Chem. Soc., 2017, 139, 9423.
33. Inoue, F.; Kashihara, M.; Yadav, M. R.; Nakao, Y. Angew. Chem. Int. Ed., 2017, 56,
13307.
34. Cismesia, M. A.; Ryan, S. J.; Bland, D. C.; Sanford, M. S. J. Org. Chem., 2017, 82, 5020.
35. Igoe, N.; Bayle, E. D.; Fedorov, O.; Tallant, C.; Savitsky, P.; Rogers, C.; Owen, D. R.;
Deb, G.; Somervaille, T. C. P.; Andrews, D. M.; Jones, N.; Cheasty, A.; Ryder, H.;
Brennan, P. E.; Müller, S.; Knapp, S.; Fish, P. V. J. Med. Chem., 2017, 60, 668.
36. Steinschifter, W.; Fiala, W.; Stadlbauer, W. J. Heterocycl. Chem., 1994, 31, 1647.
37. Sanchez, J. D.; Avebdano, C.; Menendez, J. C. Synlett 2008, 1371.
38. Roschger, P.; Flala, W.; Stadlbauer, W. J. Heterocycl. Chem., 1992, 29, 225.
39. Stadlbauer, W.; Täubl, A. E.; Dang, H. V.; Reidlinger, C.; Zangger, K. J. Heterocycl.
Chem., 2006, 43, 117.
40. Täubl, A. E.; Stadlbauer, W. J. Heterocycl. Chem., 1997, 34, 989.
41. Drozd, V. N.; Knyazev, V. N.; Nam, N. L.; Lezina, V. P.; Mozhaeva, T. Y.; Savel’ev, V.
L. Russ. J. Org. Chem., 1994, 653.
42. Egris, R.; Villacampa, M.; Menendez, J. C. Chem. Eur. J., 2009, 15, 10930.
43. Fujita, R.; Yoshisuji, T.; Wakayanagi, S.; Wakamatsu, H.; Matsuzaki, H. Chem. Pharm.
Bull., 2006, 54, 204.
44. Fujita, R.; Watanabe, K.; Yoshisuji, T.; Kabuto, C.; Matsuzaki, H.; Hongo, H. Chem.
29
Pharm. Bull., 2001, 49, 893.
45. Asahara, M.; Ohtsutsumi, M.; Ariga, M.; Nishiwaki, N. Heterocycles 2009, 78, 2851.
46. Asahara, M.; Katayama, T.; Tohda, Y.; Nishiwaki, N.; Ariga, M. Chem. Pharm. Bull.,
2004, 52, 1134.
47. Aasahara, M.; Ohtsutsumi, M.; Tamura, M.; Nishiwaki, N.; Ariga, M. Bull. Chem. Soc.
Jpn., 2005, 78, 2235.
48. Brunton, L.; Chabner, B.; Knollman, B. Goodman and Gilman’s The Pharmacological
Basis of Therapeutics; MacGraw-Hill: New York, 2010.
49. (a) Larock, R. C. Comprehensive Organic Transformations; Wiley: New York, 1999; (b)
Trost, B. M.; Fleming, I. Comprehensive Organic Synthesis; Pergamon Press: Oxford,
1991; (c) Rappoport, Z. The Chemistry of the Cyano Group; Wiley: New York, 1971.
50. (a) Kim, J.; Kim, H. J.; Chang, S. Angew. Chem. Int. Ed., 2012, 51, 11948; (b) Ding, S.;
Jiao, N. Angew. Chem. Int. Ed., 2012, 51, 9226; (c) Anbarasan, P.; Schareina, T.; Beller,
M. Chem. Soc. Rev., 2011, 40, 5049; (d) Wang, W. ; Liu, X.; Lin, L.; Feng, X. Eur. J.
Org. Chem., 2010, 4751.
51. (a) Zhang, L.; Wen, Q.; Jin, J.; Wang, C.; Lu, P.; Wang, Y. Tetrahedron 2013, 69, 4236.
(b) Yeung, P. Y.; So, C. M.; Lau, C. P.; Kwong, F. Y. Angew. Chem. Int. Ed., 2010, 49,
8918.
52. Asahara, M.; Nagamatsu, M.; Tohda, Y.; Nishiwaki, N.; Ariga, M. ARKIVOC 2005, (i), 1.
53. Nishiwaki, N.; Sakashita, M.; Azuma, M.; Tanaka, C.; Tamura, M.; Asaka, N.; Hori, K.;
Tohda, Y.; Ariga, M. Tetrahedron 2002, 58, 473.
54. (a) Terrier, F.; Sebban, M.; Goumont, R.; Hallé, J. C.; Mountriers, G.; Cangelosi, I.;
Buncel, E. J. Org. Chem., 2000, 65, 7391.
55. (a) Hallé, J. C.; Vichard, D.; Pouet, M. J.; Terrier, F. J. Org. Chem., 1997, 62, 7178; (b)
Denmark, S. E.; Kesler, B. S.; Moon, Y. C. J. Org. Chem., 1992, 57, 4912.
56. Asahara, M.; Nagamatsu, M.; Tohda, Y.; Nishiwaki, N.; Ariga, M. J. Heterocycl. Chem.,
2004, 41, 803.
57. Asahara, M.; Shibano, C.; Koyama, K.; Tamura, M.; Tohda, Y.; Ariga, M. Tetrahedron
Lett., 2005, 46, 7519.
30
Part II
1. Property of aziridines
Three-membered aza-heterocyclic compounds, aziridines, represent an important structural
motif in a large variety of natural products such as ficellomycin, porfiromycin, mitomycin,
maduropeptin, azinomycin, and miraziridine, and they reveal a series of biological activities,
such as antitumor, antimicrobial, and antibiotic activity (Figure 1).1-4 Therefore, isolation,
structural characterization, and total synthesis of aziridine-containing natural products have
received considerable attention from organic chemists in recent years.1
Figure 1. Aziridine rings in bioactive natural products
Additionally, a multitude of unnatural compounds containing aziridine rings have also been
synthesized and reported to exhibit varied and extensive biological activities such as
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antileishmanial activity,5 antibacterial activity,6 estrogenic activity,7 insecticidal activity,8 and
antitumor activity.9
Figure 2. Examples of synthetic bioactive aziridines
Functionalized aziridines are not only biologically interesting components but also serve as
versatile building blocks for the synthesis of other nitrogen-containing compounds.1,10 The
instability of aziridines is attributable to the combined effects of bond shortening and angle
compression, and the reactivity is associated with the presence of the highly electronegative
nitrogen atom possessing basicity and nucleophilicity.11 Moreover, the exocyclic
N-substituents also have an important impact on the property and reactivity of the aziridine
ring.11
Since aziridines are the nitrogen analogues of epoxides, they also display similar
electrophilic reactivity.11 As a result of ring strain, aziridines undergo various nucleophilic
ring opening reactions with various nucleophiles to yield nitrogen-containing compounds
such as substituted amines, diamines, amino alcohols and amino acids (Scheme 1).12-15
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Scheme 1. Ring opening of aziridines with nucleophiles
Nitrogen-containing heterocycles present as an important motif in both medicinal chemistry
and organic synthesis.16-17 During the last decades, a number of studies have been devoted to
the synthesis of a large variety of aza-heterocycles with highly structural diversity and
complexity.18 Among the several strategies available, cycloaddition is one of the most
efficient approaches since multiple bonds can be created in one step with high efficiency, site-
or stereoselectivity, and atom economy.19 1,3-Dipolar cycloaddition has been disclosed as a
prevalent method for the construction of heterocyclic five-membered rings in organic
synthesis.19c,20
Aziridines are the one of the most widely used synthetic precursors for 1,3-dipoles through
C-C or C-N bond-breaking.21 Therefore, functionalized aziridines undergo [3+2]
cycloaddition with various dipolarophiles, such as alkenes, alkynes, and aldehydes to afford
five-membered aza-heterocycles (Scheme 2).21
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Scheme 2. Aziridines in 1,3-dipolar cycloaddition
Furthermore, a substantial number of functionalized aziridines can be also transformed into
valuable compounds through ring expansion reactions (Scheme 3),22 multi-component
coupling reactions (Scheme 4),23 and rearrangement (Scheme 5).24
Scheme 3. Ring expansion reaction of aziridines
Scheme 4. Three-component coupling involving aziridines
Scheme 5. Rearrangement of aziridines
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Among the functionalized aziridines, C-nitroaziridines play an important role in chemical
transformations because of the strongly electron-withdrawing ability of the nitro group.
Treatment of 2,2’-dinitro-2,2’-diaziridines with sodium iodide affords
3,3’-bi(1,2,4-oxadiazole) through C-C bond cleavage (Scheme 6).25 This kind of ring opening
can occur because of the driving effect of the nitro group which is able to delocalize the
nagative charge in the intermediate anion.
Scheme 6. Nitro group driven ring enlargement of aziridine ring
In addition, a nitro group is a versatile precursor for diverse functionalities, providing
possiblity of C-nitroaziridines for further transfomation.26 Hence, the development of facile
methods for the preparation of C-nitroaziridines and efficient transformations of
C-nitroaziridines into other useful compounds is of great interest.
2. Synthesis of C-nitroaziridines
Direct aziridination of nitroalkenes is a powerful tool to introduce a nitrogen functionality
onto hydrocarbon scaffolds, leading to the formation of C-nitroaziridine rings. Thus, direct
aziridination of nitroalkenes for synthesizing diversely structural C-nitroaziridines has
captured considerable attention in modern organic synthesis.
2.1 Synthesis of N-Imido-C-nitroaziridines
N-Amino aziridines can be found in a variety of biologically active compounds.8 Moreover,
N-aminoaziridines serve as synthetic precursors of α- and β-hydrazino acids.27,28 They also
can be regarded as constrained analogues of those hydrazino acids, providing a growing
interest in the preparation of peptidomimetics with particular structural and biological
properties such as antibiotic activity29 and inhibition of the human leukocyte elastate.30
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Treatment of nitroalkenes with N-aminoimides in the presence of an oxidant affords
N-imido-C-nitroaziridines through the oxidative addition (Scheme 7).31,32
Scheme 7. Synthesis of N-imido-C-nitroaziridines through oxidative addition
2.2 Synthesis of N-alkoxycarbonyl-C-nitroaziridines
Electron-deficient nitroalkenes undergo aza-MIRC (Michael Initiated Ring Closure)
reactions with NsONHCO2Et or TsONHCO2Et in the presence of a base, giving an access to
N-alkoxycarbonyl-C-nitroaziridines (Scheme 8).33
Scheme 8. Aziridination of nitroalkenes with NsONHCO2Et or TsONHCO2Et
2.3 Synthesis of N-aryl-C-nitroaziridines
Halonitroalkenes containing highly electrophilic C=C bond are widely used as reactive
synthons for furnishing various types of heterocycles.34 A two-step method was developed for
the synthesis of N-arylated aziridines invovling the nucleophilic addition of anilines to highly
electron-deficient 1-bromo-3,3,3-trichloro-1-nitropropene and base-promoted
dehydrobromination of the resulting adducts (Scheme 9).35 Moreover, the use of aromatic
diamines in this transformation successfully affords bis-aziridines.36
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Scheme 9. Aziridination of nitroalkenes with aromatic amines
As an alternative, N-aryl-C-nitroaziridines can also be obtained upon treatment of
3-nitroacrylate or 3-bromo-3-nitroacrylate with phenyl azide which affords a nitrene through
the loss of a molecular nitrogen (Scheme 10).35
Scheme 10. Aziridination of nitroalkenes with phenyl azide
3. Research purpose
Although many methods for the synthesis of N-functionalized C-nitroaziridines have been
disclosed, there is no report on the synthesis of N-alkyl-C-nitroaziridines from nitroalkenes
through direct aziridination, except for the multistep synthesis via β-bromonitroalkenes;
however, the substrate scope is not investigated further (Scheme 11).38
Scheme 11. Synthesis of N-alkyl-C-nitroaziridines through multistep schemes
Thus, a facile and efficient aziridination of nitroalkenes for the synthesis of N-alkylated
nitroaziridines is of great interest.
As part of my continuing interest in methods for the direct functionalization of the
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2-quinolone framework, we achieved the direct aziridination by sequential treatment of
3-nitro-1-methyl-2-quinolones with an amine and N-chlorosuccinimide (NCS), which is
described in detail in Chapter 3 (Scheme 12).
Scheme 12. Direct aziridination of 3-nitro-1-methyl-2-quinolones
Inspired by this protocol, direct aziridination of nitroalkenes for preparing
N-alkyl-C-nitroaziridines is developed by sequential treatment with aliphatic amine and NCS
(Scheme 13).
Scheme 13. Synthesis of N-alkyl-C-nitroaziridines
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Chapter 2. Direct 4-Alkoxylation and 3-Halogenation of
the 1-Methyl-2-quinolone Framework
Direct 4-alkoxylation and 3-chlorination of the MeQone framework was achieved under
mild conditions by a sequential treatment of 3-nitrated MeQones with sodium alkoxide and
N-chlorosuccinimide. Moreover, a succinimide group could be introduced instead of an
alkoxy group at the 4-position, affording a masked form of the 4-amino-3-chloro-2-quinolone
derivative.
Figure 1. Direct functionalization of theMeQone framework
1. Introduction
The 1-methyl-2-quinolone (MeQone) framework is present in more than 300 quinoline
alkaloids exhibiting versatile biological activities.1 In addition to the synthesis of naturally
occurring MeQones, the synthesis of unnatural MeQone derivatives has attracted much
attention because it allows access to new biologically active compounds,2 among which
MeQone derivatives possessing a hydroxy/an alkoxy group at the 4-position are important.3
Moreover, the enol partial structure is a useful scaffold for the modification of the MeQone
framework.3 Despite their usefulness, 4-alkoxylated MeQones have not been prepared by the
direct alkoxylation of MeQone because of the inertness caused by the aromaticity.4 Instead,
an alkoxy group has been introduced into MeQone by the alkylation5 of 4-hydroxylated
MeQones constructed from anthranilic acid derivatives6 or N-methylanilines.7 However, it is
difficult to modify the MeQone framework because of the low availability of the
corresponding starting materials. Hence, the development of a direct alkoxylation method for
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theMeQone framework is in high demand.
We have shown that 1-methyl-3,6,8-trinitro-2-quinolone (TNQ) is highly reactive among
MeQones to form either a C–C or a C–N bond at the 4-position regioselectively or to undergo
a cycloaddition reaction readily.8-11 Inspired by these results, we envisioned that a direct C–O
bond formation at the 4-position of MeQone would be possible by the treatment of 3-nitrated
MeQones including TNQ with an alkoxide ion. In this case, it is necessary to trap the anionic
adduct intermediate by an electrophile because a heteronucleophile is easily eliminated even
though it adds to TNQ.10 We focused on the halogenation because MeQones bearing both an
alkoxy and a halo group serve as important precursors for various types of compounds.12,13
Halogenation at the 3-position of the MeQone framework is usually achieved by the
treatment of 4-hydroxylated MeQones with halogenating agents such as thionyl chloride,14
N-bromosuccinimide (NBS),15 bromine,16 N-iodosuccinimide (NIS)13 and iodine.17 However,
only a few examples of the halogenation of 4-alkoxylated MeQone have been reported,12,13
and there is no report on 3-chlorination. Hence, direct bis-functionalization, 4-alkoxylation
and 3-halogenation, using 3-nitrated MeQones would afford a new synthetic intermediate for
the construction of a new compound library ofMeQone derivatives.
2. Results and Discussion
2.1 Micheal addition of TNQ with sodium alkoxide
To evaluate the potential for vicinal functionalization, TNQ was chosen as a model
substrate. When TNQ was treated with sodium methoxide in methanol at room temperature,
the color of the solution immediately became reddish yellow, and a yellow solid precipitated
in the reaction mixture (Scheme 1). In the 1H NMR of solid 1a collected by filtration, two
new singlet signals appeared at 3.15 and 5.96 ppm instead of the disappearance of the singlet
at 9.26 ppm assigned to the proton at the 4-position of TNQ. This spectral change indicated
that a methoxide ion was added to the 4-position of TNQ, as confirmed by the correlations of
the methoxy group with H-4 and H-5 in the 1H−1H NOESY 2D spectrum. Furthermore, a
signal for C-4 was observed at 73 ppm in the 13C NMR spectrum, indicating the change from
the sp2 carbon to the sp3 carbon. Although 1a was confirmed to have a methoxylated structure,
TNQ was reproduced by the treatment of 1a with hydrochloric acid. Moreover, 1a was highly
soluble into water. Hence, product 1a exists in an anionic form stabilized by the adjacent nitro
and carbonyl groups. Sodium ethoxide caused a similar reaction, affording 1b quantitatively.
On the other hand, precipitates were not observed during the reaction in other alcohols;
however, the similar formation of the corresponding adducts 1 was confirmed by the 1H NMR
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spectrum of the residue after the removal of the solvent.
Scheme 1. 4-Alkoxylation of TNQ
2.2 Optimization of the chlorination conditions
Next, adduct 1a was reacted with N-chlorosuccinimide (NCS) in dichloromethane,
affording the 3-chlorinated product, 4-methoxy-3-chloro-1-methyl-6,8-dinitro-2-quinolone
(MeO-Cl-DNQ), in 45% yield (Table 1, entry 1). The structure was confirmed from the
following spectral data. In the MS spectrum, the molecular ion peaks (313 and 315) were
observed in a 3:1 intensity ratio, indicating that a chlorine atom was introduced. Although the
H-4 signal disappeared, the signal of the methoxy group remained in the 1H NMR.
Furthermore, the signal assigned to C-4 shifted from 73 to 160 ppm in the 13C NMR
spectrum.
Polar solvents were suitable for this reaction; the yield was increased up to 85% when
acetonitrile was used (entries 2−5). The methoxy group of 1a did not exchange with an ethoxy
group even though the reaction was carried out in ethanol (entry 3). In each case, 4-imidated
product 2 was also obtained and became the major product when DMF was used as the
solvent (entry 4).
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Table 1. Solvent effect on the chlorination and imidation
Entry Solvent
Yield/%
MeO-Cl-DNQ 2
1 CH2Cl2 45 trace
2 THF 83 11
3 EtOH 76 7
4 DMF 35 40
5 MeCN 85 10
2.3 Study on alkoxide scope
Under these optimized reaction conditions, EtO-Cl-DNQ was obtained similarly as a
yellow solid in 73% yield along with 2 in 21% yield (Scheme 2).
Scheme 2. 4-Ethoxylation and 3-chlorination of theMeQone framework
In the cases of other chloroalkoxylations, a one-pot method was used to simplify the
experimental operations (Table 2, entries 1–6). Namely, after a solution of TNQ and sodium
alkoxide in alcohol was stirred at room temperature for 4 h, a solution of NCS in acetonitrile
was added, and the resulting mixture was stirred at room temperature for further 6 h. Then,
the solvent was removed, and the residue was purified to afford RO-Cl-DNQ in a moderate
yield. Moreover, an allyloxy or a propargyloxy group was introduced at the 4-position,
facilitating further chemical transformations (entries 5 and 6).
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Table 2. One-pot alkoxy-chlorination
Entry R
Yield/%
RO-Cl-DNQ 2
1 Bu 42 10
2 i-Bu 46 0
3 i-Pr 45 0
4 PhCH2CH2 (Phet) 55 0
5 Allyl 51 0
6 Propargyl (Prg) 29 20
2.4 Scanning of halogenating agents
To expand the substrate scope of this protocol, sodium salt 1a was reacted with other
N-halosuccinimides. Bromination using NBS afforded the corresponding
MeO-Br-DNQ in 62% yield (Scheme 3). In this reaction, 4-methoxylated
trinitroquinolone 3 was also obtained in 27% yield, probably because of the higher
leaving ability of bromide than chloride. Indeed, product 3 was obtained without
detectable MeO-I-DNQ in the reaction of 1a with NIS. On the other hand, neither the
alkoxylated product nor halogenated product was formed in the reactions using Br2, ICl,
and I2 as the halogenating agent.
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Scheme 3. Reactions of 1a with other N-halosuccinimides
2.5 Scanning of 3-nitrated MeQones
In our previous work, we had clarified the high reactivity of TNQ was caused by the steric
repulsion between the 1-methyl and 8-nitro groups, distorting the MeQone framework to
reduce the aromaticity.9 To the contrary, such steric repulsion was not crucial for this reaction
because of the high nucleophilicity of the alkoxide anion.
1,8-Dimethyl-3,6-dinitro-2-quinolone (4), 1-methyl-3,6-dinitro-2-quinolone (5) underwent
the 4-alkoxylation efficiently under the same conditions to afford adducts 6 and 7 without
observation of a considerable decrease of the yield, respectively (Scheme 4). Subsequent
chlorination of 6 and 7 also proceeded upon treatment with NCS leading to 8 and 9 in high
yields, respectively.
Scheme 4. Study on scope of 3-nitratedMeQones
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2.6 cine-Substitution of 1,8-dimethyl-3,5-dinitro-2-quinolone 12
On the other hand, when 1,8-dimethyl-3,5-dinitro-2-quinolone 12 was employed as the
substrate, cine-substituted product 13 was obtained without any detectable adduct
intermediate 14. In this reaction, addition of a methoxide surely occurred to afford 14,
however, it is not stable because of steric repulsion with peri-substituent. In order to release
this repulsion, proton transfer to the 3-position is considered to occur, which undergoes the
elimination of nitrite ion accompanied by aromatization to afford cine-substituted product 13
(Scheme 5).
Scheme 5. Reaction of 3,5-dinitroquinolone 12 with sodium methoxide
2.7 Control experiments
To elucidate the mechanism of the reaction, several experiments were carried out. This
reaction should proceed via 3,4-dihydroquinoline intermediate 15 from which nitrous acid is
eliminated, affording RO-X-DNQ. Although all other attempts to isolate 15 were
unsuccessful, the reaction of 1a with NCS in CH2Cl2 in a short reaction time (0.5 h)
successfully produced 15 in 45% yield. Dihydroquinoline 15 remained unreacted when a
solution of 15 in acetonitrile was stirred at room temperature for 6 h. In contrast, the same
solution in the presence of triethylamine furnished MeO-Cl-DNQ quantitatively (Scheme 6).
In this reaction, sodium succinimide (Na-SI) may have acted as a base. Indeed, the addition of
Na-SI facilitated the elimination of nitrous acid from 15, affording MeO-Cl-DNQ
quantitatively without any detectable imidation product 2 (Scheme 6).
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Scheme 6. Elimination of nitrous acid from intermediate 15
Next, some experiments were carried out to obtain insights into the imidation. When
MeO-Cl-DNQ was reacted with equimolar Na-SI, no reaction occurred, indicating that
product 2 was not formed from MeO-Cl-DNQ. On the other hand, chloroimidation occurred
by the treatment of TNQ with NCS and Na-SI (Scheme 7). Hence, imidation proceeds
competitively with the alkoxylation of TNQ.
Scheme 7. Chloro-imidation of TNQ
2.8 A plausible mechanism for the formation of MeO-Cl-DNQ and 2
Based on the abovementioned results, a plausible mechanism of this transformation is
illustrated in Scheme 8. The reaction is initiated with the nucleophilic addition of an alkoxide
at the 4-position of TNQ, furnishing 1a as a relatively stable sodium salt. The reaction of 1a
with NCS facilitates chlorination at the 3-position by nucleophilic substitution, affording
3,4-dihydroquinoline 15. Then a nitrous acid molecule is eliminated, leading to the formation
of bis(functionalized) product MeO-Cl-DNQ. In some cases, TNQ was regenerated under
equilibrium and then underwent nucleophilic addition with Na-SI followed by chlorination
and rearomatization, affording imidated product 2.
In the chlorination step of 1a, NCS approaches from the trans direction to avoid the steric
hindrance of the methoxy group. Hence, nitrous acid is preferentially eliminated over
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hydrogen chloride in the next rearomatization step because a hydrogen atom and a nitro group
are antiperiplanar.18
Scheme 8. A plausible mechanism for the formation ofMeO-Cl-DNQ and 2
2.9 Transformations of MeO-Cl-DNQ and 2
Finally, to illustrate the synthetic potential of this protocol, compound MeO-Cl-DNQ was
subjected to Suzuki−Miyaura coupling reaction19 because MeQones possessing an alkoxy
group and an aryl group at the vicinal positions serve as α4 integrin inhibitors.20 When
MeO-Cl-DNQ was reacted with 4-methylphenylboronic acid in the presence of a palladium
catalyst, arylated product 16 was successfully obtained in a moderate yield (Scheme 9).
Scheme 9. Suzuki-Miyaura coupling reaction usingMeO-Cl-DNQ
Moreover, the imido-chlorinated product 2 can be regarded as a masked form of aminated
quinolone, NH2-Cl-DNQ. Indeed, NH2-Cl-DNQ was isolated in 51% yield by the
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hydrazinolysis of compound 2 (Scheme 10). Aminated MeQones are usually synthesized by
chemical conversion from hydroxy derivatives via chloro derivatives.21 As an alternative
approach, a ring is also constructed on an aniline derivative. However, no direct amination
method for the MeQone framework has been reported, except for our report.22 Hence, this
imidation is a useful method for the direct aminochlorination of theMeQone framework.
Scheme 10. Hydrazinolysis of imidated product 2
3. Conclusion
I have developed a direct and vicinal functionalization of the MeQone framework under
mild conditions by the treatment of 3-nitrated MeQones with sodium alkoxides followed by
treatment with NCS. This procedure facilitates the regioselective halo-alkoxylation readily
with simple experimental manipulations. Moreover, chloro-imidation proceeded, leading to
4-imidated product 2 which is an equivalent of aminated MeQone. The prepared vicinally
functionalized MeQones will serve as key synthetic intermediates for versatile MeQones. As
one example, the palladium-catalyzed arylation at the 3-position was demonstrated. Hence,
this protocol will be used as a powerful tool for constructing a compound library of
MeQones.
4. Experimental section
4.1 General information
The melting points were determined on a Yanaco micro-melting-points apparatus, and are
uncorrected. All the reagents and solvents were commercially available and used as received.
The 1H NMR spectra were measured on a Bruker Ascend-400 at 400 MHz with
tetramethylsilane as an internal standard. The 13C NMR spectra were measured on a Bruker
Ascend-400 at 100 MHz, and assignments of 13C NMR spectra were performed by DEPT
experiments. The IR spectra were recorded on a JASCO FT/IR-4200 spectrometer. The mass
spectra and high-resolution mass spectra were measured on an AB SCIEX Triple TOF 4600.
The gas chromatography mass spectrum was measured on a JEOL JMS-Q1050GC Ultra Quad
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GC/MS.
4.2 General procedure for the preparation of 3-nitrated quinolones
1-Methyl-2-quinolone was prepared from quinoline by methylation with Me2SO4 followed
by oxidation with K3[Fe(CN)6] under alkaline conditions. Nitration of 1-methyl-2-quinolone
with fuming HNO3 afforded TNQ in 86% total yield.23
Other nitroquinolones 4, 5 and 12 were also prepared in a similar way. Dinitroquinolones
were obtained when milder reaction conditions were used in the nitration step.9
4.3 General procedure for synthesis of 1a and 1b
To a solution of TNQ (500 mg, 1.70 mmol ) in MeOH (5.5 mL), was added a solution of
NaOMe (119 mg, 2.21mmol) in MeOH (0.6 mL), and the resultant mixture was stirred at
room temperature for 4 h. The precipitated solid was collected by filtration to afford 1a (474
mg, 1.36 mmol, 81%) as a yellow powder. The reaction of TNQ with NaOEt was performed
to prepare 1b in a similar way.
(6,8-Dinitro-4-methoxy-1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)sodium (1a)
Yellow powder (474 mg, 1.36 mmol, 81%); mp 218−220 °C (dec.); 1H NMR (DMSO-d6,
400 MHz) δ = 2.97 (s, 3H), 3.15 (s, 3H), 5.96 (s, 1H), 8.55 (d, J = 2.4 Hz, 1H), 8.60 (d, J =
2.4 Hz, 1H); 13C NMR (DMSO-d6, 100 MHz): δ = 33.6 (CH3), 53.9 (CH3), 73.0 (CH), 106.6
(C), 121.1 (CH), 126.9 (CH), 129.8 (C), 137.2 (C), 139.0 (C), 139.2 (C), 159.9 (C); IR: ν
(cm-1) 1634, 1531, 1520; HRMS (ESI): Calcd for C11H10N4NaO8 [(M+H)+]: 349.0391, found
349.0386.
(6,8-Dinitro-4-ethoxy-1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)sodium (1b)
Yellow powder (615 mg, 1.70 mmol, quant.); mp 213−215 °C (dec.); 1H NMR (DMSO-d6,
400 MHz) δ = 1.02 (t, J = 6.8 Hz, 3H), 2.97 (s, 3H), 3.47 (q, J = 6.8 Hz, 2H), 6.03 (s, 1H),
8.53 (d, J = 2.8 Hz, 1H), 8.59 (d, J = 2.8 Hz, 1H); 13C NMR (DMSO-d6, 100 MHz) δ = 15.4
(CH3), 33.6 (CH3), 61.7 (CH2), 71.7 (CH), 107.1 (C), 121.0 (CH), 126.7 (CH), 130.5 (C),
137.2 (C), 138.9 (C), 139.2 (C), 160.0 (C); IR: ν (cm-1) 1633, 1537, 1531; HRMS (ESI) Calcd
for C12H12N4NaO8 [(M+H)+]: 363.0547, found 363.0541.
4.4 General procedure for synthesis of MeO-Cl-DNQ and EtO-Cl-DNQ
To a solution of 1a (70 mg, 0.20 mmol) in MeCN (1.0 mL), NCS (32 mg, 0.24 mmol) was
added, and the resultant mixture was stirred at room temperature for 6 h. Then, the solvent
was evaporated to afford a reaction mixture as a yellow residue, from which MeO-Cl-DNQ
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was isolated through SiO2 column chromatography (eluted with CH2Cl2/hexane = 4/1),
respectively. EtO-Cl-DNQ was prepared in a similar way.
3-Chloro-4-methoxy-1-methyl-6,8-dinitroquinolin-2(1H)-one (MeO-Cl-DNQ)
Yellow powder (53 mg, 0.17 mmol, 85%); Rf = 0.21 (CH2Cl2/hexane = 4/1); mp
170−171 °C; 1H NMR (CDCl3, 400 MHz) δ = 3.54 (s, 3H), 4.35 (s, 3H), 8.73 (d, J = 2.4 Hz,
1H), 8.99 (d, J = 2.4 Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ = 35.7 (CH3), 62.1 (CH3), 116.0
(C), 121.2 (C), 122.4 (CH), 122.7 (CH), 135.2 (C), 139.0 (C), 140.8 (C), 157.9 (C), 160.0 (C);
IR: ν (cm-1) 1667, 1537, 1531; MS (EI): 315 (M+2), 313 (M), 283 (100), 149 (67); HRMS
(ESI) Calcd for C11H9ClN3O6 [(M+H)+]: 314.0174, found 314.0165.
3-Chloro-4-ethoxy-1-methyl-6,8-dinitroquinolin-2(1H)-one (EtO-Cl-DNQ)
Yellow powder (46 mg, 0.14 mmol, 73%); Rf = 0.21 (CH2Cl2/hexane = 4/1); mp
161−163 °C; 1H NMR (CDCl3, 400 MHz) δ = 1.59 (t, J = 6.8 Hz, 3H), 3.54 (s, 3H), 4.62 (q, J
= 6.8 Hz, 2H), 8.72 (d, J = 2.8 Hz, 1H), 8.99 (d, J = 2.8 Hz, 1H); 13C NMR (CDCl3, 100 MHz)
δ = 15.7 (CH3), 35.7 (CH3), 71.2 (CH2), 116.4 (C), 121.7 (C), 122.3 (CH), 122.7 (CH), 135.2
(C), 139.0 (C), 140.8 (C), 157.2 (C), 160.0 (C); IR: ν (cm-1) 1682, 1537, 1531; HRMS (ESI)
Calcd for C12H9ClN3O6 [(M-H)−]: 326.0185, found 326.0201.
4.5 General procedure for one-pot method of synthesis of RO-Cl-DNQ
To a solution of Na (7 mg, 0.31 mmol) in alcohol (0.3 mL), TNQ (70 mg, 0.24 mmol) was
added, and the resultant mixture was stirred at room temperature for 4 h. Then, a solution of
NCS (38 mg, 0.29 mmol) in MeCN (1.0 mL) was added, and the resultant mixture was stirred
at room temperature for further 6 h. Then, the solvent was evaporated to afford a reaction
mixture as a yellow residue, from which RO-Cl-DNQ was isolated through SiO2 column
chromatography (eluted with CH2Cl2/hexane = 4/1).
4-Butoxy-3-chloro-1-methyl-6,8-dinitroquinolin-2(1H)-one (BuO-Cl-DNQ)
Yellow powder (35 mg, 0.10 mmol, 42%); Rf = 0.25 (CH2Cl2/hexane = 4/1); mp
135−136 °C; 1H NMR (CDCl3, 400 MHz) δ = 1.05 (t, J = 7.6 Hz, 3H), 1.59 (tq, J = 7.6, 7.6
Hz, 2H), 1.94 (tt, J = 6.8, 6.8 Hz, 2H), 3.54 (s, 3H), 4.53 (t, J = 6.8 Hz, 2H), 8.72 (d, J = 2.8
Hz, 1H), 8.98 (d, J = 2.8 Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ = 13.7 (CH3), 19.0 (CH2),
32.1 (CH2), 35.7 (CH3), 75.1 (CH2), 116.3 (C), 121.6 (C), 122.3 (CH), 122.7 (CH), 135.2 (C),
139.0 (C), 140.8 (C), 157.4 (C), 160.1 (C); IR: ν (cm-1) 1682, 1537, 1531; HRMS (ESI) Calcd
for C14H15ClN3O6 [(M+H)+]: 356.0644, found 356.0639.
3-Chloro-4-isobutoxy-1-methyl-6,8-dinitroquinolin-2(1H)-one (i-BuO-Cl-DNQ)
Yellow powder (38 mg, 0.11 mmol, 46%); Rf = 0.30 (CH2Cl2/hexane = 4/1); mp
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146−147 °C; 1H NMR (CDCl3, 400 MHz) δ = 1.16 (d, J = 6.4 Hz, 6H), 2.28 (m, 1H), 3.54 (s,
3H), 4.29 (d, J = 6.4 Hz, 2H), 8.72 (d, J = 2.4 Hz, 1H), 9.01 (d, J = 2.4 Hz, 1H); 13C NMR
(CDCl3, 100 MHz) δ = 19.0 (CH3), 29.4 (CH), 35.6 (CH3), 81.3 (CH2), 116.2 (C), 121.5 (C),
122.2 (CH), 122.6 (CH), 135.3 (C), 139.0 (C), 140.8 (C), 157.4 (C), 160.1 (C); IR: ν (cm-1)
1674, 1537, 1531; HRMS (ESI) Calcd for C14H15ClN3O6 [(M+H)+]: 356.0644, found
356.0639.
3-Chloro-4-isopropoxy-1-methyl-6,8-dinitroquinolin-2(1H)-one (i-PrO-Cl-DNQ)
Yellow powder (37 mg, 0.11 mmol, 45%); Rf = 0.25 (CH2Cl2/hexane = 4/1); mp
168−170 °C; 1H NMR (CDCl3, 400 MHz) δ = 1.50 (d, J = 6.0 Hz, 6H), 3.55 (s, 3H), 5.28
(septet, J = 6.0 Hz, 1H), 8.72 (d, J = 2.4 Hz, 1H), 9.02 (d, J = 2.4 Hz, 1H); 13C NMR (CDCl3,
100 MHz) δ = 22.7 (CH3), 35.7 (CH3), 78.7 (CH), 116.9 (C), 122.2 (CH), 122.7 (C), 123.0
(CH), 135.2 (C), 139.0 (C), 140.7 (C), 156.5 (C), 160.0 (C); IR: ν (cm-1) 1678, 1537, 1531;
HRMS (ESI) Calcd for C13H11ClN3O6 [(M-H)−]: 340.0342, found 340.0348.
3-Chloro-6,8-dinitro-1-methyl-4-(2-phenylethoxy)quinolin-2(1H)-one (PhetO-Cl-DNQ)
Yellow powder (53 mg, 0.13 mmol, 55%); Rf = 0.22 (CH2Cl2/hexane = 4/1); mp
142−144 °C; 1H NMR (CDCl3, 400 MHz) δ = 3.23 (t, J = 6.4 Hz, 2H), 3.51 (s, 3H), 4.82 (t, J
= 6.4 Hz, 2H), 7.21−7.34 (m, 5H), 8.65 (d, J = 2.8 Hz, 1H), 8.73 (d, J = 2.8 Hz, 1H); 13C
NMR (CDCl3, 100 MHz): δ = 35.7 (CH3), 36.5 (CH2), 75.3 (CH2), 115.7 (C), 121.4 (CH),
122.2 (C), 122.8 (CH), 127.1 (CH), 128.8 (CH), 128.9 (CH), 135.1 (C), 136.6(C), 138.9 (C),
140.7 (C), 157.0 (C), 160.0 (C); IR: ν (cm-1) 1681, 1537, 1531; HRMS (ESI) Calcd for
C18H13ClN3O6 [(M-H)−]: 402.0498, found 402.0512.
3-Chloro-1-methyl-6,8-dinitro-4-(prop-2-enyloxy)quinolin-2(1H)-one (AllylO-Cl-DNQ)
Yellow powder (41 mg, 0.12 mmol, 51%); Rf = 0.22 (CH2Cl2/hexane = 4/1); mp
130−131 °C; 1H NMR (CDCl3, 400 MHz) δ = 3.54 (s, 3H), 5.04 (dt, J = 6.0, 1.2 Hz, 2H), 5.43
(dd, J = 1.2, 10.4 Hz, 1H), 5.52 (ddt, J = 16.8, 1.2, 1.2 Hz, 1H), 6.13 (ddt, J = 10.4, 16.8, 6.0
Hz, 1H), 8.72 (d, J = 2.8 Hz, 1H), 9.00 (d, J = 2.8 Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ =
35.7 (CH3), 75.4 (CH2), 117.1 (C), 121.4 (CH2), 121.8 (C), 122.3 (CH), 122.9 (CH), 131.2
(CH), 135.2 (C), 139.0 (C), 140.8 (C), 157.0 (C), 159.9 (C); IR: ν (cm-1) 1674, 1536, 1530;
HRMS (ESI) Calcd for C13H9ClN3O6 [(M-H)−]: 338.0185, found 338.0178.
3-Chloro-1-methyl-4-(prop-2-ynyloxy)-6,8-dinitroquinolin-2(1H)-one (PrgO-Cl-DNQ)
Yellow powder (23 mg, 0.07 mmol, 29%); Rf = 0.20 (CH2Cl2/hexane = 4/1); mp
153−155 °C; 1H NMR (CDCl3, 400 MHz) δ = 2.61 (t, J = 2.4 Hz, 1H), 3.56 (s, 3H), 5.23 (d, J
= 2.4 Hz, 2H), 8.74 (d, J = 2.8 Hz, 1H), 9.12 (d, J = 2.8 Hz, 1H); 13C NMR (CDCl3, 100 MHz)
δ = 35.8 (CH3), 61.5 (CH2), 76.4 (CH), 78.7 (C), 118.4 (C), 121.9 (C), 122.5 (CH), 123.6
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(CH), 135.0 (C), 139.0 (C), 140.8 (C), 156.4 (C), 159.7 (C); IR: ν (cm-1) 1682, 1537, 1531;
HRMS (ESI) Calcd for C13H7ClN3O6 [(M-H)−]: 336.0029, found 336.0038.
3-Bromo-4-methoxy-1-methyl-6,8-dinitroquinolin-2(1H)-one (MeO-Br-DNQ)
Yellow powder (43 mg, 0.12 mmol, 62%); Rf = 0.21 (CH2Cl2/hexane = 4/1); mp
155−157 °C; 1H NMR (CDCl3, 400 MHz) δ = 3.55 (s, 3H), 4.28 (s, 3H), 8.75 (d, J = 2.4 Hz,
1H), 8.97 (d, J = 2.4 Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ = 35.9 (CH3), 62.1 (CH3), 108.7
(C), 121.4 (C), 122.5 (CH), 122.6 (CH), 135.9 (C), 139.1 (C), 140.8 (C), 160.1 (C), 160.6 (C);
IR: ν (cm-1) 1667, 1537, 1531; HRMS (ESI) Calcd for C11H7BrN3O6 [(M-H)−]: 355.9524,
found 355.9538.
4-Methoxy-1-methyl-3,6,8-trinitroquinolin-2(1H)-one (3)
Yellow powder (17 mg, 0.05 mmol, 27%); Rf = 0.21 (CH2Cl2/hexane = 4/1); mp
204−207 °C; 1H NMR (DMSO-d6, 400 MHz) δ = 3.43 (s, 3H), 4.25 (s, 3H), 9.01 (d, J = 2.8
Hz, 1H), 9.13 (d, J = 2.8 Hz, 1H); 13C NMR (DMSO-d6, 100 MHz) δ = 34.8 (CH3), 60.4
(CH3), 118.9 (C), 124.0 (CH), 124.6 (CH), 129.0 (C), 136.1 (C), 138.8 (C), 140.8 (C), 152.7
(C), 156.8 (C); IR: ν (cm-1) 1672, 1537, 1531; HRMS (ESI) Calcd for C11H9N4O8 [(M+H)+]:
325.0415, found 325.0401.
(4-Methoxy-1,8-dimethyl-6-nitro-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl) sodium (6)
Yellow powder (423 mg, 1.33 mmol, 79%); mp 214−216 °C (dec.); 1H NMR (DMSO-d6,
400 MHz) δ = 2.47 (s, 3H), 3.14 (s, 3H), 3.28 (s, 3H), 5.73 (s, 1H), 8.02 (d, J = 2.8 Hz, 1H),
8.06 (d, J = 2.8 Hz, 1H); 13C NMR (DMSO-d6, 100 MHz) δ = 21.3 (CH3), 35.9 (CH3), 53.8
(CH3), 74.0 (CH), 107.5 (C), 121.5 (CH), 126.9 (CH), 127.2 (C), 127.9 (C), 140.8 (C), 146.4
(C), 162.6 (C); IR: ν (cm-1) 1634, 1520, 1514. Satisfactory analytical data were not given
despite several attempts.
(4-Methoxy-1-methyl-6-nitro-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)sodium (7)
Yellow powder (382 mg, 1.26 mmol, 75%); mp 217−220 °C (dec.); 1H NMR (DMSO-d6,
400 MHz) δ = 3.10 (s, 3H), 3.28 (s, 3H), 5.87 (s, 1H), 7.15 (d, J = 9.2 Hz, 1H), 8.17 (dd, J =
2.4, 9.2 Hz, 1H), 8.23 (d, J = 2.4 Hz, 1H); 13C NMR (DMSO-d6, 100 MHz) δ = 29.1 (CH3),
53.6 (CH3), 73.7 (CH), 107.6 (C), 113.7 (CH), 123.2 (C), 124.2 (CH), 124.3 (CH), 139.9 (C),
145.5 (C), 159.4 (C); IR: ν (cm-1) 1682, 1537, 1520. Satisfactory analytical data were not
given despite several attempts.
3-Chloro-1,8-dimethyl-4-methoxy-6-nitroquinolin-2(1H)-one (8)
Yellow powder (53.6 mg, 0.19 mmol, 95%); Rf = 0.28 (CH2Cl2); mp 185−188 °C; 1H NMR
(CDCl3, 400 MHz) δ = 2.80 (s, 3H), 3.88 (s, 3H), 4.23 (s, 3H), 8.22 (d, J = 2.4 Hz, 1H), 8.66
(d, J = 2.4 Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ = 24.1 (CH3), 37.9 (CH3), 61.6 (CH3),
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115.1 (C), 118.0 (CH), 119.6 (C), 126.8 (C), 129.4 (CH), 142.4 (C), 143.3 (C), 159.1 (C),
161.7 (C); IR: ν (cm-1) 1659, 1597, 1522; HRMS (ESI) Calcd for C12H12ClN2O4 [(M+H)+]:
283.0480, found 283.0482.
3-Chloro-4-methoxy-1-methyl-6-nitroquinolin-2(1H)-one (9)
Yellow powder (39 mg, 0.15 mmol, 73%); Rf = 0.27 (CH2Cl2); mp 197−199 °C; 1H NMR
(CDCl3, 400 MHz) δ = 3.82 (s, 3H), 4.27 (s, 3H), 7.47 (d, J = 9.6 Hz, 1H), 8.43 (dd, J = 2.4,
9.6 Hz, 1H), 8.83 (d, J = 2.4 Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ = 31.3 (CH3), 61.7
(CH3), 115.0 (CH), 115.7 (C), 117.7 (C), 120.2 (CH), 125.8 (CH), 141.6 (C), 142.7 (C), 158.8
(C), 159.9 (C); IR: ν (cm-1) 1651, 1537, 1524; HRMS (ESI) Calcd for C11H10ClN2O4
[(M+H)+]: 269.0324, found 269.0322.
3-Chloro-1-methyl-6-nitro-4-(2,5-dioxopyrrolidino)quinolin-2(1H)-one (11)
Yellow powder (2.7 mg, 0.01 mmol, 4%); Rf = 0.48 (CH2Cl2/MeOH = 20/1); mp
283−285 °C; 1H NMR (DMSO-d6, 400 MHz) δ = 2.98−3.19 (m, 4H), 3.83 (s, 3H), 7.92 (d, J
= 9.2 Hz, 1H), 8.50 (dd, J = 2.8, 9.2 Hz, 1H), 8.64 (d, J = 2.8 Hz, 1H); 13C NMR (DMSO-d6,
100 MHz) δ = 29.5 (CH2), 31.8 (CH3), 116.8 (C), 117.4 (CH), 120.7 (CH), 126.2 (CH), 127.7
(C), 137.4 (C), 141.7 (C), 142.7 (C), 157.0 (C), 175.4 (C); IR: ν (cm-1) 1651, 1537, 1520;
HRMS (ESI) Calcd for C14H11ClN3O5 [(M+H)+]: 336.0382, found 336.0387.
4.6 Synthesis of 4-methoxy-1,8-dimethyl-5-nitroquinolin-2(1H)-one (13)
To a solution of 12 (25 mg, 0.10 mmol) in MeOH (0.5 mL), was added MeONa (7 mg, 0.13
mmol), and the resultant mixture was stirred at room temperature for 4 h. Then, the solvent
was evaporated to afford a mixture as a yellow residue, from which 13 was isolated as a
yellow powder by SiO2 column chromatography (eluted with CH2Cl2, 16.8 mg, 0.07 mmol,
72%); Rf = (CH2Cl2); mp 134−136 °C; 1H NMR (DMSO-d6, 400 MHz) δ = 2.73 (s, 3H), 3.76
(s, 3H), 3.94 (s, 3H), 6.76 (d, J = 9.6 Hz, 1H), 8.06 (s, 1H), 8.12 (d, J = 9.6 Hz, 1H); 13C
NMR (DMSO-d6, 100 MHz) δ = 23.0 (CH3), 35.7 (CH3), 63.9 (CH3), 116.6 (C), 121.8 (CH),
122.2 (C), 130.0 (CH), 133.5 (CH), 135.6 (C), 145.6 (C), 149.4 (C), 162.7 (C); IR: ν (cm-1)
1667, 1566, 1556; HRMS (ESI) Calcd for C12H12N2O4Na [(M+Na)+]: 271.0689, found
271.0693.
Synthesis of 3-chloro-3,4-dihydro-4-methoxy-1-methyl-6,8-dinitroquinolin-2(1H)-one
(15)
To a solution of 1a (100 mg, 0.29 mmol) in CH2Cl2 (2.0 mL), was added NCS (46 mg, 0.34
mmol), and the resultant mixture was stirred at room temperature for 0.5 h. Then, the solvent
was evaporated to afford a mixture as a yellow residue, from which 15 was isolated as a
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yellow powder by silica gel column chromatography (eluted with CH2Cl2/hexane = 2/1, 46.4
mg, 0.13 mmol, 45%); Rf = 0.15 (CH2Cl2/hexane = 2/1); mp 158−160 °C; 1H NMR (CDCl3,
400 MHz) δ = 3.32 (s, 3H), 3.89 (s, 3H), 4.97 (s, H), 8.47 (d, J = 2.4 Hz, 1H), 8.68 (d, J = 2.4
Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ = 36.0 (CH3), 62.4 (CH3), 81.6 (CH), 97.9 (C), 122.5
(CH), 124.6 (CH), 128.4 (C), 137.2 (C), 139.6 (C), 143.3 (C), 158.3 (C); IR: ν (cm-1) 1682,
1573, 1537; HRMS (ESI) Calcd for C11H10ClN4O8 [(M+H)+]: 361.0182, found 361.0186.
4.7 Synthesis of 2,5-dioxopyrrolidino substituted MeQone 2
To a solution of TNQ (70 mg, 0.24 mmol) in MeCN (0.5 ml), was added NCS (38 mg,
0.29 mmol) and Na-SI (29 mg, 0.24 mmol), and the resultant mixture was stirred at room
temperature for 6 h. Then, the solvent was evaporated to afford a reaction mixture as a
yellow residue, from which 2 was isolated through SiO2 column chromatography (eluted
with CH2Cl2) as a yellow solid (59 mg, 0.15 mmol, 65%). Rf = 0.10 (CH2Cl2); mp
294−297 °C; 1H NMR (DMSO-d6, 400 MHz) δ = 3.05−3.23 (m, 4H), 3.52 (s, 3H), 8.98 (d, J
= 2.4 Hz, 1H), 9.04 (d, J = 2.4 Hz, 1H); 13C NMR (DMSO-d6, 100 MHz) δ = 29.6 (CH2),
36.4 (CH3), 120.2 (C), 123.4 (CH), 124.1 (CH), 128.9 (C), 135.5 (C), 137.3 (C), 139.0 (C),
141.3 (C), 157.8 (C), 175.3 (C); IR: ν (cm-1) 1682, 1537, 1531; HRMS (ESI) Calcd for
C14H10ClN4O7 [(M+H)+]: 381.0233, found 381.0238.
4.8 Hydrazinolysis of 2
To a solution of 2 (50 mg, 0.13 mmol) in MeOH (2.0 mL), NH2NH2•H2O (18 mg, 0.36
mmol) was added, and the resultant mixture was heated at 70 °C for 3 h. Then, the solvent
was evaporated to afford a reaction mixture as a yellow solid. After the solid was washed by
water (5 mL × 1), NH2-Cl-DNQ was isolated through filtration as a yellow solid (20 mg,
0.07 mmol, 51%); Rf = 0.36 (CH2Cl2/MeOH = 10/1); mp > 300 °C; 1H NMR (DMSO-d6, 400
MHz) δ = 3.29 (s, 3H), 7.54 (br s, 2H), 8.89 (d, J = 2.0 Hz, 1H), 9.35 (d, J = 2.0 Hz, 1H); 13C
NMR (DMSO-d6, 400 MHz) δ = 35.1 (CH3), 99.8 (C), 117.2 (C), 122.5 (CH), 123.2 (CH),
136.5 (C), 138.5 (C), 139.7 (C), 147.1 (C), 158.2 (C); IR: ν (cm-1) 1651, 1537, 1531; HRMS
(ESI) Calcd for C10H8ClN4O5 [(M+H)+]: 299.0178, found 299.0172.
4.9 Suzuki-Miyaura coupling reaction of MeO-Cl-DNQ
To a solution of MeO-Cl-DNQ (60 mg, 0.19 mmol) in 1,4-dioxane (1.0 mL), were added
p-MeC6H4B(OH)2 (39 mg, 0.29 mmol), Pd(PPh3)2Cl2 (14 mg, 0.02 mmol) and Cs2CO3 (94 mg,
0.29 mmol), and the resultant mixture was heated at 100 °C for 1 d. Then, the solvent was
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evaporated to afford a reaction mixture as a yellow residue, from which arylated product 16
was isolated by SiO2 column chromatography (eluted with CH2Cl2/hexane = 4/1) as a yellow
solid (38 mg, 0.10 mmol, 54%); Rf = 0.22 (CH2Cl2/hexane = 4/1); mp 172−175 °C; 1H NMR
(CDCl3, 400 MHz) δ = 2.42 (s, 3H), 3.49 (s, 3H), 3.59 (s, 3H), 7.29 (d, J = 8.0 Hz, 2H), 7.36
(d, J = 8.0 Hz, 2H), 8.71 (d, J = 2.4 Hz, 1H), 9.05 (d, J = 2.4 Hz, 1H); 13C NMR (CDCl3, 100
MHz) δ = 21.4 (CH3), 35.0 (CH3), 61.5 (CH3), 119.9 (C), 121.9 (CH), 122.0 (C), 123.2 (CH),
128.4 (C), 129.2 (CH), 130.4 (CH), 136.5 (C), 138.5 (C), 139.0 (C), 140.3 (C), 158.2 (C),
163.8 (C); IR: ν (cm-1) 1667, 1537, 1531; HRMS (ESI) Calcd for C18H16N3O6 [(M+H)+]:
370.1034, found 370.1037.
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Chapter 3. Direct Amino-halogenation and Aziridination
of the 1-Methyl-2-quinolone Framework
The sequential treatment of 3-nitro-2-quinolones with amines and N-halosuccinimides
under mild conditions facilitated the direct amino-halogenation and aziridination at the 4- and
3-positions of the 2-quinolone framework. The selectivity of the functionalization was
influenced by the electronic properties of the substituents on the benzene moiety of the
nitroquinolone. The electron-withdrawing nitro group promoted the amino-halogenation, and
replacement of the nitro group with a halogen or hydrogen markedly increased the selectivity
of the aziridination. Moreover, a succinimide group instead of an alkylamino group was
introduced at the 4-position, affording the masked form of the 4-amino-3-chloro-2-quinolone
derivative. Furthermore, the prepared bis-functionalized quinolones were subjected to
Suzuki-Miyaura coupling reaction, ring opening, and hydrazinolysis to afford differently
functionalized quinolones.
1. Introduction
4-Aminated 2-quinolones have garnered considerable attention owing to their various
applications in medicinal chemistry. For example, 4-aminated 6-thiazolyl-2-quinolones are
potent CD38 inhibitors for the treatment of metabolic syndrome (Figure 1, a).1 Recently, the
design, synthesis, and evaluation of new acetylcholinesterase inhibitors combining
4-amino-2-quinolone rings and benzylpiperidino groups joined by a carboxamide fragment
was described (Figure 1, b).2 In addition, 4-amino-2-quinolones possessing benzimidazole
rings at the 3-position have been found to serve as a novel class of receptor tyrosine kinase
inhibitors for the treatment of cancer (Figure 1, c).3 Furthermore, 4-aminated
3-phenyl-2-quinolones have been reported to be N-methyl-D-aspartate receptor antagonists
with anticonvulsant activities (Figure 1, d).4
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Figure 1. Examples of bioactive compounds based on the 4-aminated 2-quinolones
Despite these significant applications, 2-quinolones are inert because of their inherent
aromaticity, which prevents their direct amination.5 Hence, conventional strategies for the
preparation of such scaffolds involve the construction of heterocyclic rings through
cumbersome multistep reaction sequences, some of which involve expensive reagents, harsh
reaction conditions and low yields.4,6 As an alternative approach, 4-aminated 2-quinolones
can be also synthesized by chemical conversion from the 4-hydroxy4,7 or 4-chloro1,2,8
derivatives. Therefore, the direct and practical amination of the 2-quinolone framework is
strongly demanded.
A nitro group is one of the most important functional groups in organic syntheses
because of its strong electron-withdrawing ability to activate the scaffold, facilitating
the reaction with nucleophilic reagents.9 Moreover, a nitro group serves not only as a
precursor of versatile functionalities but also as a good leaving group.10 Inspired by
these properties of nitro group, we have found that 3-nitrated 1-methyl-2-quinolones
(MeQones) are highly reactive in direct C-C/C-O bond formation at the 4-position
with carbon nucleophiles11,12 and alkoxy anions,13 respectively.
Interested in these results and with the aim of achieving versatile functionalization
of the 2-quinolone framework, we decided to investigate direct C-N bond formation at
the 4-position of the MeQone framework upon treatment of 3-nitrated MeQones with
amines, in which an electrophile is necessary to trap the anionic adduct intermediate
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because a heteronucleophile is easily eliminated even though it adds to quinolone
framework.14 We focused on the halogenation because the hitherto unknown
4-aminated and 3-halogenated 2-quinolones compose a novel class of 2-quinolones
with potentially interesting and valuable bioactivities, and will surely serve as key
intermediates for constructing a library of versatile 2-quinolones.
2. Results and discussion
2.1 Amino-halogenation and aziridination of the MeQone Framework
To evaluate the potential for vicinal functionalization, trinitro-2-quinolone 1A was chosen
as a model substrate. Initially, a Meisenheimer complex Y was synthesized by treating 1A
with excess propylamine 2a; subsequent reaction with N-chlorosuccinimide (NCS) gave the
amino-chlorinated product 3Aa in 26% yield, thus confirming the feasibility of the
introduction of vicinal amino and halo groups onto the 2-quinolone framework (Scheme 1).
The N-propylaziridine ring fused compound 4Aa was obtained in 11% yield, of which the
structure was definitely confirmed by X-ray diffraction of single crystal of 4Fa,15 an analogue
of 4Aa (Figure 2). To the best of our knowledge, there is very few report about the
aziridination on the MeQone framework.16Therefore, our investigation will facilitate efficient
access to functionalized quinolones. Moreover, the imido-chlorinated product 5A, which was
formed through the reaction of 1A with NCS and a succinimide anion,13 was obtained in 39%
yield, indicating that regeneration of 1A from Y proceeded under equlibrium.
Scheme 1. Reaction of Meisenheimer complex Y with NCS
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Figure 2. Structure of 4Fa from X-ray diffraction analysis (the thermal ellipsoid plots are
drawn at 50% probability level)
2.2 Control reaction involving radical scavenger
In order to gain insight into the mechanism of the reaction, a control experiment involving
a radical scavenger was performed.17 The addition of TEMPO had a slight influence on the
reaction, but did not completely inhibit the reaction, thus suggesting that radical intermediates
were not involved in the process (Scheme 2).
Scheme 2. Control reaction involving radical scavenger
2.3 A plausible mechanism for the formation of 3Aa and 4Aa
Based on the aforementioned results, it was postulated that the amine attacks the
4-position of 1A to give dihydroquinolone X (Scheme 3). As a result of deprotonation at the
3-position by another amine, a Meisenheimer complex Y is formed. The reaction of Y with
NCS facilitates chlorination at the 3-position by nucleophilic substitution, whereby NCS
approaches from the trans direction to avoid the steric hindrance of the propylamino group,
thus affording intermediate Z.18 Hence, the base-promoted rearomatization takes place via the
preferred bimolecular antiperiplanar elimination, which leads to the formation of
amino-halogenated product 3Aa. Meanwhile, the intramolecular substitution of the chloro
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group by the adjacent amino group can occur to form the N-propylaziridine ring at the 3- and
4-positions, affording product 4Aa.16,19 Additionally, 1A was regenerated under equilibrium
from X and then underwent a nucleophilic addition with the succinimide anion followed by
chlorination and rearomatization, delivering imido-chlorinated product 5A.13
Scheme 3. A plausible mechanism for formation of 3Aa, 4Aa and 5A
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2.4 Conditions screening for one-pot amino-chlorination
In order to enhance the practicality of the method, we attempted to carry out the reaction
in a one-pot, two-step fashion using trinitroquinolone 1A, propylamine 2a, and NCS as model
substrates (Table 1). After a solution of 1A and 2a was stirred at room temperature for 3 h,
NCS was added, and the resulting mixture was stirred at room temperature for 4 h. We tested
a variety of solvents in the presence of 2.5 equiv. of 2a in order to find the optimal conditions
(Table 1). The conversion of 1A into amino-chlorinated product 3Aa did not work well in
ethanol or dichloromethane, because imido-chlorinated product 5A was the major product in
these two solvents (entries 1 and 2). The Meisenheimer complex Y is considered to be more
solvated with ethanol than C by forming hydrogen bonds, which might prevent the approach
of NCS. Thus, polar aprotic solvents (MeCN, DMF and THF) were more suitable for the
amino-chlorination, and the yield was improved to 45% when THF was used (entries 3–5). In
these cases, 4Aa was obtained as well. Next, a larger amount of 2a was added to promote the
conversion of 1A, giving 3Aa in 62% yield without concomitant formation of 5A. 4Aa
decomposed into other compounds in this process (entry 6), as confirmed by the reaction of
4Aa with propylamine 2a. However, low temperature did not further improve the yield (entry
7). This is presumably due to the incomplete conversion of 1A to X, which also underwent the
competitive reaction of 1A with the succinimide anion. Meanwhile, the decomposition of 4Aa
was suppressed at low temperature. Thus, the reaction conditions utilized in entry 6 were
determined to be optimal.
Table 1. Conditions screening for aminochlorination
Entry Solvent
PrNH2
(Equiv.)
Yield (%)
3Aa 4Aa 5A
1 EtOH 2.5 11 5 48
2 CH2Cl2 2.5 14 12 34
3 MeCN 2.5 31 11 16
4 DMF 2.5 39 15 3
5 THF 2.5 45 10 19
6 THF 3.0 62 trace 0
7a THF 3.0 37 13 21
aThe reaction was conducted at -20℃.
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2.5 Study on amine scope
With the optimized reaction conditions in hand, we surveyed the scope of amines 2 (Table
2). Reactions of 1A with various aliphatic primary amines 2b–f afforded the corresponding
vicinally amino-chlorinated compounds 3Ab–f in moderate to good yields (entries 1–5);
however, 4 was not observed. Alicyclic amines such as piperidine 2g and morpholine 2h
worked well (entries 6 and 7). Moreover, anilines 2i-m were also examined. Several
functional groups, such as butyl, methoxy and iodo groups on the benzene ring were tolerated,
and a larger amount of aniline 2i promoted the conversion of 1A (entry 8). However, only a
trace amount of 3Am was detected in the case of 4-nitroaniline 2m owing to the strong
electron-withdrawing effect of the nitro group (entry 12). Due to the steric hindrance
preventing the approach of NCS, the target product was not formed in the presence of
diethylamine 2n, and only a trace amount of the desired product was observed in the reaction
with N-methylaniline 2o (entries 13 and 14). In some cases, the succinimide anion was
produced under basic conditions, and underwent imido-chlorination to furnish 5A (entries 2, 7
and 13).
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Table 2. Study on amine scope
Entry R1 R2
Yield (%)
3A 5A
1 i-Bu H b 70 0
2 sec-Bu H c 49 26
3 HOCH2CH2 H d 56 0
4 Allyl H e 35 0
5 Benzyl H f 54 0
6 －(CH2)5－ g 48 0
7 －CH2CH2OCH2CH2－ h 62 3
8 Ph H i 41 (54a) 0
9 4-BuC6H4 H j 41 0
10 4-MeOC6H4 H k 37 0
11 4-IC6H4 H l 62a 0
12 4-NO2C6H4 H m trace 0
13 Et Et n 0 27
14 Ph Me o trace 0
a5 equiv. of amine was used.
2.6 Scanning of halogenating agents
In order to expand the scope of the protocol, two other N-halosuccinimides, NBS and NIS,
were also employed (Scheme 4). The bromo-amination proceeded smoothly to give 6Aa in
63% yield. Notably, 4-aminated trinitroquinolone 7Aa was also obtained in 16% yield, which
was presumably due to the higher leaving ability of bromide than chloride. 7Aa was obtained
in 62% yield without detectable iodo-aminated product in the reaction using NIS.
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Scheme 4. The reaction invoving NBS and NIS
2.7 Scanning of 3-nitrated MeQones
Next, 3-nitrated MeQones with different substituents on the benzene ring were further
investigated. As indicated in Table 3, a reduction in the number of nitro groups on the
benzene ring had a negative impact on the formation of amino-chlorinated product 3. When
the 8-nitro group was replaced with a methyl group or hydrogen atom, 3Ba and 3Ca were
furnished in 13% yield (entries 1 and 2). Interestingly, the reaction involving 1B afforded
3-nitro-4-propylamino substituted product 7Ba, an analogue of 7Aa, in 21% yield. This might
be due to the steric repulsion between the 1-methyl and the 8-methyl groups, leading to the
torsional strain in the 2-quinolone ring;12 accordingly, NCS could approach the carbanion Y’
from the cis direction (Scheme 5). Consequently, the elimination of nitrous acid together with
hydrogen chloride resulted in the formation of 3-chlorinated and 3-nitrated products (3Ba and
7Ba) simultaneously (Scheme 5). Moreover, a nitro group with a bromo atom or hydrogen
atom on the benzene ring markedly decreased the selectivity of the formation of 3 (entries
3–5). On the other hand, in these reactions, the N-propylaziridine ring fused compounds
4Ba–4Fa were obtained as the major products in moderate to good yields. These aziridines
were stable while 4Aa easily decomposed because the benzylic position of 4Aa, which is
activated by the electron-withdrawing effect of the nitro group at the 8-position, is easily
attacked by nucleophiles. Indeed, 4Fa caused no change even though it was heated with
propylamine at 60 °C for 12 hours. The reaction did not proceed in the case of 3-nitrated
MeQone with two electron-donating groups on the benzene ring (entry 6). Additionally, the
methyl group was not crucial for the aziridine formation, and 4Ha was obtained in 61% yield
in the reaction using 1H (entry 7).
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Table 3. Reactions of 3-nitratedMeQones with 2a and NCS
Scheme 5. Steric repulsion between peri-substituents affording 7
Entry
1 Yield (%)
R1 R6 R7 R8 3a 4a 5
1 Me NO2 H Me B 13 21 trace
2 Me NO2 H H C 13 49 7
3 Me Br H H D trace 68 0
4 Me H Br H E 0 65 0
5 Me H H H F 0 71 0
6 Me MeO MeO H G 0 0 0
7 H H H H H 0 61 0
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2.8 Selectivity in amino-chlorination and aziridination
Based on the aforementioned results, the selective formation of 3 and 4 was attributed to
the electronic effects of the substituents on the benzene ring. As depicted in Scheme 3, the
intermediate Z likely played a very important role in this reaction, and the benzylic hydrogen
atom in the 4-position determined the direct halo-amination or aziridination of the MeQone
framework. Although Z was not detected during the reaction, we could indirectly characterize
the electronic properties of the 4-H on nitroquinolone 1 and the resultant aziridine 4 by 1H
NMR analysis (Table 4).
As described previously, more nitro groups led to lower field, indicating that the electron
density at the 4-position decreased owing to the nitro group on the benzene ring through the
electron-withdrawing effect, thus increasing the acidity of the benzylic proton (Table 4).20 As
a result, a nitrous acid is easily eliminated via an antiperiplanar elimination, leading to the
formation of amino-halogenated product 3 (Scheme 3, Path 1). In contrast, the hydrogen atom
becomes less acidic in the presence of weaker electron-withdrawing groups such as bromo
atoms or in the absence of electron-withdrawing groups, thus resulting in an intramolecular
substitution to form an aziridine ring (Scheme 3, Path 2). On the other hand, when
electron-donating groups such as methoxy were introduced on the aromatic ring, the electron
density was significantly increased, thus preventing the nucleophilic addition at the 4-position
of theMeQone system.
Table 4. Chemical shift of H4 of 1 and 4a in 1H NMR spectra
R1 R6 R7 R8
Chemical shift of H4 (ppm)
1 4a
Me NO2 H NO2 A 9.26 4.32
Me NO2 H H C 9.13 4.22
Me H H H F 8.90 4.12
Me MeO MeO H G 8.82 –––
H H H H H 8.93 4.16
70
2.9 cine-Substitution of 1,8-dimethyl-3,5-dinitro-2-quinolone 12
Interestingly, when 1,8-dimethyl-3,5-dinitro-2-quinolone (1I) was employed under the
same conditions, cine-substituted product 8Ia was obtained without 3Ia or 4Ia. In this
reaction, addition of a propylamine 2a afforded the Meisenheimer complex; however, it was
not stable due to the steric repulsion of the peri-substituent (Scheme 6). Therefore, proton
transfer to the 3-position likely releasing this repulsion and facilitating the elimination of the
nitrite ion accompanied by aromatization to afford cine-substituted product 8Ia.
Scheme 6. Reaction of 3,5-dinitroquinolone 1I with propylamine 2a
2.10 Conversion of the obtained products 6Af, 5A and 4Fa
Finally, to illustrate the synthetic utility of the developed protocol, the conversion of the
resulting products into other useful synthetic building blocks was investigated. Using the
present method, benzylamino-brominated compound 6Af was synthesized in 55% yield, and
was subjected to Suzuki-Miyaura coupling,21 as MeQones with an benzylamino group and an
aryl group in the vicinal positions are known N-methyl-D-aspartate receptor antagonists.4
When 3Af and 6Af were reacted with 4-methylphenylboronic acid in the presence of a
palladium catalyst, 3-arylated product 9 was successfully obtained in 27% and 66% yields,
respectively, indicating that the higher reactivity of C-Br than C-Cl bond facilitated the
transformation (Scheme 7, a). Furthermore, imido-chlorinated product 5A is a masked form
of an aminated quinolone, and the hydrazinolysis of the imidated ring introduced an
unsubstituted amino group at the 4-position (Scheme 7, b). Compound 4Fa underwent a
ring-opening reaction followed by rearomatization in the presence of an acid, leading to
vicinally amino-nitrated MeQone 7Fa in quantitative yield (Scheme 7, c).
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Scheme 7. Conversion of 6Af, 5A and 4Fa into other useful building blocks
3. Conclusion
In conclusion, an operationally simple protocol for the direct 4-amination and
3-halogenation of MeQone was developed by treatment of 3-nitrated MeQones with amines
followed by addition of N-halosuccinimides under mild conditions. The vicinally
functionalized MeQones will serve as key synthetic intermediates for a versatile library of
MeQones, as demonstrated through the palladium-catalyzed arylation at the 3-position.
Meanwhile, we found that aziridination occurred at the 3- and 4-positions of the MeQone
framework through intramolecular substitution. The selectivity between vicinal
amino-halogenation and aziridination was associated with the electronic properties of the
substituents on the benzene ring. Moreover, imido-chlorination proceeded in some cases,
leading to 4-imidated product, a masked form of the 4-aminoquinolone. Further investigations
focused on the ring opening of the aziridine ring are currently in progress, and may facilitate
the efficient and practical functionalization ofMeQones.
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4. Experimental section
4.1 General information
The melting points were determined on SRS-Optimelt Automated Melting Point System,
and are uncorrected. All the reagents and solvents were commercially available and used as
received. The 1H NMR spectra were measured on a Bruker Ascend-400 at 400 MHz with
tetramethylsilane as an internal standard. The 13C NMR spectra were measured on a Bruker
Ascend-400 at 100 MHz, and assignments of 13C NMR spectra were performed by DEPT
experiments. The high-resolution mass spectra were measured on an AB SCIEX Triple TOF
4600. X-ray diffraction was conducted on a Rigaku AFC7R diffractometer with graphite
monochromatized Mo-K radiation. The IR spectra were recorded on a JASCO FT/IR-4200
spectrometer.
4.2 General procedure for the preparation of 3-nitrated quinolones
1-Methyl-2-quinolone was prepared from quinoline by methylation with Me2SO4 followed
by oxidation with K3[Fe(CN)6] under alkaline conditions. Nitration of 1-methyl-2-quinolone
with fuming HNO3 afforded trinitroquinolone 1A in 86% total yield.22 Other
dinitroquinolones 1B, 1C and 1I were also prepared in a similar way except for using milder
reaction conditions in the nitration step.12a
Mononitrated quinolones 1D–H were successfully synthesized using 2-nitrobenzaldehyde
as the starting material via sequential reduction using Fe/HCl,23 condensation with ethyl
nitroacetate,24 intramolecular cyclization,24 and methylation with iodomethane.25
4.3 Reaction of trinitroquinolone 1A with propylamine 2a
To a solution of trinitroquinolone 1A (100.0 mg, 0.34 mmol) in acetonitrile (2.5 mL),
propylamine 2a (102.5 mg, 1.70 mmol) was added at room temperature. When amine was
added, yellowish solid immediately precipitated. After stirring for 3 h, the Meisenheimer
complex Y was collected by filtration as a yellow solid (105.1 mg, 0.26 mmol, 75%);26 Since
this salt was not stable under ambient conditions to give TNQ and it was too hydroscopic,
only 1H NMR could be measured, and satisfactory analytical data were not obtained despite
several attempts. In the 1H NMR of Y using DMSO-d6 as the solvent, the signals were
considerably broadened, and the decomposition of Y into TNQ and propylamine 2a was
observed in CDCl3.
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4.4 General procedure for amino-halogenation and aziridination of the 2-quinolone
framework
To a solution of 3-nitrated quinolones 1 (100.0 mg) in THF (1.0 mL), amine 2 (3.0 equiv.)
was added, and the resultant mixture was stirred at room temperature for 3 h. Then, a solution
of N-halosuccinimide (1.2 equiv.) in THF (0.5 mL) was added, and the resultant mixture was
stirred at room temperature for further 4 h. The solvent was evaporated to afford a reaction
mixture as a yellow residue, from which amino-halogenated and aziridine fused quinolone, 3
and 4, were isolated through SiO2 column chromatography (eluted with CH2Cl2).
3-Chloro-1-methyl-6,8-dinitro-4-(propylamino)-2-quinolone (3Aa)
Yellow solid (71.2 mg, 0.21 mmol, 62%); Rf = 0.44 (CH2Cl2); mp 131−133 °C; 1H NMR
(CDCl3, 400 MHz) δ = 1.07 (t, J = 7.2 Hz, 3H), 1.79 (tq, J = 7.2, 7.2 Hz, 2H), 3.50 (s, 3H),
3.55 (dt, J = 6.8, 7.2 Hz, 2H), 4.86 (br s, 1H), 8.73 (d, J = 2.4 Hz, 1H), 8.96 (d, J = 2.4 Hz,
1H); 13C NMR (CDCl3, 100 MHz) δ = 11.2 (CH3), 24.8 (CH2), 35.4 (CH3), 51.0 (CH2), 110.2
(C), 118.9 (C), 121.8 (CH), 124.0 (CH), 136.7 (C), 139.1 (C), 139.5 (C), 149.0 (C), 158.4 (C);
IR: ν (cm-1) 3372, 1645, 1537, 1531; HRMS (ESI-TOF) Calcd for C13H14ClN4O5 [(M+H)+]:
341.0647, found 341.0647.
3-Chloro-1-methyl-4-(2-methylpropylamino)-6,8-dinitro-2-quinolone (3Ab)
Yellow solid (83.5 mg, 0.24 mmol, 70%); Rf = 0.44 (CH2Cl2); mp 122−123 °C; 1H NMR
(CDCl3, 400 MHz) δ = 1.07 (d, J = 6.8 Hz, 6H), 1.97 (triple septet, J = 6.8, 6.8 Hz, 1H), 3.38
(dd, J = 6.8, 6.8 Hz, 2H), 3.50 (s, 3H), 4.89 (br s, 1H), 8.73 (d, J = 2.4 Hz, 1H), 8.95 (d, J =
2.4 Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ = 20.0 (CH3), 30.5 (CH), 35.4 (CH3), 56.9 (CH2),
110.1 (C), 118.8 (C), 121.8 (CH), 124.1 (CH), 136.7 (C), 139.1 (C), 139.4 (C), 149.2 (C),
158.3 (C); IR: ν (cm-1) 3343, 1645, 1537, 1531; HRMS (ESI-TOF) Calcd for C14H16ClN4O5
[(M+H)+]: 355.0804, found 355.0802.
4-(2-Butylamino)-3-chloro-1-methyl-6,8-dinitro-2-quinolone (3Ac)
Yellow solid (58.2 mg, 0.16 mmol, 49%); Rf = 0.51 (CH2Cl2); mp 153−155 °C; 1H NMR
(CDCl3, 400 MHz) δ = 1.08 (t, J = 7.2 Hz, 3H), 1.34 (d, J = 6.4 Hz, 3H), 1.65-1.78 (m, 2H),
3.51 (s, 3H), 3.67−3.74 (m, 1H), 4.46 (d, J = 10.0 Hz, 1H), 8.72 (d, J = 2.4 Hz, 1H), 8.93 (d, J
= 2.4 Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ = 10.5 (CH3), 21.9 (CH3), 31.6 (CH2), 35.4
(CH3), 57.1 (CH), 112.7 (C), 119.4 (C), 121.8 (CH), 124.0 (CH), 136.5 (C), 139.2 (C), 139.7
(C), 148.9 (C), 158.4 (C); IR: ν (cm-1) 3345, 1667, 1537, 1531; HRMS (ESI-TOF) Calcd for
C14H16ClN4O5 [(M+H)+]: 355.0804, found 355.0814.
3-Chloro-4-(2-hydroxyethylamino)-1-methyl-6,8-dinitro-2-quinolone (3Ad)
Yellow solid (64.4 mg, 0.19 mmol, 56%); Rf = 0.35 (CH2Cl2/MeOH = 20:1); mp
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125−128 °C; 1H NMR (CD3CN, 400 MHz) δ = 3.40 (s, 3H), 3.71−3.74 (m, 4H), 5.59 (br s,
1H), 8.76 (d, J = 2.4 Hz, 1H), 9.06 (d, J = 2.4 Hz, 1H); 13C NMR (CD3CN, 100 MHz) δ =
34.8 (CH3), 49.5 (CH2), 60.8 (CH2), 107.9 (C), 119.3 (C), 121.8 (CH), 123.5 (CH), 136.7 (C),
138.6 (C), 139.5 (C), 148.6 (C), 158.6 (C); IR: ν (cm-1) 3352, 1651, 1537, 1531; HRMS
(ESI-TOF) Calcd for C12H12ClN4O6 [(M+H)+]: 343.0440, found 343.0427.
3-Chloro-1-methyl-6,8-dinitro-4-(2-propenylamino)-2-quinolone (3Ae)
Yellow solid (39.9 mg, 0.12 mmol, 35%); Rf = 0.14 (CH2Cl2); mp 148−149 °C; 1H NMR
(CDCl3, 400 MHz) δ = 3.51 (s, 3H), 4.16 (dd, J = 5.3, 5.3 Hz, 2H), 4.96 (br s, 1H), 5.38 (dd, J
= 0.8, 10.2 Hz, 1H), 5.49 (dd, J = 0.8, 17.0 Hz, 1H), 6.03 (ddt, J = 5.3, 10.2, 17.0 Hz, 1H),
8.73 (d, J = 2.4 Hz, 1H), 8.95 (d, J = 2.4 Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ = 35.5
(CH3), 51.0 (CH2), 111.1 (C), 118.5 (CH2), 118.7 (C), 121.9 (CH), 123.9 (CH), 133.7 (CH),
136.6 (C), 139.2 (C), 139.7 (C), 148.8 (C), 158.4 (C); IR: ν (cm-1) 3360, 1651, 1537, 1531;
HRMS (ESI-TOF) Calcd for C13H12ClN4O5 [(M+H)+]: 339.0491, found 339.0500.
4-(Benzylamino)-3-chloro-1-methyl-6,8-dinitro-2-quinolone (3Af)
Yellow solid (70.0 mg, 0.18 mmol, 54%); Rf = 0.40 (CH2Cl2); mp 178−179 °C; 1H NMR
(CDCl3, 400 MHz) δ = 3.50 (s, 3H), 4.73 (d, J = 6.0 Hz, 2H), 5.21 (t, J = 6.0 Hz, 1H),
7.36−7.43 (m, 5H), 8.72 (d, J = 2.4 Hz, 1H), 8.99 (d, J = 2.4 Hz, 1H); 13C NMR (CDCl3, 100
MHz) δ = 35.5 (CH3), 52.9 (CH2), 111.1 (C), 118.8 (C), 121.9 (CH), 123.9 (CH), 127.4 (CH),
128.6 (CH), 129.3 (CH), 136.6 (C), 137.3 (C), 139.2 (C), 139.6 (C), 148.6 (C), 158.4 (C); IR:
ν (cm-1) 3360, 1651, 1537, 1531; HRMS (ESI-TOF) Calcd for C17H14ClN4O5 [(M+H)+]:
389.0647, found 389.0643.
3-Chloro-1-methyl-6,8-dinitro-4-piperidino-2-quinolone (3Ag)
Yellow solid (59.8 mg, 0.16 mmol, 48%); Rf = 0.40 (CH2Cl2); mp 181−183 °C; 1H NMR
(CDCl3, 400 MHz) δ = 1.78−1.85 (m, 6H), 3.2−3.4 (m, 4H), 3.50 (s, 3H), 8.71 (d, J = 2.4 Hz,
1H), 9.07 (d, J = 2.4 Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ = 23.9 (CH2), 26.5 (CH2), 35.8
(CH3), 52.1 (CH2), 121.5 (C), 121.8 (CH), 124.0 (C), 124.4 (CH), 136.4 (C), 139.1 (C), 140.4
(C), 152.1 (C), 160.0 (C); IR: ν (cm-1) 1651, 1537, 1531; HRMS (ESI-TOF) Calcd for
C15H15ClN4NaO5 [(M+Na)+]: 389.0623, found 389.0609.
3-Chloro-1-methyl-4-morpholino-6,8-dinitro-2-quinolone (3Ah)
Yellow solid (76.9 mg, 0.21 mmol, 62%); Rf = 0.09 (CH2Cl2); mp 248−250 °C; 1H NMR
(DMSO-d6, 400 MHz) δ = 3.35−3.37 (m, 7H), 3.85 (t, J = 4.4 Hz, 4H), 8.94 (d, J = 2.4 Hz,
1H), 8.98 (d, J = 2.4 Hz, 1H); 13C NMR (DMSO-d6, 100 MHz) δ = 35.7 (CH3), 50.1 (CH2),
66.7 (CH2), 120.7 (C), 122.4 (CH), 122.8 (C), 124.2 (CH), 136.2 (C), 138.7 (C), 140.2 (C),
150.7 (C), 159.4 (C); IR: ν (cm-1) 1651, 1537, 1531; HRMS (ESI-TOF) Calcd for
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C14H13ClN4NaO6 [(M+Na)+]: 391.0416, found 391.0422.
3-Chloro-1-methyl-6,8-dinitro-4-phenylamino-2-quinolone (3Ai)
Yellow solid (68.5 mg, 0.18 mmol, 54%); Rf = 0.24 (CH2Cl2); mp 199−201 °C; 1H NMR
(CDCl3, 400 MHz) δ = 3.56 (s, 3H), 6.72 (br s, 1H), 6.99 (d, J = 7.6 Hz, 2H), 7.20 (t, J = 7.6
Hz, 1H), 7.35 (dd, J = 7.6, 7.6 Hz, 2H), 8.58 (d, J = 2.4 Hz, 1H), 8.63 (d, J = 2.4 Hz, 1H); 13C
NMR (CDCl3, 100 MHz) δ = 35.7 (CH3), 114.9 (C), 118.6 (C), 121.6 (CH), 121.7 (CH),
125.1 (CH), 125.5 (CH), 130.1 (CH), 136.5 (C), 139.3 (C), 139.6 (C), 141.1 (C), 144.1 (C),
158.6 (C); IR: ν (cm-1) 3341, 1651, 1537, 1531; HRMS (ESI-TOF) Calcd for
C16H11ClN4NaO5 [(M+Na)+]: 397.0310, found 397.0314.
4-(4-Butylphenylamino)-3-chloro-1-methyl-6,8-dinitro-2-quinolone (3Aj)
Yellow solid (58.9 mg, 0.14 mmol, 41%); Rf = 0.50 (CH2Cl2); mp 109−110 °C; 1H NMR
(CDCl3, 400 MHz) δ = 0.92 (t, J = 7.6 Hz, 3H), 1.33 (tq, J = 7.6, 7.6 Hz, 2H), 1.58 (tt, J = 7.6,
7.6 Hz, 2H), 2.60 (t, J = 7.6 Hz, 3H), 3.55 (s, 3H), 6.72 (s, 1H), 6.93 (d, J = 8.0 Hz, 2H), 7.15
(d, J = 8.0 Hz, 2H), 8.57 (d, J = 2.8 Hz, 1H), 8.61 (d, J = 2.8 Hz, 1H); 13C NMR (CDCl3, 100
MHz) δ = 13.9 (CH3), 22.1 (CH2), 33.4 (CH2), 35.0 (CH2), 35.7 (CH3), 113.6 (C), 118.4 (C),
121.6 (CH), 122.3 (CH), 125.3 (CH), 130.1 (CH), 136.6 (C), 138.6 (C), 139.2 (C), 139.4 (C),
140.9 (C), 144.5 (C), 158.6 (C); IR: ν (cm-1) 3352, 1667, 1537, 1531; HRMS (ESI-TOF)
Calcd for C20H20ClN4O5 [(M+H)+]: 431.1117, found 431.1115.
3-Chloro-4-(4-methoxyphenylamino)-1-methyl-6,8-dinitro-2-quinolone (3Ak)
Yellow solid (50.7 mg, 0.13 mmol, 37%); Rf = 0.36 (CH2Cl2); mp 100−102 °C; 1H NMR
(CDCl3, 400 MHz) δ = 3.54 (s, 3H), 3.81 (s, 3H), 6.69 (s, 1H), 6.88 (d, J = 8.8 Hz, 2H), 7.00
(d, J = 8.8 Hz, 2H), 8.59 (d, J = 2.8 Hz, 1H), 8.61 (d, J = 2.8 Hz, 1H); 13C NMR (CDCl3, 100
MHz) δ = 35.7 (CH3), 55.6 (CH3), 112.7 (C), 115.4 (CH), 118.3 (C), 121.6 (CH), 124.5 (CH),
125.2 (CH), 133.8 (C), 136.7 (C), 139.2 (C), 139.3 (C), 144.8 (C), 158.0 (C), 158.5 (C); IR: ν
(cm-1) 3354, 1651, 1537, 1531; HRMS (ESI-TOF) Calcd for C17H14ClN4O6 [(M+H)+]:
405.0596, found 405.0604.
3-Chloro-4-(4-iodophenylamino)-1-methyl-6,8-dinitro-2-quinolone (3Al)
Yellow solid (104.7 mg, 0.21 mmol, 62%); Rf = 0.39 (CH2Cl2); mp 135−137°C; 1H NMR
(CDCl3, 400 MHz) δ = 3.57 (s, 3H), 6.56 (s, 1H), 6.71 (d, J = 8.4 Hz, 2H), 7.63 (d, J = 8.4 Hz,
2H), 8.59 (d, J = 2.4 Hz, 1H), 8.66 (d, J = 2.4 Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ = 35.8
(CH3), 88.4 (C), 116.7 (C), 118.8 (C), 121.9 (CH), 122.6 (CH), 124.7 (CH), 136.3 (C), 139.0
(CH), 139.4 (C), 139.9 (C), 141.1 (C), 143.4 (C), 158.5 (C); IR: ν (cm-1) 3306, 1651, 1537,
1531; HRMS (ESI-TOF) Calcd for C16H10ClIN4NaO5 [(M+Na)+]: 522.9277, found 522.9259.
3-Chloro-1,8-dimethyl-6-nitro-4-(propylamino)-2-quinolone (3Ba)
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Yellow solid (15.1 mg, 0.05 mmol, 13%); Rf = 0.27 (CH2Cl2); mp 156−158 °C; 1H NMR
(CDCl3, 400 MHz) δ = 1.04 (t, J = 7.2 Hz, 3H), 1.74 (tq, J = 7.2, 7.2 Hz, 2H), 2.76 (s, 3H),
3.41 (t, J = 7.2 Hz, 2H), 3.81 (s, 3H), 4.67 (br s, 1H), 8.18 (d, J = 2.4 Hz, 1H), 8.62 (d, J = 2.4
Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ = 11.2 (CH3), 24.1 (CH3), 24.8 (CH2), 38.0 (CH3),
50.9 (CH2), 109.3 (C), 117.5 (C), 119.4 (CH), 127.2 (C), 128.5 (CH), 141.4 (C), 144.4 (C),
150.1 (C), 160.5 (C); IR: ν (cm-1) 3372, 1651, 1599, 1574; HRMS (ESI-TOF) Calcd for
C14H16ClN3NaO3 [(M+Na)+]: 332.0772, found 332.0768.
3-Chloro-1-methyl-6-nitro-4-(propylamino)-2-quinolone (3Ca)
Yellow solid (15.3 mg, 0.05 mmol, 13%); Rf = 0.18 (CH2Cl2); mp 217−219 °C; 1H NMR
(CDCl3, 400 MHz) δ = 1.06 (t, J = 7.2 Hz, 3H), 1.76 (tq, J = 7.2, 7.2 Hz, 2H), 3.58 (dt, J = 6.0,
7.2 Hz, 2H), 3.79 (s, 3H), 4.76 (br s, 1H), 7.46 (d, J = 9.6 Hz, 1H), 8.39 (dd, J = 2.4, 9.6 Hz,
1H), 8.84 (d, J = 2.4 Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ = 11.2 (CH3), 24.8 (CH2), 31.0
(CH3), 50.8 (CH2), 109.3 (C), 115.3 (C), 115.4 (CH), 121.6 (CH), 125.0 (CH), 141.5 (C),
142.5 (C), 149.4 (C), 158.3 (C); IR: ν (cm-1) 3337, 1643, 1557, 1550; HRMS (ESI-TOF)
Calcd for C13H15ClN3O3 [(M+H)+]: 296.0797 found 296.0806.
1a,2,3,7b-Tetrahydro-3-methyl-1a,4,6-trinitro-2-oxo-1-propyl-1H-azirino[2,3-c]quinolin
e (4Aa)
Yellow oil (17.6 mg, 0.05 mmol, 15%); Rf = 0.67 (CH2Cl2); 1H NMR (CDCl3, 400 MHz) δ
= 0.93 (t, J = 7.2 Hz, 3H), 1.56 (ddq, J = 7.2, 7.2, 7.2 Hz, 2H), 2.11 (dt, J = 6.8, 7.2 Hz, 1H),
2.33 (dt, J = 6.8, 7.2 Hz, 1H), 3.39 (s, 3H), 4.32 (s, 1H), 8.58 (d, J = 2.8 Hz, 1H), 8.68 (d, J =
2.8 Hz, 1H); 13C NMR (DMSO-d6, 100 MHz) δ = 11.2 (CH3), 21.9 (CH2), 35.4 (CH3), 46.8
(CH), 47.4 (CH2), 77.7 (C), 119.8 (C), 122.7 (CH), 129.1 (CH), 136.9 (C), 139.2 (C), 141.8
(C), 160.1 (C); IR: ν (cm-1) 1694, 1543, 1537; HRMS (ESI-TOF) Calcd for C13H12N5O7
[(M-H)－]: 350.0742, found 350.0759.
1a,2,3,7b-Tetrahydro-3,4-dimethyl-1a,6-dinitro-2-oxo-1-propyl-1H-azirino[2,3-c]quinoli
ne (4Ba)
Pale yellow solid (24.4 mg, 0.08 mmol, 21%); Rf = 0.61 (CH2Cl2); mp 159−160 °C; 1H
NMR (DMSO-d6, 400 MHz) δ = 0.84 (t, J = 7.2 Hz, 3H), 1.43 (ddq, J = 7.2, 7.2, 7.2 Hz, 2H),
1.95 (dt, J = 5.6, 7.2 Hz, 1H), 2.31 (dt, J = 5.6, 7.2 Hz, 1H), 2.67 (s, 3H), 3.58 (s, 3H), 4.77 (s,
1H), 8.26 (d, J = 2.8 Hz, 1H), 8.42 (d, J = 2.8 Hz, 1H); 13C NMR (DMSO-d6, 100 MHz) δ =
11.3 (CH3), 22.0 (CH2), 22.7 (CH3), 37.3 (CH3), 47.2 (CH2), 47.3 (CH), 77.9 (C), 117.4 (C),
124.0 (CH), 129.1 (C), 129.5 (CH), 142.8 (C), 144.2 (C), 161.1 (C); IR: ν (cm-1) 1682, 1562,
1524; HRMS (ESI-TOF) Calcd for C14H16N4NaO5 [(M+Na)+]: 343.1013, found 343.1014.
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1a,2,3,7b-Tetrahydro-3-methyl-1a,6-dinitro-2-oxo-1-propyl-1H-azirino[2,3-c]quinoline
(4Ca)
Pale yellow solid (60.2 mg, 0.20 mmol, 49%); Rf = 0.60 (CH2Cl2); mp 144−145 °C; 1H
NMR (CDCl3, 400 MHz) δ = 0.90 (t, J = 7.2 Hz, 3H), 1.55 (ddq, J = 6.8, 6.8, 7.2 Hz, 2H),
2.02 (dt, J = 5.2, 6.8 Hz, 1H), 2.30 (dt, J = 5.2, 6.8 Hz, 1H), 3.62 (s, 3H), 4.22 (s, 1H), 7.33 (d,
J = 9.2 Hz, 1H), 8.39 (dd, J = 2.4, 9.2 Hz, 1H), 8.43 (d, J = 2.4 Hz, 1H); 13C NMR (DMSO-d6,
100 MHz) δ = 11.3 (CH3), 21.9 (CH2), 30.4 (CH3), 46.5 (CH), 46.9 (CH2), 78.2 (C), 115.4 (C),
117.0 (CH), 125.8 (CH), 126.3 (CH), 142.7 (C), 142.8 (C), 158.7 (C); IR: ν (cm-1) 1682, 1562,
1526; HRMS (ESI-TOF) Calcd for C13H14N4NaO5 [(M+Na)+]: 329.0856, found 329.0855.
6-Bromo-1a,2,3,7b-tetrahydro-3-methyl-1a-nitro-2-oxo-1-propyl-1H-azirino[2,3-c]quinol
ine (4Da)
White solid (81.2 mg, 0.24 mmol, 68%); Rf = 0.69 (CH2Cl2); mp 171−172 °C; 1H NMR
(CDCl3, 400 MHz) δ = 0.89 (t, J = 7.2 Hz, 3H), 1.54 (ddq, J = 7.2, 7.2, 7.2 Hz, 2H), 2.00 (dt,
J = 5.2, 7.2 Hz, 1H), 2.28 (dt, J = 5.2, 7.2 Hz, 1H), 3.53 (s, 3H), 4.05 (s, 1H), 7.05 (d, J = 8.8
Hz, 1H), 7.60−7.63 (m, 2H); 13C NMR (CDCl3, 100 MHz) δ = 11.5 (CH3), 22.4 (CH2), 29.9
(CH3), 47.4 (CH), 47.7 (CH2), 77.8 (C), 116.5 (CH), 116.6 (C), 116.9 (C), 133.3 (CH), 133.6
(CH), 137.3 (C), 158.4 (C); IR: ν (cm-1) 1667, 1562, 1557; HRMS (ESI-TOF) Calcd for
C13H13BrN3O3 [(M-H)－]: 338.0146, found 338.0160.
5-Bromo-1a,2,3,7b-tetrahydro-3-methyl-1a-nitro-2-oxo-1-propyl-1H-azirino[2,3-c]quinol
ine (4Ea)
Pale yellow solid (77.6 mg, 0.23 mmol, 65%); Rf = 0.73 (CH2Cl2); mp 120−122 °C; 1H
NMR (CDCl3, 400 MHz) δ = 0.88 (t, J = 7.2 Hz, 3H), 1.52 (ddq, J = 7.2, 7.2, 7.2 Hz, 2H),
1.96 (dt, J = 5.2, 7.2 Hz, 1H), 2.30 (dt, J = 5.2, 7.2 Hz, 1H), 3.53 (s, 3H), 4.08 (s, 1H),
7.32−7.37 (m, 3H); 13C NMR (CDCl3, 100 MHz) δ = 11.5 (CH3), 22.4 (CH2), 29.9 (CH3),
47.6 (CH2), 47.7 (CH), 77.8 (C), 113.5 (C), 118.1 (CH), 124.6 (C), 127.0 (CH), 132.0 (CH),
139.3 (C), 158.6 (C); IR: ν (cm-1) 1678, 1597, 1562; HRMS (ESI-TOF) Calcd for
C13H13BrN3O3 [(M-H)－]: 338.0146, found 338.0159.
1a,2,3,7b-Tetrahydro-3-methyl-1a-nitro-2-oxo-1-propyl-1H-azirino[2,3-c]quinoline
(4Fa)
Pale yellow solid (89.8 mg, 0.34 mmol, 71%); Rf = 0.55 (CH2Cl2); mp 98−100 °C; 1H
NMR (CDCl3, 400 MHz) δ = 0.86 (t, J = 7.2 Hz, 3H), 1.52 (ddq, J = 7.2, 7.2, 7.2 Hz, 2H),
1.95 (dt, J = 5.2, 7.2 Hz, 1H), 2.31 (dt, J = 5.2, 7.2 Hz, 1H), 3.55 (s, 3H), 4.12 (s, 1H), 7.18 (d,
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J = 8.4 Hz, 1H), 7.26 (d, J = 8.4 Hz, 1H), 7.50-7.54 (m, 2H); 13C NMR (CDCl3, 100 MHz) δ
= 11.5 (CH3), 22.4 (CH2), 29.8 (CH3), 47.5 (CH2), 48.2 (CH), 78.2 (C), 114.5 (C), 114.8 (CH),
124.1 (CH), 130.7 (CH), 130.8 (CH), 138.1 (C), 158.7 (C); IR: ν (cm-1) 1668, 1562, 1557;
HRMS (ESI-TOF) Calcd for C13H15N3NaO3 [(M+Na)+]: 284.1006, found 284.1012.
1a,2,3,7b-Tetrahydro-1a-nitro-2-oxo-1-propyl-1H-azirino[2,3-c]quinoline (4Ha)
Yellow solid (78.1 mg, 0.32 mmol, 61%); Rf = 0.18 (CH2Cl2); mp 122−123 °C; 1H NMR
(CDCl3, 400 MHz) δ = 0.89 (t, J = 7.2 Hz, 3H), 1.56 (ddq, J = 7.2, 7.2, 7.2 Hz, 2H), 2.08 (dt,
J = 5.2, 7.2 Hz, 1H), 2.44 (dt, J = 5.2, 7.2 Hz, 1H), 4.16 (s, 1H), 7.07 (d, J = 7.6 Hz, 1H), 7.22
(dd, J = 7.6, 7.6 Hz, 1H), 7.44 (dd, J = 7.6, 7.6 Hz, 1H), 7.49 (d, J = 7.6 Hz, 1H); 13C NMR
(CDCl3, 100 MHz) δ = 11.5 (CH3), 22.4 (CH2), 47.6 (CH2), 49.1 (CH), 77.9 (C), 113.6 (C),
116.3 (CH), 124.7 (CH), 130.2 (CH), 130.7 (CH), 135.4 (C), 160.3 (C); IR: ν (cm-1) 1681,
1562, 1557; HRMS (ESI-TOF) Calcd for C12H13N3NaO3 [(M+Na)+]: 270.0849, found
270.0843.
3-Chloro-1-methyl-6,8-dinitro-4-(2,5-dioxopyrrolidino)-2-quinolone (5A)
Yellow solid (61.2 mg, 0.16 mmol, 48%). Rf = 0.10 (CH2Cl2); mp 294−297 °C; 1H NMR
(DMSO-d6, 400 MHz) δ = 3.05−3.23 (m, 4H), 3.52 (s, 3H), 8.98 (d, J = 2.4 Hz, 1H), 9.04 (d,
J = 2.4 Hz, 1H); 13C NMR (DMSO-d6, 100 MHz) δ = 29.6 (CH2), 36.4 (CH3), 120.2 (C),
123.4 (CH), 124.1 (CH), 128.9 (C), 135.5 (C), 137.3 (C), 139.0 (C), 141.3 (C), 157.8 (C),
175.3 (C); IR: ν (cm-1) 1682, 1537, 1531; HRMS (ESI-TOF) Calcd for C14H10ClN4O7
[(M+H)+]: 381.0233, found 381.0238.
3-Chloro-1-methyl-6-nitro-4-(2,5-dioxopyrrolidino)-2-quinolone (5C)
Yellow powder (8.9 mg, 0.03 mmol, 7%); Rf = 0.48 (CH2Cl2/MeOH = 20/1); mp
283−285 °C; 1H NMR (DMSO-d6, 400 MHz) δ = 2.98−3.19 (m, 4H), 3.83 (s, 3H), 7.92 (d, J
= 9.2 Hz, 1H), 8.50 (dd, J = 2.8, 9.2 Hz, 1H), 8.64 (d, J = 2.8 Hz, 1H); 13C NMR (DMSO-d6,
100 MHz) δ = 29.5 (CH2), 31.8 (CH3), 116.8 (C), 117.4 (CH), 120.7 (CH), 126.2 (CH), 127.7
(C), 137.4 (C), 141.7 (C), 142.7 (C), 157.0 (C), 175.4 (C); IR: ν (cm-1) 1651, 1537, 1520;
HRMS (ESI-TOF) Calcd for C14H11ClN3O5 [(M+H)+]: 336.0382, found 336.0387.
3-Bromo-1-methyl-6,8-dinitro-4-(propylamino)-2-quinolone (6Aa)
Yellow solid (81.8 mg, 0.21 mmol, 63%); Rf = 0.35 (ethyl acetate/hexane = 1/2); mp
213-215 °C; 1H NMR (CDCl3, 400 MHz) δ = 1.06 (t, J = 7.2 Hz, 3H), 1.66 (tq, J = 7.2, 7.2 Hz,
2H), 3.49−3.53 (m, 5H), 4.89 (br s, 1H), 8.73 (d, J = 2.4 Hz, 1H), 8.96 (d, J = 2.4 Hz, 1H);
13C NMR (CDCl3, 400 MHz) δ = 11.2 (CH3), 24.8 (CH2), 35.7 (CH3), 51.5 (CH2), 103.0 (C),
118.6 (C), 122.0 (CH), 124.3 (CH), 137.2 (C), 139.1 (C), 139.4 (C), 151.3 (C), 158.5 (C); IR:
ν (cm-1) 3374, 1651, 1537, 1531; HRMS (ESI-TOF) Calcd for C13H12BrN4O5 [(M-H) － ]:
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382.9997, found 383.0007.
4-(Benzylamino)-3-bromo-1-methyl-6,8-dinitro-2-quinolone (6Af)
Yellow solid (79.8 mg, 0.19 mmol, 55%); Rf = 0.45 (CH2Cl2); mp 134−136 °C; 1H NMR
(CDCl3, 400 MHz) δ = 3.51 (s, 3H), 4.69 (d, J = 6.4 Hz, 2H), 5.26 (t, J = 6.4 Hz, 1H),
7.34−7.44 (m, 5H), 8.73 (d, J = 2.4 Hz, 1H), 8.99 (d, J = 2.4 Hz, 1H); 13C NMR (CDCl3, 100
MHz) δ = 35.8 (CH3), 53.2 (CH2), 104.1 (C), 118.6 (C), 122.0 (CH), 124.2 (CH), 127.4 (CH),
128.6 (CH), 129.3 (CH), 137.1 (C), 137.2 (C), 139.1 (C), 139.5 (C), 150.9 (C), 158.5 (C); IR:
ν (cm-1) 3352, 1651, 1537, 1531; HRMS (ESI-TOF) Calcd for C17H14BrN4O5 [(M+H)+]:
433.0142, found 433.0160.
1-Methyl-3,6,8-trinitro-4-(propylamino)-2-quinolone (7Aa)
Yellow solid (73.0 mg, 0.21 mmol, 62%); Rf = 0.10 (CH2Cl2); mp 184−187 °C; 1H NMR
(CDCl3, 400 MHz) δ = 1.07 (t, J = 7.2 Hz, 3H), 1.85 (tq, J = 7.2, 7.2 Hz, 2H), 3.43 (s, 3H),
3.56 (dt, J = 6.8, 7.2 Hz, 2H), 7.69 (br s, 1H), 8.81 (d, J = 2.4 Hz, 1H), 9.04 (d, J = 2.4 Hz,
1H); 13C NMR (CDCl3, 100 MHz) δ = 11.1 (CH3), 23.8 (CH2), 35.0 (CH3), 48.9 (CH2), 117.9
(C), 122.7 (C), 124.0 (CH), 124.5 (CH), 138.4 (C), 139.3 (C), 139.6 (C), 146.2 (C), 156.2 (C);
IR: ν (cm-1) 3343, 1651, 1537, 1531; HRMS (ESI-TOF) Calcd for C13H14N5O7 [(M+H)+]:
352.0888, found 352.0904.
1,8-Dimethyl-3,6-dinitro-4-(propylamino)-2-quinolone (7Ba)
Yellow solid (25.2 mg, 0.08 mmol, 21%); Rf = 0.17 (CH2Cl2); mp 208−210 °C; 1H NMR
(CDCl3, 400 MHz) δ = 1.07 (t, J = 7.2 Hz, 3H), 1.84 (tq, J = 7.2, 7.2 Hz, 2H), 2.72 (s, 3H),
3.61 (dt, J = 5.2, 7.2 Hz, 2H), 3.70 (s, 3H), 8.06 (br s, 1H), 8.27 (d, J = 2.4 Hz, 1H), 8.67 (d, J
= 2.4 Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ = 11.2 (CH3), 23.7 (CH3), 23.9 (CH2), 37.6
(CH3), 49.2 (CH2), 116.3 (C), 119.8 (CH), 121.9 (C), 128.4 (C), 130.7 (CH), 141.6 (C), 145.9
(C), 149.0 (C), 158.1 (C); IR: ν (cm-1) 3331, 1643, 1524, 1518; HRMS (ESI-TOF) Calcd for
C14H16N4NaO5 [(M+Na)+]: 343.1013, found 343.1022.
4.5 cine-Substitution of 1,8-dimethyl-3,5-dinitro-2-quinolone (1I)
To a solution of 1I (70.0 mg, 0.27 mmol) in THF (1.0 mL) was added propylamine 2a
(47.2 mg, 0.80 mmol), and the resultant mixture was stirred at room temperature for 3 h. Then,
the solvent was evaporated to afford a reaction mixture 8Ia as a yellow solid (75.5 mg, 0.27
mmol, quant.); Rf = 0.27 (CH2Cl2); 1H NMR (CDCl3, 400 MHz) δ = 0.97 (t, J = 7.2 Hz, 3H),
1.67 (tq, J = 7.2, 7.2 Hz, 2H), 2.59 (s, 3H), 3.41 (dt, J = 5.6, 7.2 Hz, 2H), 3.77 (s, 3H), 6.60 (d,
J = 9.6 Hz, 1H), 7.82 (br s, 1H), 7.96 (d, J = 9.6 Hz, 1H), 8.04 (s, 1H); 13C NMR (CDCl3, 100
MHz) δ = 11.3 (CH3), 23.2 (CH3), 24.9 (CH2), 36.9 (CH3), 54.0 (CH2), 113.7 (C), 117.0 (C),
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117.9 (CH), 131.0 (CH), 131.1 (C), 136.6 (CH), 146.0 (C), 149.0 (C), 163.9 (C); IR: ν (cm-1)
3300, 1651, 1580, 1574; HRMS (ESI-TOF) Calcd for C14H18N3O3 [(M+H)+]: 276.1343, found
276.1339.
4.6 Suzuki-Miyaura coupling reaction of benzylamino-brominated 6Af
To a solution of 6Af (63.0 mg, 0.15 mmol) in 1,4-dioxane (2.0 mL), were added
p-MeC6H4B(OH)2 (29.7 mg, 0.22 mmol), Pd(PPh3)2Cl2 (10.2 mg, 0.01 mmol) and K2CO3
(40 .3 mg, 0.29 mmol) . Then , the resu l tan t mixtu re was hea ted at 80 °C for
22 h. After the mixture was filtrated, the solvent was evaporated to afford a reaction mixture
as a yellow residue, from which arylated product 9 was isolated by SiO2 column
chromatography (eluted with ethyl acetate/hexane = 1/5) as a yellow solid (42.4 mg, 0.10
mmol, 66%); Rf = 0.29 (ethyl acetate/hexane = 1/5); mp 143−145 °C; 1H NMR (CDCl3, 400
MHz) δ = 2.38 (s, 3H), 3.46 (s, 3H), 4.22 (d, J = 6.4 Hz, 2H), 4.57 (t, J = 6.4 Hz, 1H),
7.10−7.13 (m, 4H), 7.23 (d, J = 7.6 Hz, 2H), 7.31−7.32 (m, 3H), 8.72 (d, J = 2.4 Hz, 1H),
8.92 (d, J = 2.4 Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ = 20.3 (CH3), 33.8 (CH3), 51.9 (CH2),
116.8 (C), 119.4 (C), 120.7 (CH), 122.4 (CH), 126.5 (CH), 127.1 (CH), 128.0 (CH), 128.5 (C),
128.7 (CH), 129.1 (CH), 136.5 (C), 137.0 (C), 137.5 (C), 137.8 (C), 138.3 (C), 147.8 (C),
161.4 (C); IR: ν (cm-1) 3352, 1651, 1537, 1531; HRMS (ESI-TOF) Calcd for C24H21N4O5
[(M+H)+]: 445.1507, found 445.1505.
4.7 Hydrazinolysis of 5A
To a solution of 5A (50.0 mg, 0.13 mmol) in MeOH (2.0 mL), NH2NH2•H2O (17.8 mg,
0.36 mmol) was added, and the resultant mixture was heated at 70 °C for 3 h. Then, the
solvent was evaporated to afford a reaction mixture as a yellow solid. After the solid was
washed by water (5 mL × 1), 4-aminoquinolone 10 was isolated through filtration as a yellow
solid (20.0 mg, 0.07 mmol, 51%); Rf = 0.36 (CH2Cl2/MeOH = 10/1); mp > 300 °C; 1H NMR
(DMSO-d6, 400 MHz) δ = 3.29 (s, 3H), 7.54 (br s, 2H), 8.89 (d, J = 2.0 Hz, 1H), 9.35 (d, J =
2.0 Hz, 1H); 13C NMR (DMSO-d6, 400 MHz) δ = 35.1 (CH3), 99.8 (C), 117.2 (C), 122.5 (CH),
123.2 (CH), 136.5 (C), 138.5 (C), 139.7 (C), 147.1 (C), 158.2 (C); IR: ν (cm-1) 1651, 1537,
1531; HRMS (ESI-TOF) Calcd for C10H8ClN4O5 [(M+H)+]: 299.0178, found 299.0172.
4.8 Acid-catalyzed ring opening of aziridine ring
To a solution of 4Fa (38.5 mg, 0.15 mmol) in MeOH (0.5 mL), acid (p-TsOH•H2O or 1
N HCl aq. or BF3•Et2O, 0.18 mmol, 1.2 equiv.) was added, and the resultant mixture was
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stirred at room temperature for 3 h. Then, the solvent was evaporated to afford a mixture as a
yellow residue, from which vicinally amino-nitrated product 7Fa was isolated by SiO2
column chromatography (eluted with CH2Cl2) as a yellow solid (38.5 mg, 0.15 mmol,
quant.); Rf = 0.60 (CH2Cl2); mp 121−122 °C; 1H NMR (CDCl3, 400 MHz) δ = 1.00 (t, J =
7.2 Hz, 3H), 1.69 (tq, J = 7.2, 7.2 Hz, 2H), 3.11 (dt, J = 5.6, 7.2 Hz, 2H), 3.80 (s, 3H), 6.09
(br s, 1H), 7.27−7.30 (m, 1H), 7.33−7.40 (m, 2H), 7.48 (dd, J = 0.8, 8.0 Hz, 1H); 13C NMR
(CDCl3, 100 MHz) δ = 11.3 (CH3), 23.2 (CH2), 31.1 (CH3), 45.0 (CH2), 114.3 (CH), 115.5
(C), 120.3 (CH), 124.1 (CH), 126.4 (CH), 128.2 (C), 129.6 (C), 131.2 (C), 158.9 (C); IR: ν
(cm-1) 3312, 1651, 1574, 1557; HRMS (ESI-TOF) Calcd for C13H16N3O3 [(M+H)+]:
262.1186, found 262.1195.
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Chapter 4. Direct Aziridination of Nitroalkenes Affording
N-Alkyl-C-nitroaziridines and the Subsequent Lewis Acid
Mediated Isomerization to β-Nitroenamines
A mild and highly diastereoselective one-pot synthesis of trans-N-alkyl-C-nitroaziridines
was achieved by the treatment of nitroalkenes with aliphatic amines and N-chlorosuccinimide.
Treatment of the obtained aziridines with a Lewis acid resulted in a facile ring opening
reaction, accompanied by rearrangement and isomerization into functionalized
(Z)-β-nitroenamines.
1. Introduction
The aziridines are an important class of nitrogen containing heterocycles and can be found
in a number of biologically active compounds, such as mitomycin, porfiromycin, and
azinomycin.1 In addition, functionalized aziridines also serve as versatile building blocks in
organic synthesis.1,2 The ring opening reaction of aziridines with nucleophiles affords various
1,2-difunctionalized compounds.1,2 A substantial number of functionalized aziridines can also
be transformed into useful products such as HIV protease inhibitor,3 communesin,4 ceramide,5
oseltamivir,6 and isochroman7 through rearrangement, cycloaddition, and ring expansion
reactions.2 Among the functionalized aziridines, C-nitroaziridines play an important role in
chemical transformations because of the strong electron-withdrawing ability of the nitro
group.8 Hence, the development of efficient methods for the preparation of C-nitroaziridines
has attracted much attention among organic chemists.
Among preparative methods for C-nitroaziridines, the direct aziridination of nitroalkenes is
the most efficient approach from a practical viewpoint, as it requires only simple experimental
manipulations. N-Imidoaziridines are obtained by the treatment of N-aminoimides with
nitroalkenes in the presence of an oxidant (Scheme 1, a).9 NsONHCO2Et and TsONHCO2Et
serve as an N1 unit that can undergo direct aziridination of nitroalkenes under basic
conditions to afford N-alkoxycarbonylaziridines (Scheme 1, b).10 Additionally,
N-arylaziridines are also available through the reaction of electron-deficient nitroalkenes with
aromatic amines followed by ring closure (Scheme 1, c).11 Unexpectedly, there are no reports
on the synthesis of N-alkyl-C-nitroaziridines from nitroalkenes through direct aziridination,
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except for the multistep synthesis via α-bromonitroalkenes; however, the substrate scope is
not investigated further (Scheme 1, d).12 Thus, a facile and efficient aziridination of
nitroalkenes for the synthesis of N-alkylated nitroaziridines is of great interest.
Scheme 1. Direct aziridination of nitroalkenes
As part of my continuing interest in methods for the direct functionalization of the
2-quinolone framework, I achieved the direct aziridination by a sequential treatment of
3-nitro-2-quinolones with an amine and N-chlorosuccinimide (NCS) (Scheme 1, e).13 Inspired
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by this protocol, we envisaged that direct aziridination of nitroalkenes might proceed to afford
N-alkyl-C-nitroaziridines by the sequential treatment with aliphatic amine and NCS (Scheme
1, f).
2. Results and Discussion
2.1 Optimization of reaction conditions for aziridination
To evaluate the potential for direct aziridination, nitrostyrene 1a and propylamine 2a were
selected as model substrates. When β-nitrostyrene 1a was reacted with propylamine 2a and
NCS at room temperature in THF in the presence of Et3N, N-propyl-C-nitroaziridine 3a was
successfully obtained (Table 1, entry1). In the 1H NMR, signals for the ring protons H2 and H3
were observed at 3.85 and 4.90 ppm, respectively, with a coupling constant of 1.6 Hz, located
in the range (≤ 2 Hz) for the trans configuration.14 Moreover, a correlation between protons
H3 and ortho proton (Ho) of the benzene ring in the NOESY spectrum revealed the resultant
aziridine is a trans isomer.
As depicted in Table 1, the organic bases did not work enough, giving the aziridinated
product 3a in low yields even though the prolonged reaction time was used (entries 1–9). In
some cases, the starting material 1a was not consumed completely owing to the formation of
ammonium nitronate of aza-Micheal adduct with another molecule of amine (entries 1–6).
Although a complete conversion of 1a was observed in the presence of more basic DBU, the
imine 4a was formed as a major product rather than the aziridine 3a (entry 7). Compared to
organic bases, inorganic bases such as carbonate and hydroxide were more suitable for this
reaction, and the best result was obtained in the reaction using Cs2CO3 as the base (entries
10–14). Indeed, the use of Cs2CO3 as a base was proved to be crucial in a variety of
aziridinations due to its proper solubility and basicity.15
Next, different solvents were screened in this transformation. However, replacing THF with
other solvents did not improve the yield of 3a (entries 15–19). In order to examine whether
low temperature could suppress the formation of imine 4a or not, the reaction was conducted
at -10 °C, however, both reactions affording 3a and 4a were almost suppressed (entry 20). A
better result was obtained in the presence of a slightly excess amount of propylamine 2a and
N-chlorosuccinimide (NCS), giving 3a in 85% yield (entry 21). Although higher loadings of
propylamine and NCS were employed to promote the conversion of nitroalkene, the
transformation did not proceed thoroughly, which might be caused by the equilibrium process
between propylamine and NCS (entry 22).16
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Table 1. Optimization of reaction conditions for the aziridination of 1a
Entry Base
Time
(h)
Solvent
Yielda (%) Recov.a
(%)3a 4a
1 Et3N 5 THF 23 0 77
2 Et3N 28 THF 21 39 38
3b Et3N 28 THF 17 32 51
4 PrNH2 5 THF 17 19 64
5 PrNH2 28 THF 39 20 38
6 Pyridine 28 THF 11 13 60
7 DBU 5 THF 0 74 0
8 t-BuOK 5 THF 52 48 0
9 AcONa 5 THF 29 3 37
10 K2CO3 5 THF 55 0 45
11 K2CO3 28 THF 73 18 5
12 NaOH 5 THF 47 9 33
13 NaOH 28 THF 71 22 0
14 Cs2CO3 5 THF 79 11 10
15 Cs2CO3 5 MeOH 14 86 0
16 Cs2CO3 5 MeCN 77 23 0
17 Cs2CO3 5 DMF 52 48 0
18 Cs2CO3 5 hexane 18 25 19
19 Cs2CO3 5 CH2Cl2 70 27 0
20c Cs2CO3 5 THF 4 3 93
21d Cs2CO3 5 THF 85 6 9
22e Cs2CO3 5 THF 73 11 15
aYield and recovery were determined by the integral of 1H NMR of the reaction mixture. b2.0 Equiv. Of Et3N was
used. cThe reaction was conducted at -10℃. d1.1 Equiv. of propylamine and NCS was used. eThe reaction involved
1.3 equiv. of propylamine and NCS together with 1.1 equiv. of Cs2CO3.
Overall, the reaction conditions utilized in entry 21 were determined to be optimal. Instead
of NCS, other halosuccinimides such as N-bromosuccinimide (NBS) and N-iodosuccinimide
(NIS) were also examined, however, the aziridine was not formed owing to the higher steric
hindrance of bromo and iodo groups than chloro group.
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2.2 A plausible mechanism for aziridination
On the basis of the above results, a plausible mechanism for aziridination is proposed. The
conjugate addition of amine to 1a affords intermediate 5, in which the conformation is fixed
by intramolecular hydrogen bond (Scheme 2). Thus, NCS approaches to 5 from the anti
direction of the aromatic group to avoid the steric hindrance, affording the adduct 6. The
subsequent backside attack of the amino group affords aziridine 3a with the trans
configuration (Path a). Meanwhile, the competitive proton transfer followed by elimination of
anionic nitromethane leads to imine 4a (Path b).17 Indeed, 4a was quantitatively obtained
when the reaction was conducted in the absence of NCS.
Scheme 2. A plausible mechanism for aziridination
2.3 Instability of N-alkyl-C-nitroaziridine 3a
Although the yield of the conversion of β-nitrostyrene 1a into aziridine 3a reached up to
85%, the isolated yield decreased to 31% after workup using water and purification by silica
gel column chromatography. Control experiments revealed that aziridine 3a in CDCl3
gradually decomposed into p-tolualdehyde at room temperature (Table 2, entries 1–4).
Furthermore, decomposition of 3a readily occurs within shorter time under upon heating
(entries 5 and 6).
The 1H NMR spectra of the isolated aziridine 3a were shown in Figure 1, by which
formation of p-tolualdehyde was observed as a result of decomposition of 3a.
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Table 2. Decomposition of 3a
Entry Time (h) Temp. (°C)
Ratioa of
3a/p-tolualdehyde
1 — rt 90/10
2 12 rt 70/30
3 24 rt 62/38
4 36 rt 50/50
5 1.5 45 75/25
6 2 60 43/57
aRatio was determined by the integral values in the 1H NMR.
Figure 1. Confirmation of decomposition of 3a through 1H NMR
2.4 Lewis acid mediated ring opening and rearrangement of aziridine
Due to the instability at ambient conditions, we studied the conversion of aziridine 3a into a
useful and easily treatable reagent. N-propyl-C-nitroaziridine 3a was found to isomerize into
β-aryl-β-nitroenamine 8a in the presence of a Lewis acid. Notably, the aryl group rearranged
to the adjacent carbon. Due to their “push-pull” property, β-nitroenamines serve as key
90
synthetic intermediates for functional materials such as bioactive compounds and optical
materials.18However, very few reports are focused on β-aryl-β-nitroenamines because of their
poor availability.19 Therefore, our method potentially yields a novel class of β-nitroenamines
with structural diversity.
Among the several Lewis acids tested in MeCN, the isomerization of 3a occurred most
efficiently in the presence of SnCl2·2H2O, giving 8a with a 76% yield, as a mixture of Z/E
isomers with a 93/7 ratio (Table 3, entry 9). The replacement of MeCN with other solvents
did not afford better results (entries 11–14). Moreover, a low temperature had no impact on
the reaction (entry 15). The correlation between protons Hα and ortho proton (Ho) of the
benzene ring in the NOESY spectrum revealed the major isomer has a Z-configuration, which
was finally confirmed by X-ray crystallography (Figure 2)。
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Table 3. Screening of the Lewis acids for the rearrangement of the aryl group
Entry Lewis acid Solvent Yielda (%) Z:Eb
1 CuI MeCN 0 –
2 Cu(OAc)2 MeCN 0 –
3 TsOH MeCN 47 93:7
4 BF3·Et2O MeCN 63 93:7
5 ZnCl2 MeCN 65 93:7
6 FeCl3 MeCN 55 92:8
7 FeCl2·4H2O MeCN 66 93:7
8 AlCl3 MeCN 32 91:9
9 SnCl2·2H2O MeCN 81 (76c) 93:7
10 SnCl4·5H2O MeCN 69 93:7
11 SnCl2·2H2O THF 27 93:7
12 SnCl2·2H2O MeOH 15 93:7
13 SnCl2·2H2O hexane 0 93:7
14 SnCl2·2H2O CH2Cl2 62 93:7
15b SnCl2·2H2O MeCN 78 93:7
aThe yield and ratio were determined by 1H NMR using dibromomethane as internal standard.
bThe reaction was conducted at -10℃. cIsolated yield based on 3a.
Figure 2. X-ray single crystal structure of 8a (50% probability factor for the thermal
ellipsoids)
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2.5 A plausible mechanism for isomerization of 3a into 8a
Lewis acid-catalyzed conversion of aziridines into enamines is hitherto unknown reaction
to the best of our knowledge. Sugihara et al. reported a BF3-catalyzed aza-pinacol
rearrangement of N-tosylaziridines into N-tosylimines, tautomers of enamines, in which the
hydrogen migration is preferable to the alkyl migration.20 On the basis of our preliminary
results and Sugihara’s study, the plausible mechanism for this isomerization is illustrated
(Scheme 3). Although a benzylic carbocation should be predominantly formed due to the
resonance stabilization after ring opening of aziridine upon coordination of Lewis acid to the
ring nitrogen (Path c),21 the ring closure instead of the migration of the electron-deficient nitro
group may easily proceed to regenerate aziridine ring. Thus, the ring opening is considered to
proceed in Path d, in which the migration of the electron-rich tolyl group is preferable than
the hydrogen migration due to the formation of lower-energy bridged phenonium ion; the
subsequent deprotonation affords 8a. In this step, the (Z)-isomer was mainly formed due to
the stabilization by an intramolecular hydrogen bond between nitro and amino groups.10a,19
Scheme 3. A plausible mechanism for isomerization
2.6 Study on nitroalkene scope
With the optimized reaction conditions in hand, the scope of these successive reactions was
explored. We firstly screened a wide array of nitroalkenes (Table 4). After reactions of
nitroalkenes 1 with amine 2a and NCS, the mixtures were treated by a sequential workup;
evaporation of the solvent, aqueous wash, extraction with CH2Cl2, and evaporation, which
affords the crude aziridines 3 as an oil. Under the optimized reaction conditions,
β-nitrostyrenes 1a–g bearing electron-donating Me and MeO groups or weakly
electron-withdrawing halo groups successfully gave the corresponding aziridines 3a–g in
moderate to good yields, respectively (entries 1–7). However, introduction of the strong
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electron-withdrawing groups such as CN and NO2 markedly decreased the formation of
aziridines 3h and 3i (entries 8 and 9). In these cases, the low electron density at the benzylic
position increases the acidity and decreases the nucleophilicity of the adjacent amino group in
the intermediate 5 (Scheme 2). Consequently, the imidization is promoted.
While α-naphthylalkene 1j afforded aziridine 3j efficiently, neither electron-rich
β-methylalkene 1k nor electron-poor α-nitroacrylate 1l underwent aziridination owing to the
steric hindrance of the β-substituents, which suppressed the chlorination of carbanion (entries
10–12). Furthermore, the hetaryl-substituted nitroalkenes were also usable as the substrates to
afford the corresponding aziridines 3m–o, respectively (entries 13–15). Even though
(Z)-nitroalkene 1e’ was instead of (E)-isomer 1e, the trans-aziridine 3e was obtained with
similar reactivity and selectivity, indicating that both substrates 1e and 1e’ afforded common
intermediate 5 (entries 5 and 16). This protocol was also compatible with the aliphatic
nitroalkene 1p, affording N-alkyl-C-nitroaziridine 3p in a moderate yield (entry 17).
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Table 4. Scanning of nitroalkenes
Entry R1 R2
Yielda (%) ratio
of 3/43 4
1 4-MeC6H4 H a 72 5 93:7
2 4-MeOC6H4 H b 53c 8 87:13
3 2-MeOC6H4 H c 54c 4 93:7
4 3,5-(MeO)2C6H3 H d 63 8 89:11
5 C6H5 H e 63 9 88:12
6 4-BrC6H4 H f 56 16 78:22
7 4-ClC6H4 H g 51 20 72:28
8 4-NCC6H4 H h 30 24 56:44
9 4-O2NC6H4 H i 6c 29 17:83
10 2-naphthyl H j 63 10 86:14
11 4-MeC6H4 Me k 0 19 0:100
12 4-MeC6H4 COOEt l 0 100 0:100
13 2-thienyl H m 34c 27 56:44
14 2-furyl H n 40c 11 78:22
15 3-pyridyl H o 46 13 78:22
16b C6H5 H e’ 55 11 83:17
17 PhCH2CH2 H p 65 0 100:0
aThe yield was determined by 1H NMR using 1,1,2,2-tetrachloroethane as internal standard. b(Z)-β-nitrostyrene was
used. cThese compounds were characterized by 1H NMR because they were unstable and rearranged to enamines 8
on silica gel.
The SnCl2-mediated conversions of crude aziridines 3a–p to β-nitroenamines 8a–p were
studied (Table 5). While electron-rich aromatic groups efficiently migrated (entries 1–3,
9–11), the efficiency of rearrangement of slightly electron-poor aromatic group decreased
(entries 4–7). Furthermore, strongly electron-poor 4-cyanophenyl and 2-pyridyl groups did
not migrate at all, which is due to the low migratory ability (entries 8 and 12).
N-Alkylaziridine 3p did not undergo the isomerization because of a similar reason (entry 13).
In all these successful cases, β-nitroenamines 8 were diastereoselectively obtained in
(Z)-configuration.
95
Table 5. Isomerization of aziridines into β-nitroenamines
Entry R1 Yield (%) of 8c/(Z:E)d
1 4-MeC6H4 a 76 (93:7)
2 4-MeOC6H4 b 87 (93:7)
3a 2-MeOC6H4 c 89 (89:11)
4b 3,5-(MeO)2C6H3 d 45 (93:7)
5a C6H5 e 40 (94:6)
6b 4-BrC6H4 f 49 (96:4)
7b 4-ClC6H4 g 45 (96:4)
8b 4-NCC6H4 h n.d.e
9a 2-naphthyl j 83 (94:6)
10a 2-thienyl m quant. (94:6)
11a 2-furyl n 80 (92:8)
12b 3-pyridyl o n.r.f
13a PhCH2CH2 p n.r.f
a1.0 equiv. of SnCl2·2H2O was used. b1.5 equiv. of SnCl2·2H2O was used. cIsolated yield based on 3.
dThe ratio of Z and E isomers was determined by the integral of 1H NMR. eNo desired product. fNo reaction.
2.7 Scanning of amines
Next, the scope of this protocol was expanded to other aliphatic amines such as
isobutylamine and sec-butylamine, which afforded the corresponding aziridines 3q and 3r in
moderate to good yields, however, bulkier tert-butylamine did not furnish product 3s while
benzylamine afforded product 3t (Table 6, entries 1–5). In the case of an aromatic amine, no
aziridination proceeded (entry 6). Pleasingly, allyl group was well tolerated, facilitating
further functionalizations (entry 7). Additionally, it was possible to introduce a hydroxy group
on the alkyl group, however decomposition of aziridines 3w and 3x to p-tolualdehyde was
considerably accelerated (entries 8–9). On the other hand, when ethylenediamine was
employed to undergo the ring expansion, a complex mixture was obtained (entry 10). The
produced crude aziridines were subjected to the next isomerization step without further
purification, by which the corresponding β-nitroenamines 8q–x were furnished in satisfactory
yields (Table 1). Regardless of different N-substituents in 3, β-nitroenamines 8 were formed
with high Z-selectivity.
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Table 6. Study on amine scope
Entry R
Yield (%)
3a 8b/(Z:E)d
1 Pr 3a: 72 8a:76 (93:7)
2 i-Bu 3q:54 8q:73 (93:7)
3c sec-Bu 3r:31 8r:80 (93:7)
4 t-Bu 3s:0 －
5c Benzyl 3t:41 8t:86 (92:8)
6 4-MeOC6H4 3u:0 －
7 Allyl 3v:67 8v:82 (92:8)
8 HOCH2CH2 3w:30 8w:64 (93:7)
9 HOCH2CH2CH2 3x:35 8x:74 (92:8)
10 H2NCH2CH2 3y:cme －
aThe yield was determined by 1H NMR using 1,1,2,2-tetrachloroethane as internal standard. bIsolated
yield based on 3. c1.0 equiv. of SnCl2·2H2O was used. dThe ratio of Z and E isomers was determined
by the integral of 1H NMR. eComplex mixture.
3. Conclusion
In conclusion, we have developed an efficient and highly diastereoselective one-pot
synthesis of trans-N-alkyl-C-nitroaziridines 3 upon treatment of nitroalkenes 1 with aliphatic
amines 2 and NCS under mild conditions. The resultant aziridines 3 were isomerized into
functionalized (Z)-β-nitroenamines 8 with high diastereoselectivity through Lewis
acid-mediated ring opening and rearrangement. Further efforts about the application of these
protocols for synthesizing versatile functionalized compounds is under investigation in our
group.
4. Experimental section
4.1 General information
The melting points were determined on SRS-Optimelt Automated Melting Point System,
and are uncorrected. All the reagents and solvents were commercially available and used as
received. The 1H NMR spectra were measured on a Bruker Ascend-400 at 400 MHz with
tetramethylsilane as an internal standard. The 13C NMR spectra were measured on a Bruker
Ascend-400 at 100 MHz, and assignments of 13C NMR spectra were performed by DEPT
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experiments. The high-resolution mass spectra were measured on an AB SCIEX Triple TOF
4600. The IR spectra were recorded on a JASCO FT/IR-4200 spectrometer. As observed for
aziridine 3a, the isolated yield was considerably diminished compared with NMR yield
because of the instability to decompose. Hence, aziridines 3 were subjected to the subsequent
reactions without further purification. The yields of unpurified aziridines were determined by
1H NMR using 1,1,2,2-tetrachloroethane as internal standard. Some signals of E-isomers of
nitroenamines 8 could not be detected in 1H NMR and 13C NMR owing to the low
concentration of the compounds in the deuterated solvent. Hence, only spectrum data of
Z-isomer were shown.
4.2 General procedure for the preparation of nitroalkenes
(E)-Aromatic nitrostyrenes 1a–k and 1m–o were successfully synthesized in moderate to
good yields upon treatment of aromatic aldehydes with nitromethane or nitroethane in the
presence of ammonium acetate.22
α-Nitro-β-arylenoate 1l was prepared through the condensation reaction of p-tolualdehyde
with ethyl nitroacetate in the presence of dimethylamine hydrochloride.23
(Z)-nitrostyrene 1e’ was prepared through photoisomerization of the (E)-nitrostyrene under
the irradiation of a mercury-vapour lamp.24 It was also confirmed that Z-isomer 1e’ did not
isomerize to E-isomer 1e under the reaction conditions employed for aziridination.
Aliphatic nitroalkene 1p was prepared through the condensation reaction of aliphatic
aldehyde with nitromethane in the presence of sodium hydroxide followed by MsCl–mediated
dehydration.25
4.3 General procedure for one-pot synthesis of trans-N-alkyl-C-nitroaziridine 3
trans-2-(4-methylphenyl)-3-nitro-1-propylaziridine (3a)
To a solution of (E)-β-nitrostyrenes 1a (99 mg, 0.61 mmol) and propylamine 2a (55 L,
0.67 mmol) in THF (2.5 mL), were added NCS (89 mg, 0.67 mmol) and Cs2CO3 (198 mg,
0.61 mmol) successively, and the resultant mixture was stirred at room temperature for 5 h.
Then, the solvent was evaporated to afford a reaction mixture as a purple residue, which
underwent aqueous workup followed by extraction using CH2Cl2. The crude aziridines were
obtained as oil after concentration of organic phase, in which aziridine 3a was included in
72% NMR yield. The mixture was subjected to column chromatography on silica gel to
isolate 3a (eluted with CH2Cl2/hexane = 1:2, 41.2 mg, 0.19 mmol, 31% yield) as a yellow oil.
1H NMR (CDCl3) δ 0.89 (t, J = 7.2 Hz, 3H), 1.50–1.65 (m, 2H), 2.36 (s, 3H), 2.51–2.64 (m,
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2H), 3.85 (d, J = 1.2 Hz, 1H), 4.90 (d, J = 1.2 Hz, 1H), 7.17 (s, 4H, overlap); 13C NMR
(CDCl3) δ 11.6 (CH3), 21.2 (CH3), 22.6 (CH2), 48.3 (CH), 51.9 (CH2), 75.2 (CH), 128.2 (CH),
128.5 (C), 129.4 (CH), 138.8 (C); IR (ATR/cm-1) ν 1559; HRMS (ESI/TOF) Calcd for
C12H16N2O2Na [(M+Na)+]: 243.1104, found 243.1100.
trans-2-(4-methoxyphenyl)-3-nitro-1-propylaziridine (3b)
Yellow oil (76.4 mg, 0.32 mmol, 53%). 1H NMR (CDCl3) δ 0.89 (t, J = 7.2 Hz, 3H),
1.49–1.64 (m, 2H), 2.50–2.62 (m, 2H), 3.81 (s, 3H), 3.83 (d, J = 1.2 Hz, 1H), 4.88 (d, J = 1.2
Hz, 1H), 6.89 (d, J = 8.4 Hz, 2H), 7.20 (d, J = 8.4 Hz, 2H).
trans-2-(2-methoxyphenyl)-3-nitro-1-propylaziridine (3c)
Yellow oil (77.9 mg, 0.33 mmol, 54% yield). 1H NMR (CDCl3) δ 0.90 (t, J = 7.2 Hz, 3H),
1.53–1.63 (m, 2H), 2.36–2.42 (m, 1H), 2.58–2.66 (m, 1H), 3.87 (s, 3H), 4.01 (d, J = 1.6 Hz,
1H), 4.90 (d, J = 1.6 Hz, 1H), 6.89–6.94 (m, 2H), 7.17 (dd, J = 1.6, 7.6 Hz, 1H), 7.17 (ddd, J
= 1.6, 7.6, 7.6 Hz, 1H).
trans-2-(3,5-dimethoxyphenyl)-3-nitro-1-propylaziridine (3d)
Yellow oil (101.9 mg, 0.38 mol, 63% yield). 1H NMR (CDCl3) δ 0.93 (t, J = 7.6 Hz, 3H),
1.53–1.67 (m, 2H), 2.58–2.73 (m, 2H), 3.78 (d, J = 1.2 Hz, 1H), 3.79 (s, 6H), 4.88 (d, J = 1.2
Hz, 1H), 6.43 (s, 3H, overlap); 13C NMR (CDCl3) δ 11.6 (CH3), 22.6 (CH2), 48.3 (CH), 52.0
(CH2), 55.4 (CH3), 75.2 (CH), 100.5 (CH), 106.1 (CH), 134.5 (C), 161.1 (C); IR (ATR/cm-1) ν
1554; HRMS (ESI/TOF) Calcd for C13H19N2O4 [(M+H)+]: 267.1339, found 267.1326.
trans-3-nitro-2-phenyl-1-propylaziridine (3e)
Yellow oil (78.3 mg, 0.38 mmol, 63% yield). 1H NMR (CDCl3) δ 0.90 (t, J = 7.2 Hz,
3H), 1.52-1.68 (m, 2H), 2.56-2.67 (m, 2H), 3.87 (d, J = 1.2 Hz, 1H), 4.93 (d, J = 1.2 Hz, 1H),
7.28-7.30 (m, 2H), 7.36-7.39 (m, 3H); 13C NMR (CDCl3) δ 11.6 (CH3), 22.6 (CH2), 48.3 (CH),
52.0 (CH2), 75.2 (CH), 128.2 (CH), 128.7 (CH), 128.8 (CH), 132.0 (C); IR (ATR/cm-1) ν
1558; HRMS (ESI/TOF) Calcd for C11H15N2O2 [(M+H)+]: 207.1128, found 207.1124.
trans-2-(4-bromophenyl)-3-nitro-1-propylaziridine (3f)
Yellow oil (96.3 mg, 0.34 mmol, 56% yield). 1H NMR (CDCl3) δ 0.92 (t, J = 7.2 Hz,
3H), 1.52–1.66 (m, 2H), 2.62–2.73 (m, 2H), 3.78 (d, J = 1.2 Hz, 1H), 4.87 (d, J = 1.2 Hz, 1H),
7.17 (d, J = 8.4 Hz, 2H), 7.50 (d, J = 8.4 Hz, 2H); 13C NMR (CDCl3) δ 11.6 (CH3), 22.6
(CH2), 47.5 (CH), 52.0 (CH2), 75.1 (CH), 123.0 (C), 129.5 (CH), 131.6 (C), 131.9 (CH); IR
(ATR/cm-1) ν 1559; HRMS (ESI/TOF) Calcd for C11H14BrN2O2 [(M+H)+]: 285.0233, found
285.0222.
trans-2-(4-chlorophenyl)-3-nitro-1-propylaziridine (3g)
Yellow oil (73.9 mg, 0.31 mmol, 51% yield). 1H NMR (CDCl3) δ 0.92 (t, J = 7.2 Hz, 3H),
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1.50–1.68 (m, 2H), 2.62–2.73 (m, 2H), 3.79 (d, J = 1.2 Hz, 1H), 4.87 (d, J = 1.2 Hz, 1H), 7.23
(d, J = 8.4 Hz, 2H), 7.35 (d, J = 8.4 Hz, 2H); 13C NMR (CDCl3) δ 11.6 (CH3), 22.6 (CH2),
47.4 (CH), 52.0 (CH2), 75.2 (CH), 129.0 (CH), 129.2 (CH), 131.1 (C), 134.9 (C); IR
(ATR/cm-1) ν 1559; HRMS (ESI/TOF) Calcd for C11H14ClN2O2 [(M+H)+]: 241.0738, found
241.0727.
trans-2-(4-cyanophenyl)-3-nitro-1-propylaziridine (3h)
Yellow oil (42.0 mg, 0.18 mmol, 30% yield). 1H NMR (CDCl3) δ 0.95 (t, J = 7.2 Hz, 3H),
1.74 (tq, J = 7.2, 7.2 Hz, 2H), 2.83 (t, J = 7.2 Hz, 2H), 3.80 (d, J = 1.2 Hz, 1H), 4.90 (d, J =
1.2 Hz, 1H), 7.42 (d, J = 8.4 Hz, 2H), 7.67 (d, J = 8.4 Hz, 2H); 13C NMR (CDCl3) δ 11.6
(CH3), 22.7 (CH2), 47.0 (CH), 52.2 (CH2), 75.2 (CH), 112.7 (C), 118.2 (C), 128.1 (CH), 132.5
(CH), 139.0 (C); IR (ATR/cm-1) ν 1560; HRMS (ESI/TOF) Calcd for C12H14N3O2 [(M+H)+]:
232.1081, found 232.1085.
trans-2-(2-naphthyl)-3-nitro-1-propylaziridine (3j)
Yellow oil (97.6 mg, 0.38 mmol, 63% yield). 1H NMR (CDCl3) δ 0.90 (t, J = 7.2 Hz, 3H),
1.53–1.67 (m, 2H), 2.59–2.70 (m, 2H), 4.01 (d, J = 1.6 Hz, 1H), 5.04 (d, J = 1.6 Hz, 1H), 7.35
(dd, J = 1.6, 8.4 Hz, 1H), 7.49–7.54 (m, 2H), 7.76 (d, J = 1.6 Hz, 1H), 7.83–7.88 (m, 3H); 13C
NMR (CDCl3) δ 11.6 (CH3), 22.7 (CH2), 48.5 (CH), 52.1 (CH2), 75.3 (CH), 125.2 (CH),
126.7 (CH), 126.8 (CH), 127.7 (CH), 127.8 (CH), 127.9 (CH), 128.6 (CH), 129.5 (C), 133.0
(C), 133.3 (C); IR (ATR/cm-1) ν 1558; HRMS (ESI/TOF) Calcd for C15H17N2O2 [(M+H)+]:
257.1285, found 257.1272.
trans-3-nitro-1-propyl-2-(2-thienyl)aziridine (3m)
Yellow oil (44.1 mg, 0.21 mmol, 34% yield). 1H NMR (CDCl3) δ 0.91 (t, J = 7.2 Hz, 3H),
1.68–1.76 (m, 2H), 2.60 (t, J = 7.2 Hz, 2H), 4.07 (d, J = 1.2 Hz, 1H), 4.87 (d, J = 1.2 Hz, 1H),
7.03 (dd, J = 4.0, 4.4 Hz, 1H), 7.28 (d, J = 4.0 Hz, 1H), 7.37 (d, J = 4.4 Hz, 1H).
trans-2-(2-furyl)-1-propyl-3-nitroaziridine (3n)
Yellow oil (47.1 mg, 0.24 mmol, 40% yield). 1H NMR (CDCl3) δ 0.89 (t, J = 7.2 Hz, 3H),
1.49–1.62 (m, 2H), 2.48–2.54 (m, 1H), 2.61–2.67 (m, 1H), 3.88 (d, J = 1.6 Hz, 1H), 5.01 (d, J
= 1.6 Hz, 1H), 6.41 (dd, J = 2.0, 3.6 Hz, 1H), 6.48 (d, J = 3.6 Hz, 1H), 7.42 (d, J = 2.0 Hz,
1H).
trans-3-nitro-1-propyl-2-(3-pyridyl)aziridine (3o)
Yellow oil (57.4 mg, 0.28 mmol, 46% yield). 1H NMR (CDCl3) δ 0.93 (t, J = 7.2 Hz, 3H),
1.60 (tq, J = 7.2, 7.2 Hz, 2H), 2.72 (t, J = 7.2 Hz, 2H), 3.83 (d, J = 1.2 Hz, 1H), 4.95 (d, J =
1.2 Hz, 1H), 7.30–7.35 (m, 1H), 7.59 (d, J = 8.0 Hz, 1H), 8.60 (s, 2H, overlap); 13C NMR
(CDCl3) δ 11.5 (CH3), 22.5 (CH2), 45.6 (CH), 52.0 (CH2), 74.7 (CH), 123.4 (CH), 128.6 (C),
100
135.2 (CH), 149.4 (CH), 150.0 (CH); IR (ATR/cm-1) ν 1559; HRMS (ESI/TOF) Calcd for
C10H14N3O2 [(M+H)+]: 208.1081, found 208.1078.
trans-3-nitro-2-(2-phenylethyl)-1-propylaziridine (3p)
Colorless oil (92.0 mg, 0.39 mmol, 65% yield). 1H NMR (CDCl3) δ 0.94 (t, J = 7.2 Hz, 3H),
1.56–1.65 (m, 2H), 1.76–1.85 (m, 1H), 1.92–2.00 (m, 1H), 2.49–2.55 (m, 1H), 2.62–2.68 (m,
1H), 2.72–2.87 (m, 3H), 4.20 (d, J = 1.2 Hz, 1H), 7.16 (dd, J = 1.2, 8.0 Hz, 2H), 7.22 (tt, J =
1.2, 8.0 Hz, 1H), 7.30 (dd, J = 8.0, 8.0 Hz, 2H); 13C NMR (CDCl3) δ 11.6 (CH3), 22.8 (CH2),
27.7 (CH2), 33.6 (CH2), 46.1 (CH), 51.9 (CH2), 75.5 (CH), 126.5 (CH), 128.2 (CH), 128.7
(CH), 140.1 (C); IR (ATR/cm-1) ν 1555; HRMS (ESI/TOF) Calcd for C13H19N2O2 [(M+H)+]:
235.1441, found 235.1430.
trans-2-(4-methylphenyl)-1-(2-methylpropyl)-3-nitroaziridine (3q)
Yellow oil (77.5 mg, 0.33 mmol, 54% yield). 1H NMR (CDCl3) δ 0.90 (d, J = 6.8 Hz, 3H),
0.94 (d, J = 6.8 Hz, 3H), 1.76–1.95 (m, 1H), 2.36 (s, 3H), 2.36–2.45 (m, 1H), 2.49-2.54 (m,
1H), 3.80 (d, J = 1.6 Hz, 1H), 4.89 (d, J = 1.6 Hz, 1H), 7.17 (s, 4H, overlap); 13C NMR
(CDCl3) δ 20.5 (CH3), 20.5 (CH3), 21.2 (CH3), 28.9 (CH), 48.1 (CH), 57.9 (CH2), 75.7 (CH),
128.0 (CH), 129.4 (CH), 129.7 (C), 138.8 (C); IR (ATR/cm-1) ν 1557; HRMS (ESI/TOF)
Calcd for C13H19N2O2 [(M+H)+]: 235.1441, found 235.1446.
trans-1-(2-butyl)-2-(4-methylphenyl)-3-nitroaziridine (3r)
Yellow oil (43.8 mg, 0.19 mmol, 31% yield). 1H NMR (CDCl3) δ 0.74 (t, J = 7.2 Hz, 1H),
0.89-0.93 (m, 4H, overlap), 1.20 (d, J = 6.0 Hz, 1H), 1.36–1.39 (m, 1H), 1.54-1.66 (m, 1H),
2.35 (s, 3H), 2.56–2.62 (m, 1H), 3.85 (d, J = 1.2 Hz, 1H), 4.96 (d, J = 1.2 Hz, 1H), 7.17 (s, 4H,
overlap); 13C NMR (CDCl3) δ 10.0 (CH3), 18.6 (CH3), 21.1 (CH3), 29.6 (CH2), 48.2 (CH),
55.9 (CH), 74.6 (CH), 127.9 (CH), 129.3 (CH), 129.4 (C), 138.7 (C); IR (ATR/cm-1) ν 1559;
HRMS (ESI/TOF) Calcd for C13H19N2O2 [(M+H)+]: 235.1441, found 235.1431.
trans-2-(4-methylphenyl)-3-nitro-1-(phenylmethyl)aziridine (3t)
Yellow oil (67.1 mg, 0.25 mmol, 41% yield). 1H NMR (CDCl3) δ 2.35 (s, 3H), 3.75 (d, J =
14.0 Hz, 1H), 3.83 (d, J = 14.0 Hz, 1H), 3.99 (d, J = 1.2 Hz, 1H), 5.00 (d, J = 1.2 Hz, 1H),
7.16 (s, 4H, overlap), 7.27–7.35 (m, 5H); 13C NMR (CDCl3) δ 21.2 (CH3), 48.9 (CH), 53.5
(CH2), 74.8 (CH), 127.6 (CH), 128.0 (CH), 128.2 (C), 128.4 (CH), 128.6 (CH), 129.5 (CH),
137.0 (C), 139.1 (C); IR (ATR/cm-1) ν 1559; HRMS (ESI/TOF) Calcd for C16H17N2O2
[(M+H)+]: 269.1285, found 269.1274.
trans-2-(4-methylphenyl)-3-nitro-1-(propene-3-yl)aziridine (3v)
Yellow oil (88.7 mg, 0.41 mmol, 67% yield). 1H NMR (CDCl3) δ 2.35 (s, 3H), 3.18 (dd, J
= 4.8, 14.0 Hz, 1H), 3.28 (dd, J = 4.8, 14.0 Hz, 1H), 3.92 (d, J = 1.6 Hz, 1H), 4.94 (d, J = 1.6
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Hz, 1H), 5.14 (dd, J = 1.2, 9.2 Hz, 1H), 5.16 (dd, J = 1.2, 17.2 Hz, 1H), 5.83–5.93 (m, 1H),
7.18 (s, 4H, overlap); 13C NMR (CDCl3) δ 21.2 (CH3), 48.4 (CH), 52.2 (CH2), 74.6 (CH),
117.7 (CH2), 128.0 (C), 128.4 (CH), 129.4 (CH), 133.2 (C), 139.0 (C); IR (ATR/cm-1) ν 1558;
HRMS (ESI/TOF) Calcd for C12H15N2O2 [(M+H)+]: 219.1128, found 219.1117.
trans-1-(2-hydroxyethyl)-2-(4-methylphenyl)-3-nitroaziridine (3w)
Yellow oil (39.6 mg, 0.18 mmol, 30% yield). 1H NMR (CDCl3) δ 2.35 (s, 3H), 2.72 (br s,
1H), 2.73 (t, J = 5.2 Hz, 2H), 3.68–3.86 (m, 2H), 3.87 (d, J = 1.6 Hz, 1H), 5.07 (d, J = 1.6 Hz,
1H), 7.18 (s, 4H, overlap); 13C NMR (CDCl3) δ 21.1 (CH3), 47.6 (CH), 51.8 (CH2), 61.4
(CH2), 75.0 (CH), 127.7 (C), 128.4 (CH), 129.5 (CH), 139.1 (C); IR (ATR/cm-1) ν 1557;
HRMS (ESI/TOF) Calcd for C11H15N2O3 [(M+H)+]: 223.1077, found 223.1066.
trans-1-(3-hydroxypropyl)-2-(4-methylphenyl)-3-nitroaziridine (3x)
Yellow oil (49.9 mg, 0.21 mmol, 35% yield). 1H NMR (CDCl3) δ 1.73–1.77 (m, 2H), 2.25
(br s, 1H), 2.36 (s, 3H), 2.72 (t, J = 6.4 Hz, 2H), 3.74 (t, J = 5.6 Hz, 2H), 3.89 (s, 1H), 4.98 (s,
1H), 7.17 (s, 4H, overlap); 13C NMR (CDCl3) δ 21.2 (CH3), 31.5 (CH2), 47.8 (CH2), 48.4
(CH), 61.2 (CH2), 74.9 (CH), 127.6 (C), 128.4 (CH), 129.5 (CH), 139.1 (C); IR (ATR/cm-1) ν
1558; HRMS (ESI/TOF) Calcd for C12H17N2O3 [(M+H)+]: 237.1234, found 237.1228.
4.4 Isomerization of trans-N-alkyl-C-nitroaziridine 3a to β-nitroenamine 8a
(Z)-1-(4-methylphenyl)-1-nitro-2-(propylamino)ethene (8a)
To a solution of trans-N-alkyl-C-nitroaziridines 3a (44 mg, 0.20 mmol) in MeCN (1.5 mL),
was added SnCl2·2H2O (14 mg, 0.06 mmol), and the resultant mixture was stirred at room
temperature for 4 h. Then, the solvent was evaporated to afford a mixture as a yellow residue,
which was treated by column chromatography on silica gel to afford β-nitroenamines 8a
(eluted with CH2Cl2, 33.1 mg, 0.15 mmol, 76% yield) as a yellow solid.
Mp 84−86 °C. 1H NMR (CDCl3) δ 1.01 (t, J = 7.2 Hz, 3H), 1.71 (tq, J = 7.2, 7.2 Hz, 2H),
2.36 (s, 3H), 3.38 (dt, J = 6.8, 7.2 Hz, 2H), 7.08 (d, J = 14.0 Hz, 1H), 7.18 (d, J = 8.0 Hz, 2H),
7.25 (d, J = 8.0 Hz, 2H), 9.45−9.55 (br, 1H); 13C NMR (CDCl3) δ 11.0 (CH3), 21.2 (CH3),
24.1 (CH2), 51.6 (CH2), 122.4 (C), 129.0 (CH), 129.6 (CH), 130.2 (C), 137.7 (C), 148.4 (CH);
IR (ATR/cm-1) ν 3288, 1646, 1517; HRMS (ESI/TOF) Calcd for C12H16N2O2Na [(M+Na)+]:
243.1104, found 243.1093.
When other aziridines 3 were used, experiments were conducted in a similar way.
(Z)-1-(4-methoxyphenyl)-1-nitro-2-(propylamino)ethene (8b)
Yellow solid (41.1 mg, 0.17 mmol, 87%). Mp 122−124 °C; 1H NMR (CDCl3,) δ 1.01 (t, J =
7.2 Hz, 3H), 1.71 (tq, J = 7.2, 7.2 Hz, 2H), 3.37 (dt, J = 6.8, 7.2 Hz, 2H), 3.81 (s, 3H), 6.98 (d,
102
J = 8.4 Hz, 2H), 7.06 (d, J = 14.0 Hz, 1H), 7.22 (d, J = 8.4 Hz, 2H), 9.45−9.53 (br, 1H); 13C
NMR (CDCl3) δ 11.0 (CH3), 24.0 (CH2), 51.6 (CH2), 55.3 (CH3), 113.8 (CH), 122.1 (C),
125.5 (C), 131.1 (CH), 148.3 (CH), 159.2 (C); IR (ATR/cm-1) ν 3291, 1643, 1517; HRMS
(ESI/TOF) Calcd for C12H17N2O3 [(M+H)+]: 237.1234, found 237.1232.
(Z)-1-(2-methoxyphenyl)-1-nitro-2-(propylamino)ethene (8c)
Yellow oil (41.9 mg, 0.18 mmol, 89%). 1H NMR (CDCl3) δ 1.00 (t, J = 7.2 Hz, 3H), 1.70
(tq, J = 7.2, 7.2 Hz, 2H), 3.35 (dt, J = 6.8, 7.2 Hz, 2H), 3.80 (s, 3H), 6.92 (d, J = 8.0 Hz, 1H),
6.96 (dd, J = 8.0, 8.0 Hz, 1H), 7.00 (d, J = 14.4 Hz, 1H), 7.20 (dd, J = 1.6, 8.0 Hz, 1H), 7.33
(ddd, J = 1.6, 8.0, 8.0 Hz, 1H), 9.42−9.50 (br, 1H); 13C NMR (CDCl3) δ 11.0 (CH3), 24.0
(CH2), 51.5 (CH2), 55.7 (CH3), 111.2 (CH), 118.5 (C), 120.5 (CH), 122.1 (C), 130.1 (CH),
132.0 (CH), 149.0 (CH), 157.9 (C); IR (ATR/cm-1) ν 3300, 1646, 1560; HRMS (ESI/TOF)
Calcd for C12H17N2O3 [(M+H)+]: 237.1234, found 237.1240.
(Z)-1-(3,5-dimethoxyphenyl)-1-nitro-2-(propylamino)ethene (8d)
Yellow oil (23.6 mg, 0.09 mmol, 45%). 1H NMR (CDCl3) δ 1.01 (t, J = 7.2 Hz, 3H), 1.71
(tq, J = 7.2, 7.2 Hz, 2H), 3.38 (dt, J = 6.8, 7.2 Hz, 2H), 6.42 (t, J = 2.4 Hz, 1H), 6.53 (d, J =
2.4 Hz, 2H), 7.12 (d, J = 14.0 Hz, 1H), 9.47−9.53 (br, 1H); 13C NMR (CDCl3) δ 11.0 (CH3),
24.0 (CH2), 51.7 (CH2), 55.4 (CH3), 99.9 (CH), 107.9 (CH), 122.3 (C), 134.9 (C), 148.6 (CH),
160.6 (C); IR (ATR/cm-1) ν 3293, 1645, 1559; HRMS (ESI/TOF) Calcd for C13H19N2O4
[(M+H)+]: 267.1339, found 267.1338.
(Z)-1-nitro-1-phenyl-2-(propylamino)ethene (8e)
Yellow oil (16.2 mg, 0.08 mmol, 40%). 1H NMR (CDCl3) δ 1.02 (t, J = 7.2 Hz, 3H), 1.72
(tq, J = 7.2, 7.2 Hz, 2H), 3.39 (dt, J = 6.8, 7.2 Hz, 2H), 7.10 (d, J = 13.6 Hz, 1H), 7.28−7.33
(m, 1H), 7.35−7.38 (m, 4H), 9.50−9.56 (br, 1H); 13C NMR (CDCl3) δ 11.0 (CH3), 24.0 (CH2),
51.7 (CH2), 126.8 (C), 127.7 (CH), 128.3 (CH), 129.6 (CH), 133.1 (C), 148.6 (CH); IR
(ATR/cm-1) ν 3277, 1646, 1559; HRMS (ESI/TOF) Calcd for C11H15N2O2 [(M+H)+]:
207.1128, found 207.1131.
(Z)-1-(4-bromophenyl)-1-nitro-2-(propylamino)ethene (8f)
Yellow solid (27.8 mg, 0.10 mmol, 49%). Mp 61−62 °C; 1H NMR (CDCl3) δ 1.02 (t, J =
7.2 Hz, 3H), 1.73 (tq, J = 7.2, 7.2 Hz, 2H), 3.40 (dt, J = 6.8, 7.2 Hz, 2H), 7.08 (d, J = 14.0 Hz,
1H), 7.24 (d, J = 8.4 Hz, 2H), 7.50 (d, J = 8.4 Hz, 2H), 9.47−9.55 (br, 1H); 13C NMR (CDCl3)
δ 11.0 (CH3), 24.0 (CH2), 51.7 (CH2), 121.5 (C), 121.7 (C), 131.1 (CH), 131.5 (CH), 132.0
(C), 148.3 (CH); IR (ATR/cm-1) ν 3268, 1637, 1539; HRMS (ESI/TOF) Calcd for
C11H14BrN2O2 [(M+H)+]: 285.0233, found 285.0235.
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(Z)-1-(4-chlorophenyl)-1-nitro-2-(propylamino)ethene (8g)
Yellow solid (21.3 mg, 0.09 mmol, 45%). Mp 77−79 °C; 1H NMR (CDCl3) δ 1.02 (t, J =
7.2 Hz, 3H), 1.72 (tq, J = 7.2, 7.2 Hz, 2H), 3.40 (dt, J = 6.8, 7.2 Hz, 2H), 7.08 (d, J = 14.0 Hz,
1H), 7.30 (d, J = 8.8 Hz, 2H), 7.34 (d, J = 8.8 Hz, 2H), 9.48−9.54 (br, 1H); 13C NMR (CDCl3)
δ 11.0 (CH3), 24.0 (CH2), 51.7 (CH2), 121.5 (C), 128.5 (CH), 130.9 (CH), 131.5 (C), 133.6
(C), 148.3 (CH); IR (ATR/cm-1) ν 3280, 1642, 1539; HRMS (ESI/TOF) Calcd for
C11H14ClN2O2 [(M+H)+]: 241.0738, found 241.0749.
(Z)-1-(2-naphthyl)-1-nitro-2-(propylamino)ethene (8j)
Yellow solid (42.3 mg, 0.17 mmol, 83%). Mp 82−85 °C; 1H NMR (CDCl3) δ 1.02 (t, J =
7.2 Hz, 3H), 1.72 (tq, J = 7.2, 7.2 Hz, 2H), 3.40 (dt, J = 6.8, 7.2 Hz, 2H), 7.21 (d, J = 14.0 Hz,
1H), 7.45−7.49 (m, 2H), 7.56 (dd, J = 1.2, 8.4 Hz, 1H), 7.71 (d, J = 1.2 Hz, 1H), 7.78−7.83
(m, 3H), 9.54−9.60 (br, 1H); 13C NMR (CDCl3) δ 11.0 (CH3), 24.1 (CH2), 51.7 (CH2), 122.5
(C), 126.2 (CH), 126.3 (CH), 127.6 (CH), 127.7 (CH), 127.8 (CH), 127.8 (CH), 127.9 (CH),
130.7 (C), 132.7 (C), 133.2 (C), 148.8 (CH); IR (ATR/cm-1) ν 3295, 1643, 1560; HRMS
(ESI/TOF) Calcd for C15H17N2O2 [(M+H)+]: 257.1285, found 257.1283.
(Z)-1-nitro-2-propylamino-1-(2-thienyl)ethene (8m)
Yellow oil (42.5 mg, 0.20 mmol, quant.). 1H NMR (CDCl3) δ 1.03 (t, J = 7.2 Hz, 3H), 1.74
(tq, J = 7.2, 7.2 Hz, 2H), 3.44 (dt, J = 6.8, 7.2 Hz, 2H), 6.99 (dd, J = 3.6, 5.2 Hz, 1H), 7.03 (d,
J = 3.6 Hz, 1H), 7.30 (d, J = 5.2 Hz, 1H), 7.43 (d, J = 14.0 Hz, 1H), 9.74−9.80 (br, 1H); 13C
NMR (CDCl3) δ 11.0 (CH3), 23.9 (CH2), 51.9 (CH2), 117.6 (C), 123.8 (CH), 125.7 (CH),
126.2 (CH), 134.8 (C), 148.3 (CH); IR (ATR/cm-1) ν 3288, 1646, 1559; HRMS (ESI/TOF)
Calcd for C9H13N2O2S [(M+H)+]: 213.0692, found 213.0691.
(Z)-1-(2-furyl)-1-nitro-2-(propylamino)ethene (8n)
Yellow solid (31.1 mg, 0.16 mmol, 80%). Mp 63−64 °C; 1H NMR (CDCl3) δ 1.03 (t, J =
7.2 Hz, 3H), 1.75 (tq, J = 7.2, 7.2 Hz, 2H), 3.47 (dt, J = 6.8, 7.2 Hz, 2H), 6.44 (dd, J = 1.6, 3.6
Hz, 1H), 6.81 (dd, J = 0.8, 3.6 Hz, 1H), 7.31 (dd, J = 0.8, 1.6 Hz, 1H), 7.68 (d, J = 14.4 Hz,
1H), 9.82−9.90 (br, 1H); 13C NMR (CDCl3) δ 10.9 (CH3), 23.9 (CH2), 52.1 (CH2), 107.6 (CH),
111.6 (CH), 116.4 (C), 140.1 (CH), 145.8 (C), 147.7 (CH); IR (ATR/cm-1) ν 3255, 1653, 1559;
HRMS (ESI/TOF) Calcd for C9H13N2O3 [(M+H)+]: 197.0921, found 197.0916.
(Z)-1-(4-methylphenyl)-2-[(2-methylpropyl)amino]-1-nitroethene (8q)
Yellow oil (34.1 mg, 0.15 mmol, 73%). 1H NMR (CDCl3) δ 1.00 (d, J = 6.8 Hz, 6H), 1.91
(triple septet, J = 6.4, 6.8 Hz, 1H), 2.36 (s, 3H), 3.22 (dt, J = 6.4, 6.4 Hz, 2H), 7.05 (d, J =
14.0 Hz, 1H), 7.18 (1H, J = 8.0 Hz, 2H), 7.25 (1H, J = 8.0 Hz, 2H), 9.50−9.59 (br, 1H); 13C
NMR (CDCl3) δ 19.7 (CH3), 21.2 (CH3), 29.7 (CH), 57.6 (CH2), 122.3 (C), 129.0 (CH), 129.6
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(CH), 130.2 (C), 137.6 (C), 148.7 (CH); IR (ATR/cm-1) ν 3281, 1643, 1517; HRMS
(ESI/TOF) Calcd for C13H19N2O2 [(M+H)+]: 235.1441, found 235.1431.
(Z)-2-(2-butylamino)-1-(4-methylphenyl)-1-nitroethene (8r)
Yellow solid (37.4 mg, 0.16 mmol, 80%). Mp 68−70 °C; 1H NMR (CDCl3) δ 0.99 (t, J =
7.2 Hz, 3H), 1.35 (d, J = 6.4 Hz, 3H), 1.61−1.69 (m, 2H), 2.36 (s, 3H), 3.37 (dtq, J = 6.4, 6.8,
7.2 Hz, 1H), 7.11 (d, J = 14.0 Hz, 1H), 7.18 (d, J = 8.0 Hz, 2H), 7.26 (d, J = 8.0 Hz, 2H),
9.40−9.48 (br, 1H); 13C NMR (CDCl3) δ 10.3 (CH3), 21.2 (CH3), 21.3 (CH3), 30.5 (CH2), 57.7
(CH), 122.1 (C), 129.0 (CH), 129.6 (CH), 130.3 (C), 137.6 (C), 146.9 (CH); IR (ATR/cm-1) ν
3276, 1638, 1517; HRMS (ESI/TOF) Calcd for C13H19N2O2 [(M+H)+]: 235.1441, found
235.1442.
(Z)-1-(4-methylphenyl)-1-nitro-2-[(phenylmethyl)amino]ethene (8t)
Yellow solid (45.7 mg, 0.17 mmol, 86%). Mp 92−94 °C; 1H NMR (CDCl3) δ 2.35 (s, 3H),
4.57 (d, J = 6.0 Hz, 2H), 7.12 (d, J = 14.0 Hz, 1H), 7.16−7.42 (m, 9H), 9.60−9.68 (br, 1H);
13C NMR (CDCl3) δ 21.2 (CH3), 53.3 (CH2), 123.2 (C), 127.5 (CH), 128.5 (CH), 129.1 (CH),
129.2 (CH), 129.6 (CH), 130.0 (C), 136.1 (C), 137.8 (C), 147.7 (CH); IR (ATR/cm-1) ν 3287,
1640, 1517; HRMS (ESI/TOF) Calcd for C16H17N2O2 [(M+H)+]: 269.1285, found 269.1284.
(Z)-1-(4-methylphenyl)-1-nitro-2-[(propene-3-yl)amino]ethene (8v)
Yellow solid (35.6 mg, 0.16 mmol, 82%). Mp 88−90 °C; 1H NMR (CDCl3) δ 2.35 (s, 3H),
4.01 (dd, J = 5.6, 5.6 Hz, 2H), 5.30 (dd, J = 0.8, 8.8 Hz, 1H), 5.33 (dd, J = 0.8, 17.2 Hz, 1H),
5.87-5.97 (m, 1H), 7.05 (d, J = 13.6 Hz, 1H), 7.18 (d, J = 8.0 Hz, 2H), 7.24 (d, J = 8.0 Hz,
2H), 9.38−9.46 (br, 1H); 13C NMR (CDCl3) δ 21.2 (CH3), 51.5 (CH2), 118.7 (CH2), 123.1 (C),
129.0 (CH), 129.6 (CH), 130.0 (C), 132.8 (CH), 137.8 (C), 147.8 (CH); IR (ATR/cm-1) ν
3292, 1637, 1518; HRMS (ESI/TOF) Calcd for C12H15N2O2 [(M+H)+]: 219.1128, found
219.1128.
(Z)-2-[(2-hydroxyethyl)amino]]-1-(4-methylphenyl)-1-nitroethene (8w)
Yellow solid (28.3 mg, 0.13 mmol, 64%). Mp 96−98 °C; 1H NMR (CDCl3) δ 2.34 (s, 3H),
2.97−3.02 (br, 1H), 3.52 (dt, J = 5.6, 5.6 Hz, 2H), 3.83 (dt, J = 4.4, 5.6 Hz, 2H), 7.14 (d, J =
8.4 Hz, 2H), 7.17 (d, J = 15.2 Hz, 1H), 7.23 (d, J = 8.4 Hz, 2H), 9.58−9.66 (br, 1H); 13C NMR
(CDCl3) δ 21.2 (CH3), 52.1 (CH2), 61.5 (CH2), 122.4 (C), 129.0 (CH), 129.6 (CH), 129.9 (C),
137.7 (C), 149.8 (CH); IR (ATR/cm-1) ν 3296, 1642, 1517; HRMS (ESI/TOF) Calcd for
C11H15N2O3 [(M+H)+]: 223.1077, found 223.1073.
(Z)-2-[(3-hydroxypropyl)amino]-1-(4-methylphenyl)-1-nitroethene (8x)
Yellow oil (34.9 mg, 0.15 mmol, 74%). 1H NMR (CDCl3) δ 1.80−1.85 (br, 1H), 1.92 (tt, J
= 5.6, 5.6 Hz, 2H), 2.36 (s, 3H), 3.59 (dt, J = 5.6, 6.4 Hz, 2H), 3.81 (dt, J = 4.8, 5.6 Hz, 2H),
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7.12 (d, J = 14.0 Hz, 1H), 7.18 (d, J = 7.6 Hz, 2H), 7.25 (d, J = 7.6 Hz, 2H), 9.62−9.70 (br,
1H); 13C NMR (CDCl3) δ 21.2 (CH3), 32.7 (CH2), 47.0 (CH2), 59.4 (CH2), 122.4 (C), 129.0
(CH), 129.5 (CH), 130.1 (C), 137.7 (C), 148.8 (CH); IR (ATR/cm-1) ν 3373, 1646, 1517;
HRMS (ESI/TOF) Calcd for C12H16N2O3Na [(M+Na)+]: 259.1053, found 259.1060.
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